data_1rpc_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1rpc _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.498 1.955 0 N-CA-C 118.742 2.868 . . . . 0.0 118.742 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.3 173.51 11.53 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 121.056 1.753 . . . . 0.0 114.203 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.1 55.11 0.65 Allowed Glycine 0 N--CA 1.501 3.005 0 N-CA-C 116.217 1.247 . . . . 0.0 116.217 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.86 -52.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 C-N-CA 124.662 1.185 . . . . 0.0 109.195 177.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.82 172.87 23.65 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 118.506 2.163 . . . . 0.0 118.506 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -117.61 49.08 1.26 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 115.185 1.55 . . . . 0.0 115.185 -177.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.25 26.2 p -159.23 -122.8 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.85 -1.156 . . . . 0.0 110.961 175.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -147.56 142.35 26.78 Favored 'General case' 0 N--CA 1.491 1.625 0 CA-C-N 120.934 1.697 . . . . 0.0 111.999 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -91.01 -63.21 1.3 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 124.515 1.126 . . . . 0.0 113.343 176.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 94.4 m-85 -140.77 78.13 1.63 Allowed 'General case' 0 N--CA 1.495 1.808 0 CA-C-N 119.079 0.854 . . . . 0.0 111.237 -173.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 38.79 75.24 0.08 Allowed 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 118.717 2.858 . . . . 0.0 118.717 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.14 -19.83 51.09 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 119.545 2.578 . . . . 0.0 119.545 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.9 t -61.49 -41.35 97.14 Favored 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 117.766 2.506 . . . . 0.0 117.766 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.34 -128.04 1.49 Allowed Glycine 0 N--CA 1.489 2.198 0 O-C-N 121.361 -0.837 . . . . 0.0 111.726 177.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -120.04 174.25 6.59 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-O 122.058 0.932 . . . . 0.0 113.242 -173.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.26 147.36 25.59 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.403 -1.435 . . . . 0.0 112.787 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -73.4 -42.14 56.86 Favored 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 165.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.6 t . . . . . 0 N--CA 1.495 1.786 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 170.183 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.499 1.977 0 N-CA-C 120.745 3.609 . . . . 0.0 120.745 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.254 0.2 OUTLIER -80.56 176.18 10.01 Favored 'General case' 0 CA--C 1.579 2.075 0 CA-C-N 122.044 2.202 . . . . 0.0 114.139 177.942 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.45 56.27 0.61 Allowed Glycine 0 N--CA 1.501 3.013 0 O-C-N 120.206 -1.558 . . . . 0.0 116.828 176.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.0 mt -129.48 -59.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 C-N-CA 124.273 1.029 . . . . 0.0 109.455 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.31 172.02 42.26 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 119.836 2.694 . . . . 0.0 119.836 -175.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.8 p -110.74 51.23 0.78 Allowed 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -175.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.4 p -169.9 140.01 1.99 Allowed 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.44 1.096 . . . . 0.0 109.627 178.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -66.48 133.67 50.87 Favored 'General case' 0 CA--C 1.576 1.964 0 N-CA-C 115.652 1.723 . . . . 0.0 115.652 -176.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.254 26.3 p30 -71.54 -72.34 0.23 Allowed 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 123.77 0.828 . . . . 0.0 112.884 177.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -144.21 87.75 1.91 Allowed 'General case' 0 CA--C 1.566 1.588 0 CA-C-N 119.42 1.009 . . . . 0.0 110.923 -178.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.79 82.72 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 118.366 2.728 . . . . 0.0 118.366 173.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.94 -23.94 5.58 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 120.097 2.799 . . . . 0.0 120.097 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.9 t -58.82 -40.78 85.17 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 117.907 2.558 . . . . 0.0 117.907 -176.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.15 -126.11 1.47 Allowed Glycine 0 N--CA 1.488 2.137 0 C-N-CA 124.003 0.811 . . . . 0.0 111.368 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -131.18 169.1 16.38 Favored 'General case' 0 CA--C 1.569 1.694 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -172.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.61 142.75 49.96 Favored 'General case' 0 CA--C 1.564 1.507 0 O-C-N 120.569 -1.332 . . . . 0.0 110.796 174.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.2 t -75.03 -38.53 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.294 0 O-C-N 120.954 -1.091 . . . . 0.0 113.57 173.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t . . . . . 0 N--CA 1.495 1.791 0 O-C-N 120.802 -1.186 . . . . 0.0 108.307 176.3 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.575 1.917 0 N-CA-C 120.421 3.489 . . . . 0.0 120.421 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.04 173.76 6.16 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 121.006 1.73 . . . . 0.0 113.882 177.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -117.81 54.03 0.62 Allowed Glycine 0 N--CA 1.501 2.976 0 O-C-N 120.306 -1.496 . . . . 0.0 116.595 176.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.25 -54.94 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 124.274 1.03 . . . . 0.0 109.631 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.88 173.86 30.27 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 118.09 1.996 . . . . 0.0 118.09 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.8 t -116.04 43.83 2.06 Favored 'General case' 0 N--CA 1.504 2.249 0 N-CA-C 116.083 1.882 . . . . 0.0 116.083 -175.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 18.5 p -166.77 142.55 4.43 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.752 -1.218 . . . . 0.0 110.367 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -57.55 133.78 55.55 Favored 'General case' 0 CA--C 1.581 2.173 0 N-CA-C 117.616 2.45 . . . . 0.0 117.616 -174.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -81.85 -64.14 1.24 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 123.041 0.536 . . . . 0.0 112.406 171.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -148.59 120.98 8.45 Favored 'General case' 0 CA--C 1.566 1.565 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.46 105.64 0.06 Allowed 'General case' 0 CA--C 1.573 1.828 0 N-CA-C 116.834 2.161 . . . . 0.0 116.834 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.68 -45.59 1.13 Allowed Glycine 0 N--CA 1.491 2.354 0 CA-C-O 118.548 -1.14 . . . . 0.0 115.816 -170.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 31.2 t -83.52 -59.01 2.58 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 116.809 2.151 . . . . 0.0 116.809 -178.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.62 -121.64 0.9 Allowed Glycine 0 N--CA 1.487 2.07 0 CA-C-N 119.918 1.236 . . . . 0.0 114.242 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -124.37 172.37 9.19 Favored 'General case' 0 CA--C 1.566 1.573 0 N-CA-C 115.248 1.573 . . . . 0.0 115.248 -167.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.22 144.48 48.46 Favored 'General case' 0 CA--C 1.561 1.381 0 O-C-N 120.542 -1.349 . . . . 0.0 111.073 174.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -72.31 -43.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 121.0 -1.063 . . . . 0.0 111.57 168.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t . . . . . 0 N--CA 1.495 1.778 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 168.732 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.4 t . . . . . 0 CA--C 1.575 1.937 0 N-CA-C 121.185 3.772 . . . . 0.0 121.185 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 173.36 6.34 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-N 121.364 1.893 . . . . 0.0 113.806 177.034 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.71 51.21 0.73 Allowed Glycine 0 N--CA 1.502 3.034 0 O-C-N 119.971 -1.706 . . . . 0.0 117.326 176.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -132.53 -56.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 C-N-CA 123.938 0.895 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.97 168.13 41.2 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 119.283 2.473 . . . . 0.0 119.283 -174.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.7 p -105.99 55.13 0.68 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -174.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 19.2 p -178.15 140.62 0.23 Allowed 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 125.021 1.329 . . . . 0.0 109.263 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -69.64 136.25 50.93 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 116.274 1.953 . . . . 0.0 116.274 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 49.7 p30 -78.2 -63.66 1.34 Allowed 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 123.194 0.597 . . . . 0.0 112.104 175.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -147.93 124.41 11.01 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.653 -2.351 . . . . 0.0 104.653 175.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.08 105.81 0.06 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.386 1.995 . . . . 0.0 116.386 179.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.89 -47.23 1.03 Allowed Glycine 0 N--CA 1.491 2.329 0 CA-C-O 118.366 -1.241 . . . . 0.0 115.335 -169.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 t -86.08 -61.95 1.63 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.37 -119.98 0.78 Allowed Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.942 1.246 . . . . 0.0 114.351 -175.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -126.89 172.83 10.08 Favored 'General case' 0 CA--C 1.571 1.754 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -167.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -130.5 141.56 50.5 Favored 'General case' 0 CA--C 1.563 1.473 0 O-C-N 120.281 -1.512 . . . . 0.0 110.855 174.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 -41.8 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.02 -1.05 . . . . 0.0 112.628 171.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t . . . . . 0 N--CA 1.495 1.799 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 172.625 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 m . . . . . 0 CA--C 1.575 1.919 0 N-CA-C 120.431 3.493 . . . . 0.0 120.431 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.255 0.3 OUTLIER -89.99 169.26 11.36 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-N 122.247 2.294 . . . . 0.0 116.066 -172.449 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.01 51.83 0.68 Allowed Glycine 0 N--CA 1.5 2.932 0 N-CA-C 117.032 1.573 . . . . 0.0 117.032 177.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.07 -56.66 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 C-N-CA 123.883 0.873 . . . . 0.0 110.228 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -69.75 175.91 33.45 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 118.712 2.245 . . . . 0.0 118.712 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 p -114.24 56.23 0.72 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 115.499 1.666 . . . . 0.0 115.499 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.269 11.7 p -164.59 -129.38 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.194 -0.941 . . . . 0.0 110.98 176.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -144.92 142.42 29.85 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 121.143 1.792 . . . . 0.0 111.74 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -91.9 -73.54 0.54 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-N 114.254 -1.339 . . . . 0.0 110.118 172.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -137.72 76.42 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -172.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.22 80.9 0.05 OUTLIER 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 172.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.29 -23.98 6.7 Favored Glycine 0 N--CA 1.5 2.908 0 N-CA-C 119.016 2.367 . . . . 0.0 119.016 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -54.37 -46.41 73.0 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 117.024 2.231 . . . . 0.0 117.024 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.47 -132.6 2.36 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 124.053 0.835 . . . . 0.0 111.148 175.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -119.83 -178.63 3.68 Favored 'General case' 0 CA--C 1.567 1.604 0 CA-C-O 122.231 1.015 . . . . 0.0 112.353 -173.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.2 145.11 26.97 Favored 'General case' 0 CA--C 1.562 1.41 0 O-C-N 120.115 -1.616 . . . . 0.0 111.665 172.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.5 t -71.81 -45.77 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 O-C-N 121.185 -0.947 . . . . 0.0 112.044 172.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t . . . . . 0 N--CA 1.495 1.792 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 167.561 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 t . . . . . 0 CA--C 1.574 1.893 0 N-CA-C 119.056 2.984 . . . . 0.0 119.056 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.46 174.07 6.03 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 120.62 1.555 . . . . 0.0 114.489 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.86 56.35 0.64 Allowed Glycine 0 N--CA 1.501 2.969 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 175.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.19 -53.39 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 C-N-CA 124.579 1.152 . . . . 0.0 109.32 177.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.07 173.6 27.74 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 118.783 2.273 . . . . 0.0 118.783 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -115.82 50.09 1.05 Allowed 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 115.914 1.82 . . . . 0.0 115.914 -175.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.271 18.8 p -160.53 -124.26 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.884 -1.135 . . . . 0.0 110.782 175.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -146.05 138.08 25.17 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-N 121.149 1.795 . . . . 0.0 112.126 -179.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.7 p-10 -87.65 -61.85 1.63 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.108 171.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -146.83 128.38 15.08 Favored 'General case' 0 CA--C 1.568 1.637 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 174.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.85 106.29 0.1 Allowed 'General case' 0 CA--C 1.571 1.771 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.58 -46.55 1.07 Allowed Glycine 0 N--CA 1.491 2.363 0 CA-C-O 118.406 -1.219 . . . . 0.0 115.416 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -84.15 -61.93 1.69 Allowed 'General case' 0 CA--C 1.57 1.726 0 N-CA-C 116.291 1.959 . . . . 0.0 116.291 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.97 -121.47 0.77 Allowed Glycine 0 N--CA 1.489 2.174 0 CA-C-N 120.471 1.487 . . . . 0.0 115.752 -176.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -116.27 176.51 5.07 Favored 'General case' 0 CA--C 1.566 1.578 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -166.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.52 147.85 28.69 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.234 -1.541 . . . . 0.0 112.363 175.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -75.1 -46.24 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.627 -0.671 . . . . 0.0 111.263 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t . . . . . 0 N--CA 1.495 1.781 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 169.5 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.576 1.957 0 N-CA-C 119.459 3.133 . . . . 0.0 119.459 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.3 0.2 OUTLIER -90.15 179.23 5.97 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 121.613 2.006 . . . . 0.0 115.004 -174.401 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -98.25 -42.78 2.92 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 118.707 2.243 . . . . 0.0 118.707 178.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -82.85 56.41 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 117.486 2.402 . . . . 0.0 117.486 -173.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -153.0 175.25 31.58 Favored Glycine 0 N--CA 1.49 2.255 0 O-C-N 120.902 -1.124 . . . . 0.0 115.302 172.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.6 p -122.03 54.7 1.15 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.267 12.4 p -164.49 -130.82 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 C-N-CA 123.875 0.87 . . . . 0.0 110.156 174.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -150.05 133.1 16.2 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 119.988 -1.695 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.13 -58.06 2.92 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -141.35 77.11 1.58 Allowed 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 118.845 0.748 . . . . 0.0 111.909 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 36.38 75.5 0.06 Allowed 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 119.036 2.976 . . . . 0.0 119.036 175.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.24 -17.95 57.26 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 119.16 2.424 . . . . 0.0 119.16 -173.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.7 t -60.68 -52.75 63.81 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 116.758 2.133 . . . . 0.0 116.758 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.1 -120.86 0.65 Allowed Glycine 0 N--CA 1.489 2.169 0 O-C-N 121.573 -0.705 . . . . 0.0 112.258 175.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -122.62 172.54 8.32 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.941 0.897 . . . . 0.0 112.319 -173.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.0 141.96 34.31 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.393 -1.442 . . . . 0.0 111.606 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.7 m -73.18 -35.21 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 175.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t . . . . . 0 N--CA 1.497 1.911 0 CA-C-N 120.027 1.285 . . . . 0.0 107.875 175.239 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.2 m . . . . . 0 CA--C 1.577 1.982 0 N-CA-C 119.127 3.01 . . . . 0.0 119.127 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.259 0.3 OUTLIER -88.84 170.92 10.32 Favored 'General case' 0 N--CA 1.499 1.996 0 CA-C-N 122.024 2.193 . . . . 0.0 115.691 -172.741 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.9 50.12 0.8 Allowed Glycine 0 N--CA 1.5 2.921 0 N-CA-C 116.734 1.454 . . . . 0.0 116.734 176.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.53 -53.97 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 C-N-CA 124.193 0.997 . . . . 0.0 110.181 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.97 175.91 17.61 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 118.186 2.034 . . . . 0.0 118.186 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 t -116.67 48.03 1.35 Allowed 'General case' 0 N--CA 1.502 2.157 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -176.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 22.9 p -162.68 -120.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.787 -1.196 . . . . 0.0 111.426 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -148.13 138.61 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 CA-C-N 121.477 1.944 . . . . 0.0 112.966 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.41 -68.33 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 114.514 -1.221 . . . . 0.0 111.934 174.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.69 81.43 1.65 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 123.1 0.56 . . . . 0.0 112.057 -172.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.9 77.86 0.09 Allowed 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 117.991 2.589 . . . . 0.0 117.991 174.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.47 -16.76 22.88 Favored Glycine 0 N--CA 1.499 2.883 0 N-CA-C 119.876 2.71 . . . . 0.0 119.876 -176.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.2 t -56.83 -47.0 81.31 Favored 'General case' 0 N--CA 1.501 2.09 0 N-CA-C 117.447 2.388 . . . . 0.0 117.447 -178.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.66 -129.71 1.49 Allowed Glycine 0 N--CA 1.486 1.981 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -118.17 179.67 4.03 Favored 'General case' 0 CA--C 1.564 1.491 0 CA-C-O 122.01 0.909 . . . . 0.0 113.1 -174.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -158.79 148.97 19.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.342 -1.474 . . . . 0.0 112.287 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -70.76 -42.88 77.61 Favored 'Isoleucine or valine' 0 CA--C 1.581 2.162 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 165.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t . . . . . 0 N--CA 1.497 1.886 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 168.373 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.573 1.859 0 N-CA-C 119.43 3.122 . . . . 0.0 119.43 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.324 0.9 OUTLIER -110.42 -161.89 0.77 Allowed 'General case' 0 CA--C 1.58 2.105 0 CA-C-N 120.843 1.656 . . . . 0.0 114.871 -176.107 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.33 63.19 0.42 Allowed Glycine 0 N--CA 1.502 3.041 0 N-CA-C 117.89 1.916 . . . . 0.0 117.89 -175.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.575 1.927 0 C-N-CA 124.343 1.057 . . . . 0.0 108.948 172.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -73.35 177.53 43.02 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 119.766 2.667 . . . . 0.0 119.766 -177.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 p -114.68 54.01 0.79 Allowed 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 115.165 1.543 . . . . 0.0 115.165 -175.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.4 p -169.22 134.27 1.51 Allowed 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 124.332 1.053 . . . . 0.0 109.546 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -70.12 129.25 38.91 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 37.8 p-10 -75.19 -60.29 2.36 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 177.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -144.01 85.76 1.82 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 123.448 0.699 . . . . 0.0 109.476 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 11.19 74.87 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.207 0 N-CA-C 121.024 3.713 . . . . 0.0 121.024 175.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.58 -38.8 2.53 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 117.008 1.563 . . . . 0.0 117.008 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.4 t -63.91 -56.98 11.24 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 116.873 2.175 . . . . 0.0 116.873 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.91 -122.31 0.87 Allowed Glycine 0 N--CA 1.488 2.104 0 O-C-N 121.269 -0.894 . . . . 0.0 113.921 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -136.55 150.37 48.58 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 124.031 0.932 . . . . 0.0 113.487 -170.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.31 141.13 39.14 Favored 'General case' 0 CA--C 1.563 1.447 0 C-N-CA 123.768 0.827 . . . . 0.0 110.984 175.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -73.54 -40.49 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 120.94 -1.1 . . . . 0.0 112.645 171.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t . . . . . 0 N--CA 1.495 1.819 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 171.825 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.576 1.943 0 N-CA-C 119.995 3.331 . . . . 0.0 119.995 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -78.48 178.45 7.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 121.859 2.118 . . . . 0.0 113.933 177.469 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -123.51 56.13 0.68 Allowed Glycine 0 N--CA 1.501 3.012 0 O-C-N 120.297 -1.502 . . . . 0.0 116.725 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.86 -53.45 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.576 1.961 0 C-N-CA 124.411 1.084 . . . . 0.0 109.54 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -63.63 158.89 39.41 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 119.137 2.415 . . . . 0.0 119.137 -177.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -99.47 44.77 1.01 Allowed 'General case' 0 N--CA 1.5 2.075 0 N-CA-C 116.239 1.941 . . . . 0.0 116.239 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.5 p -175.62 152.42 1.3 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 125.156 1.383 . . . . 0.0 109.676 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -67.38 144.81 55.6 Favored 'General case' 0 CA--C 1.58 2.111 0 N-CA-C 116.708 2.114 . . . . 0.0 116.708 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -76.14 -70.03 0.47 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 118.002 -0.999 . . . . 0.0 112.139 172.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -153.48 100.96 2.46 Favored 'General case' 0 CA--C 1.563 1.476 0 CA-C-N 120.012 1.278 . . . . 0.0 109.39 -173.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 45.62 67.81 0.68 Allowed 'General case' 0 CA--C 1.574 1.889 0 N-CA-C 119.005 2.965 . . . . 0.0 119.005 173.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.65 -11.97 57.71 Favored Glycine 0 N--CA 1.499 2.874 0 N-CA-C 120.93 3.132 . . . . 0.0 120.93 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.14 -39.26 93.64 Favored 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 117.975 2.583 . . . . 0.0 117.975 -176.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.95 -123.02 1.08 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 124.277 0.942 . . . . 0.0 111.126 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -131.21 171.73 12.95 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.89 151.71 29.79 Favored 'General case' 0 CA--C 1.562 1.434 0 O-C-N 120.344 -1.472 . . . . 0.0 111.738 174.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.67 -46.46 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.389 0 O-C-N 121.027 -1.046 . . . . 0.0 111.686 166.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.9 t . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 169.342 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 t . . . . . 0 N--CA 1.498 1.938 0 N-CA-C 119.609 3.189 . . . . 0.0 119.609 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.36 171.47 13.48 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-N 121.583 1.992 . . . . 0.0 114.57 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -119.75 55.21 0.62 Allowed Glycine 0 N--CA 1.502 3.038 0 N-CA-C 116.149 1.22 . . . . 0.0 116.149 175.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.11 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 124.61 1.164 . . . . 0.0 109.099 177.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.28 170.55 34.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 118.631 2.212 . . . . 0.0 118.631 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.2 p -114.63 55.73 0.74 Allowed 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 115.184 1.55 . . . . 0.0 115.184 -175.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 25.2 p -162.92 -129.05 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.14 -0.975 . . . . 0.0 110.967 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -145.24 138.3 26.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 119.983 -1.698 . . . . 0.0 111.301 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -85.79 -58.17 2.76 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 123.926 0.89 . . . . 0.0 111.303 172.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -150.14 134.48 17.25 Favored 'General case' 0 CA--C 1.571 1.762 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 172.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -44.9 113.12 0.51 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.802 2.149 . . . . 0.0 116.802 -177.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.65 -27.96 16.88 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 118.358 2.103 . . . . 0.0 118.358 -171.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.49 -53.78 5.44 Favored 'General case' 0 CA--C 1.573 1.845 0 CA-C-N 119.806 1.803 . . . . 0.0 115.687 -177.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.5 -133.08 2.71 Favored Glycine 0 N--CA 1.49 2.266 0 O-C-N 121.09 -1.006 . . . . 0.0 113.939 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -113.09 175.73 5.32 Favored 'General case' 0 CA--C 1.566 1.589 0 CA-C-O 122.02 0.914 . . . . 0.0 113.383 -170.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.2 146.54 31.78 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.106 -1.621 . . . . 0.0 112.542 176.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.5 t -77.87 -43.23 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.578 -0.701 . . . . 0.0 111.874 170.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t . . . . . 0 N--CA 1.497 1.88 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 172.758 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.574 1.885 0 N-CA-C 119.561 3.171 . . . . 0.0 119.561 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.365 1.3 pt? -98.35 -161.02 0.84 Allowed 'General case' 0 CA--C 1.577 2.016 0 CA-C-N 121.647 2.021 . . . . 0.0 115.397 -173.096 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.44 64.57 0.41 Allowed Glycine 0 N--CA 1.5 2.938 0 O-C-N 119.758 -1.839 . . . . 0.0 117.647 -175.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.11 -54.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.899 0 C-N-CA 124.227 1.011 . . . . 0.0 108.941 172.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.81 179.12 47.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 119.674 2.63 . . . . 0.0 119.674 -177.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.6 p -115.21 53.06 0.84 Allowed 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 -177.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.0 p -167.61 134.49 2.22 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 124.342 1.057 . . . . 0.0 109.695 -179.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -69.37 132.33 46.21 Favored 'General case' 0 CA--C 1.573 1.831 0 N-CA-C 115.462 1.653 . . . . 0.0 115.462 -173.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.2 p-10 -73.68 -67.44 0.59 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 113.455 0.909 . . . . 0.0 113.455 176.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -139.42 76.43 1.56 Allowed 'General case' 0 N--CA 1.494 1.767 0 CA-C-N 118.634 0.652 . . . . 0.0 112.007 -171.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 41.7 79.08 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 118.392 2.738 . . . . 0.0 118.392 175.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.22 -22.93 20.66 Favored Glycine 0 N--CA 1.498 2.81 0 N-CA-C 119.164 2.425 . . . . 0.0 119.164 -174.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -58.22 -49.66 76.31 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 117.552 2.427 . . . . 0.0 117.552 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.37 -125.92 1.15 Allowed Glycine 0 N--CA 1.487 2.036 0 O-C-N 121.547 -0.721 . . . . 0.0 112.332 177.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -140.72 146.94 38.42 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -173.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -109.38 142.85 39.74 Favored 'General case' 0 CA--C 1.563 1.443 0 C-N-CA 123.558 0.743 . . . . 0.0 111.366 174.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -71.42 -43.8 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 120.797 -1.189 . . . . 0.0 112.423 170.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t . . . . . 0 N--CA 1.496 1.848 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 169.934 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 t . . . . . 0 CA--C 1.574 1.868 0 N-CA-C 119.36 3.096 . . . . 0.0 119.36 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.13 173.19 6.41 Favored 'General case' 0 CA--C 1.576 1.959 0 CA-C-N 120.618 1.554 . . . . 0.0 114.452 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.52 56.29 0.63 Allowed Glycine 0 N--CA 1.501 3.026 0 N-CA-C 116.127 1.211 . . . . 0.0 116.127 175.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.5 -52.91 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 C-N-CA 124.488 1.115 . . . . 0.0 109.418 177.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.91 178.44 25.48 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 119.064 2.385 . . . . 0.0 119.064 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -119.82 50.41 1.28 Allowed 'General case' 0 N--CA 1.5 2.05 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 -175.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.253 22.4 p -157.25 -129.31 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.84 -1.162 . . . . 0.0 110.821 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -144.42 135.67 25.4 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.765 1.621 . . . . 0.0 111.071 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.4 p-10 -86.82 -60.41 1.99 Allowed 'General case' 0 N--CA 1.491 1.608 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.336 173.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -147.16 127.42 13.88 Favored 'General case' 0 CA--C 1.566 1.595 0 N-CA-C 105.364 -2.087 . . . . 0.0 105.364 173.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.85 106.8 0.1 Allowed 'General case' 0 CA--C 1.574 1.868 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.1 -46.03 1.1 Allowed Glycine 0 N--CA 1.492 2.406 0 CA-C-O 118.436 -1.202 . . . . 0.0 115.497 -169.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.4 t -83.57 -61.62 1.79 Allowed 'General case' 0 CA--C 1.569 1.677 0 N-CA-C 116.282 1.956 . . . . 0.0 116.282 -178.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.53 -121.19 0.76 Allowed Glycine 0 N--CA 1.488 2.133 0 CA-C-N 120.504 1.502 . . . . 0.0 115.803 -177.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.43 174.72 5.91 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -166.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.89 147.03 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 120.348 -1.47 . . . . 0.0 112.113 174.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.7 t -76.93 -44.0 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.575 -0.703 . . . . 0.0 112.61 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.5 t . . . . . 0 N--CA 1.496 1.861 0 CA-C-N 119.668 1.122 . . . . 0.0 108.095 175.613 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.574 1.887 0 N-CA-C 120.325 3.454 . . . . 0.0 120.325 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.3 179.55 4.55 Favored 'General case' 0 CA--C 1.579 2.073 0 CA-C-N 121.093 1.77 . . . . 0.0 114.088 178.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -124.21 58.46 0.64 Allowed Glycine 0 N--CA 1.501 3.005 0 O-C-N 120.259 -1.525 . . . . 0.0 116.697 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -131.54 -54.75 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 124.403 1.081 . . . . 0.0 109.391 176.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.58 -179.97 28.76 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 119.232 2.453 . . . . 0.0 119.232 -177.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -121.29 43.79 2.71 Favored 'General case' 0 N--CA 1.504 2.272 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -175.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 21.1 p -163.56 139.81 6.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.79 -1.194 . . . . 0.0 109.821 177.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -63.5 137.81 58.27 Favored 'General case' 0 CA--C 1.577 2.014 0 N-CA-C 116.266 1.95 . . . . 0.0 116.266 -174.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.277 39.1 p-10 -80.68 -80.86 0.13 Allowed 'General case' 0 N--CA 1.489 1.512 0 CA-C-O 118.237 -0.887 . . . . 0.0 113.223 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -121.29 55.42 1.07 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -173.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . 0.264 . . 57.65 7.56 0.56 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 121.762 3.986 . . . . 0.0 121.762 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.61 64.02 0.03 OUTLIER Glycine 0 N--CA 1.491 2.322 0 O-C-N 120.866 -1.146 . . . . 0.0 115.152 -177.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 54.0 t -156.84 -64.68 0.1 Allowed 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 123.589 0.756 . . . . 0.0 111.464 177.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.77 -117.83 0.46 Allowed Glycine 0 N--CA 1.483 1.788 0 O-C-N 121.633 -0.667 . . . . 0.0 112.391 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -129.23 172.23 11.66 Favored 'General case' 0 CA--C 1.566 1.591 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -168.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.45 143.87 47.78 Favored 'General case' 0 CA--C 1.563 1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 110.705 173.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.1 t -74.06 -43.92 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.106 -0.996 . . . . 0.0 112.326 171.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.6 t . . . . . 0 N--CA 1.495 1.804 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 172.035 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 120.275 3.435 . . . . 0.0 120.275 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.43 166.75 18.11 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 121.859 2.118 . . . . 0.0 115.161 -178.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.37 49.96 0.81 Allowed Glycine 0 N--CA 1.5 2.9 0 N-CA-C 116.701 1.441 . . . . 0.0 116.701 176.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -133.58 -55.23 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 124.334 1.054 . . . . 0.0 109.991 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.71 169.35 38.09 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 118.311 2.084 . . . . 0.0 118.311 -178.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.8 p -109.77 56.15 0.63 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 115.526 1.676 . . . . 0.0 115.526 -174.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.254 22.5 p -164.26 -131.71 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.124 -0.985 . . . . 0.0 111.111 176.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -146.36 136.26 23.4 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 119.933 -1.73 . . . . 0.0 111.295 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.0 p30 -82.84 -63.32 1.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.012 -0.995 . . . . 0.0 111.136 174.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -145.24 124.0 12.61 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.956 -2.239 . . . . 0.0 104.956 174.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -38.36 111.18 0.16 Allowed 'General case' 0 CA--C 1.573 1.839 0 N-CA-C 117.892 2.553 . . . . 0.0 117.892 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.05 -32.25 7.04 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 117.917 1.927 . . . . 0.0 117.917 -171.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -80.31 -51.67 8.62 Favored 'General case' 0 CA--C 1.574 1.867 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 -176.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.14 -135.13 3.46 Favored Glycine 0 N--CA 1.49 2.295 0 O-C-N 121.203 -0.936 . . . . 0.0 113.243 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -114.23 178.98 4.09 Favored 'General case' 0 CA--C 1.567 1.607 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -171.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.96 145.3 30.6 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.058 -1.651 . . . . 0.0 112.262 175.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.4 t -75.82 -45.34 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 O-C-N 121.393 -0.817 . . . . 0.0 111.691 171.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t . . . . . 0 N--CA 1.496 1.842 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 171.576 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.497 1.898 0 N-CA-C 119.781 3.252 . . . . 0.0 119.781 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.41 171.6 13.3 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 121.59 1.996 . . . . 0.0 114.571 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.48 55.57 0.63 Allowed Glycine 0 N--CA 1.5 2.955 0 N-CA-C 116.015 1.166 . . . . 0.0 116.015 175.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.58 -52.55 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.89 0 C-N-CA 124.737 1.215 . . . . 0.0 109.055 177.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.16 173.92 31.18 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 118.673 2.229 . . . . 0.0 118.673 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -117.8 51.16 1.07 Allowed 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 115.317 1.599 . . . . 0.0 115.317 -175.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.256 25.6 p -157.48 -128.63 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.83 -1.169 . . . . 0.0 110.963 174.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -145.66 135.87 23.87 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-N 120.903 1.683 . . . . 0.0 111.533 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p-10 -83.34 -60.6 2.09 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.988 172.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -147.53 135.3 21.08 Favored 'General case' 0 CA--C 1.572 1.816 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 171.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.17 113.69 0.61 Allowed 'General case' 0 CA--C 1.573 1.842 0 N-CA-C 116.795 2.146 . . . . 0.0 116.795 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.26 -26.88 22.28 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 118.431 2.132 . . . . 0.0 118.431 -171.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.57 -54.02 5.24 Favored 'General case' 0 CA--C 1.573 1.849 0 CA-C-N 119.809 1.805 . . . . 0.0 115.606 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.46 -133.0 2.69 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 121.079 -1.013 . . . . 0.0 113.942 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -112.86 175.32 5.49 Favored 'General case' 0 CA--C 1.567 1.605 0 CA-C-O 122.121 0.962 . . . . 0.0 113.354 -170.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.09 147.01 33.19 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.159 -1.588 . . . . 0.0 112.092 175.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 66.2 t -77.77 -42.52 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 O-C-N 121.544 -0.722 . . . . 0.0 112.493 172.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t . . . . . 0 N--CA 1.497 1.901 0 CA-C-N 119.839 1.2 . . . . 0.0 108.12 175.105 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 t . . . . . 0 N--CA 1.498 1.97 0 N-CA-C 119.886 3.291 . . . . 0.0 119.886 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.77 166.04 17.29 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 121.615 2.007 . . . . 0.0 114.861 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -110.85 48.77 0.9 Allowed Glycine 0 N--CA 1.501 2.984 0 N-CA-C 116.957 1.543 . . . . 0.0 116.957 177.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.53 -55.67 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 C-N-CA 124.168 0.987 . . . . 0.0 110.267 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.52 34.84 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 118.612 2.205 . . . . 0.0 118.612 -177.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.7 p -112.99 58.15 0.66 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 19.4 p -165.71 -132.7 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 110.868 175.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -144.03 139.3 28.91 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 119.877 -1.765 . . . . 0.0 111.313 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.4 p-10 -90.65 -65.61 1.0 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.95 176.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -139.82 77.44 1.61 Allowed 'General case' 0 N--CA 1.494 1.744 0 CA-C-N 119.06 0.845 . . . . 0.0 111.254 -175.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 32.64 80.68 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 119.403 3.112 . . . . 0.0 119.403 174.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.48 -28.45 14.13 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 118.391 2.116 . . . . 0.0 118.391 -173.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.4 t -59.93 -41.37 91.63 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 117.298 2.333 . . . . 0.0 117.298 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.35 -135.94 3.93 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 124.024 0.821 . . . . 0.0 111.814 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -115.36 176.65 4.97 Favored 'General case' 0 CA--C 1.565 1.533 0 CA-C-O 122.084 0.945 . . . . 0.0 113.257 -173.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.0 144.92 37.22 Favored 'General case' 0 CA--C 1.562 1.432 0 O-C-N 120.258 -1.526 . . . . 0.0 111.776 175.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -74.75 -42.26 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 174.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 N--CA 1.496 1.845 0 CA-C-N 119.883 1.22 . . . . 0.0 108.033 175.712 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 119.08 2.993 . . . . 0.0 119.08 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.85 169.15 14.43 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 121.34 1.882 . . . . 0.0 114.585 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -112.48 48.17 0.97 Allowed Glycine 0 N--CA 1.499 2.878 0 N-CA-C 117.097 1.599 . . . . 0.0 117.097 177.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -131.5 -54.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 124.156 0.982 . . . . 0.0 110.179 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.8 172.67 23.93 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 p -114.34 54.06 0.78 Allowed 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 115.53 1.678 . . . . 0.0 115.53 -175.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.262 22.0 p -165.99 -124.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.18 -0.95 . . . . 0.0 110.841 176.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -147.85 140.44 24.6 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-N 120.94 1.7 . . . . 0.0 111.717 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -82.47 -71.67 0.48 Allowed 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.469 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -145.26 85.91 1.75 Allowed 'General case' 0 CA--C 1.566 1.585 0 CA-C-N 119.548 1.067 . . . . 0.0 111.736 -179.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 50.89 81.66 0.07 Allowed 'General case' 0 CA--C 1.571 1.782 0 N-CA-C 118.017 2.599 . . . . 0.0 118.017 173.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.52 -21.97 8.19 Favored Glycine 0 N--CA 1.5 2.929 0 N-CA-C 120.31 2.884 . . . . 0.0 120.31 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.1 t -59.43 -39.55 83.9 Favored 'General case' 0 N--CA 1.5 2.074 0 N-CA-C 117.689 2.477 . . . . 0.0 117.689 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.5 -132.85 2.61 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 124.108 0.861 . . . . 0.0 111.239 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -117.95 178.47 4.41 Favored 'General case' 0 CA--C 1.565 1.548 0 CA-C-O 122.127 0.965 . . . . 0.0 113.446 -173.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -155.73 146.28 21.96 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.371 -1.456 . . . . 0.0 112.594 175.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . 0.253 9.4 p -69.15 -45.95 78.79 Favored 'Isoleucine or valine' 0 CA--C 1.58 2.096 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 166.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.5 t . . . . . 0 CA--C 1.571 1.757 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 169.317 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.498 1.927 0 N-CA-C 120.815 3.635 . . . . 0.0 120.815 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.252 0.3 OUTLIER -80.77 174.32 11.73 Favored 'General case' 0 CA--C 1.578 2.025 0 CA-C-N 122.136 2.244 . . . . 0.0 114.381 178.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.49 57.74 0.6 Allowed Glycine 0 N--CA 1.501 2.981 0 O-C-N 120.404 -1.435 . . . . 0.0 116.455 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.29 -53.91 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 C-N-CA 124.513 1.125 . . . . 0.0 108.981 176.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.46 168.67 42.12 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 118.417 2.127 . . . . 0.0 118.417 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -112.66 43.11 1.71 Allowed 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.8 p -164.83 142.77 6.43 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 124.546 1.138 . . . . 0.0 109.729 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.7 140.23 58.85 Favored 'General case' 0 CA--C 1.579 2.085 0 N-CA-C 118.006 2.595 . . . . 0.0 118.006 -171.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p30 -79.7 -60.99 2.13 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 123.444 0.698 . . . . 0.0 111.637 172.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -151.7 94.0 1.93 Allowed 'General case' 0 CA--C 1.566 1.595 0 CA-C-N 119.732 1.151 . . . . 0.0 109.202 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 13.42 83.28 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 121.438 3.866 . . . . 0.0 121.438 175.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.42 -35.74 4.2 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 117.648 1.819 . . . . 0.0 117.648 -174.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.7 t -68.88 -45.04 72.0 Favored 'General case' 0 CA--C 1.577 2.005 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 -177.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 160.47 -130.88 2.49 Favored Glycine 0 N--CA 1.489 2.203 0 O-C-N 121.359 -0.838 . . . . 0.0 112.745 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -125.09 171.66 10.1 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -170.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.23 140.96 37.88 Favored 'General case' 0 CA--C 1.564 1.49 0 O-C-N 120.364 -1.46 . . . . 0.0 110.615 175.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.1 m -69.03 -39.56 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.058 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.1 t . . . . . 0 N--CA 1.494 1.756 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 168.714 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.573 1.865 0 N-CA-C 119.177 3.029 . . . . 0.0 119.177 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.43 169.47 8.68 Favored 'General case' 0 CA--C 1.575 1.906 0 CA-C-N 120.664 1.575 . . . . 0.0 114.703 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.26 52.26 0.66 Allowed Glycine 0 N--CA 1.5 2.937 0 N-CA-C 116.669 1.428 . . . . 0.0 116.669 177.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.23 -54.83 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 C-N-CA 124.112 0.965 . . . . 0.0 110.211 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.53 177.73 25.27 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 118.825 2.29 . . . . 0.0 118.825 -177.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.7 t -116.43 53.46 0.88 Allowed 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 115.047 1.499 . . . . 0.0 115.047 -175.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -162.16 -129.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.92 -1.113 . . . . 0.0 110.974 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -144.1 139.89 29.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.932 -1.73 . . . . 0.0 110.832 178.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -90.97 -60.06 2.01 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 123.637 0.775 . . . . 0.0 111.256 172.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -147.22 127.25 13.67 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 174.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.84 106.56 0.09 Allowed 'General case' 0 CA--C 1.572 1.81 0 N-CA-C 116.001 1.852 . . . . 0.0 116.001 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.39 -46.02 1.1 Allowed Glycine 0 N--CA 1.492 2.381 0 CA-C-O 118.509 -1.162 . . . . 0.0 115.687 -169.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.3 t -83.46 -60.71 2.05 Favored 'General case' 0 CA--C 1.569 1.698 0 N-CA-C 116.611 2.078 . . . . 0.0 116.611 -178.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 178.24 -124.9 0.95 Allowed Glycine 0 N--CA 1.49 2.284 0 CA-C-N 120.314 1.416 . . . . 0.0 115.356 -176.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -115.05 178.19 4.38 Favored 'General case' 0 CA--C 1.566 1.577 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -168.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.6 141.29 33.47 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.346 -1.472 . . . . 0.0 112.087 175.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.86 -39.8 52.39 Favored 'Isoleucine or valine' 0 CA--C 1.576 1.951 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 170.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.1 t . . . . . 0 N--CA 1.496 1.848 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 170.94 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.498 1.955 0 N-CA-C 118.742 2.868 . . . . 0.0 118.742 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.3 173.51 11.53 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 121.056 1.753 . . . . 0.0 114.203 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.1 55.11 0.65 Allowed Glycine 0 N--CA 1.501 3.005 0 N-CA-C 116.217 1.247 . . . . 0.0 116.217 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.86 -52.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 C-N-CA 124.662 1.185 . . . . 0.0 109.195 177.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.82 172.87 23.65 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 118.506 2.163 . . . . 0.0 118.506 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -117.61 49.08 1.26 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 115.185 1.55 . . . . 0.0 115.185 -177.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.25 26.2 p -159.23 -122.8 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.85 -1.156 . . . . 0.0 110.961 175.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -147.56 142.35 26.78 Favored 'General case' 0 N--CA 1.491 1.625 0 CA-C-N 120.934 1.697 . . . . 0.0 111.999 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -91.01 -63.21 1.3 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 124.515 1.126 . . . . 0.0 113.343 176.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 94.4 m-85 -140.77 78.13 1.63 Allowed 'General case' 0 N--CA 1.495 1.808 0 CA-C-N 119.079 0.854 . . . . 0.0 111.237 -173.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 38.79 75.24 0.08 Allowed 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 118.717 2.858 . . . . 0.0 118.717 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.14 -19.83 51.09 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 119.545 2.578 . . . . 0.0 119.545 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.9 t -61.49 -41.35 97.14 Favored 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 117.766 2.506 . . . . 0.0 117.766 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.34 -128.04 1.49 Allowed Glycine 0 N--CA 1.489 2.198 0 O-C-N 121.361 -0.837 . . . . 0.0 111.726 177.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -120.04 174.25 6.59 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-O 122.058 0.932 . . . . 0.0 113.242 -173.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.26 147.36 25.59 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.403 -1.435 . . . . 0.0 112.787 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -73.4 -42.14 56.86 Favored 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 165.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.6 t -91.74 110.92 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 170.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 63.6 m -84.62 122.94 29.76 Favored 'General case' 0 CA--C 1.568 1.641 0 O-C-N 121.534 -0.729 . . . . 0.0 112.714 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -73.62 97.83 2.73 Favored 'General case' 0 CA--C 1.573 1.862 0 CA-C-O 122.991 1.377 . . . . 0.0 113.884 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 60.9 p-90 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 124.719 2.199 . . . . 0.0 114.064 -177.577 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.499 1.977 0 N-CA-C 120.745 3.609 . . . . 0.0 120.745 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.254 0.2 OUTLIER -80.56 176.18 10.01 Favored 'General case' 0 CA--C 1.579 2.075 0 CA-C-N 122.044 2.202 . . . . 0.0 114.139 177.942 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.45 56.27 0.61 Allowed Glycine 0 N--CA 1.501 3.013 0 O-C-N 120.206 -1.558 . . . . 0.0 116.828 176.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.0 mt -129.48 -59.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 C-N-CA 124.273 1.029 . . . . 0.0 109.455 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.31 172.02 42.26 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 119.836 2.694 . . . . 0.0 119.836 -175.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.8 p -110.74 51.23 0.78 Allowed 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -175.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.4 p -169.9 140.01 1.99 Allowed 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.44 1.096 . . . . 0.0 109.627 178.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -66.48 133.67 50.87 Favored 'General case' 0 CA--C 1.576 1.964 0 N-CA-C 115.652 1.723 . . . . 0.0 115.652 -176.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.254 26.3 p30 -71.54 -72.34 0.23 Allowed 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 123.77 0.828 . . . . 0.0 112.884 177.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -144.21 87.75 1.91 Allowed 'General case' 0 CA--C 1.566 1.588 0 CA-C-N 119.42 1.009 . . . . 0.0 110.923 -178.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.79 82.72 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 118.366 2.728 . . . . 0.0 118.366 173.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.94 -23.94 5.58 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 120.097 2.799 . . . . 0.0 120.097 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.9 t -58.82 -40.78 85.17 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 117.907 2.558 . . . . 0.0 117.907 -176.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.15 -126.11 1.47 Allowed Glycine 0 N--CA 1.488 2.137 0 C-N-CA 124.003 0.811 . . . . 0.0 111.368 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -131.18 169.1 16.38 Favored 'General case' 0 CA--C 1.569 1.694 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -172.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.61 142.75 49.96 Favored 'General case' 0 CA--C 1.564 1.507 0 O-C-N 120.569 -1.332 . . . . 0.0 110.796 174.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.2 t -75.03 -38.53 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.294 0 O-C-N 120.954 -1.091 . . . . 0.0 113.57 173.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -87.82 96.5 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.802 -1.186 . . . . 0.0 108.307 176.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 82.1 m -91.25 83.24 5.49 Favored 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 114.079 1.141 . . . . 0.0 114.079 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.58 108.91 4.82 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 122.205 1.002 . . . . 0.0 108.878 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 59.8 m95 . . . . . 0 N--CA 1.495 1.824 0 CA-C-O 124.355 2.026 . . . . 0.0 113.871 -175.329 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.575 1.917 0 N-CA-C 120.421 3.489 . . . . 0.0 120.421 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.04 173.76 6.16 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 121.006 1.73 . . . . 0.0 113.882 177.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -117.81 54.03 0.62 Allowed Glycine 0 N--CA 1.501 2.976 0 O-C-N 120.306 -1.496 . . . . 0.0 116.595 176.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.25 -54.94 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 124.274 1.03 . . . . 0.0 109.631 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.88 173.86 30.27 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 118.09 1.996 . . . . 0.0 118.09 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.8 t -116.04 43.83 2.06 Favored 'General case' 0 N--CA 1.504 2.249 0 N-CA-C 116.083 1.882 . . . . 0.0 116.083 -175.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 18.5 p -166.77 142.55 4.43 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.752 -1.218 . . . . 0.0 110.367 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -57.55 133.78 55.55 Favored 'General case' 0 CA--C 1.581 2.173 0 N-CA-C 117.616 2.45 . . . . 0.0 117.616 -174.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -81.85 -64.14 1.24 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 123.041 0.536 . . . . 0.0 112.406 171.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -148.59 120.98 8.45 Favored 'General case' 0 CA--C 1.566 1.565 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.46 105.64 0.06 Allowed 'General case' 0 CA--C 1.573 1.828 0 N-CA-C 116.834 2.161 . . . . 0.0 116.834 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.68 -45.59 1.13 Allowed Glycine 0 N--CA 1.491 2.354 0 CA-C-O 118.548 -1.14 . . . . 0.0 115.816 -170.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 31.2 t -83.52 -59.01 2.58 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 116.809 2.151 . . . . 0.0 116.809 -178.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.62 -121.64 0.9 Allowed Glycine 0 N--CA 1.487 2.07 0 CA-C-N 119.918 1.236 . . . . 0.0 114.242 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -124.37 172.37 9.19 Favored 'General case' 0 CA--C 1.566 1.573 0 N-CA-C 115.248 1.573 . . . . 0.0 115.248 -167.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.22 144.48 48.46 Favored 'General case' 0 CA--C 1.561 1.381 0 O-C-N 120.542 -1.349 . . . . 0.0 111.073 174.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -72.31 -43.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 121.0 -1.063 . . . . 0.0 111.57 168.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -86.12 110.98 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 168.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 97.3 m -73.0 115.59 12.49 Favored 'General case' 0 CA--C 1.567 1.62 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -82.79 97.05 8.4 Favored 'General case' 0 CA--C 1.569 1.687 0 CA-C-O 122.155 0.979 . . . . 0.0 112.988 -173.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 57.1 p-90 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 123.091 1.425 . . . . 0.0 111.969 179.712 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.4 t . . . . . 0 CA--C 1.575 1.937 0 N-CA-C 121.185 3.772 . . . . 0.0 121.185 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 173.36 6.34 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-N 121.364 1.893 . . . . 0.0 113.806 177.034 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.71 51.21 0.73 Allowed Glycine 0 N--CA 1.502 3.034 0 O-C-N 119.971 -1.706 . . . . 0.0 117.326 176.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -132.53 -56.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 C-N-CA 123.938 0.895 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.97 168.13 41.2 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 119.283 2.473 . . . . 0.0 119.283 -174.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.7 p -105.99 55.13 0.68 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -174.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 19.2 p -178.15 140.62 0.23 Allowed 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 125.021 1.329 . . . . 0.0 109.263 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -69.64 136.25 50.93 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 116.274 1.953 . . . . 0.0 116.274 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 49.7 p30 -78.2 -63.66 1.34 Allowed 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 123.194 0.597 . . . . 0.0 112.104 175.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -147.93 124.41 11.01 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.653 -2.351 . . . . 0.0 104.653 175.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.08 105.81 0.06 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.386 1.995 . . . . 0.0 116.386 179.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.89 -47.23 1.03 Allowed Glycine 0 N--CA 1.491 2.329 0 CA-C-O 118.366 -1.241 . . . . 0.0 115.335 -169.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 t -86.08 -61.95 1.63 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.37 -119.98 0.78 Allowed Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.942 1.246 . . . . 0.0 114.351 -175.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -126.89 172.83 10.08 Favored 'General case' 0 CA--C 1.571 1.754 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -167.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -130.5 141.56 50.5 Favored 'General case' 0 CA--C 1.563 1.473 0 O-C-N 120.281 -1.512 . . . . 0.0 110.855 174.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 -41.8 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.02 -1.05 . . . . 0.0 112.628 171.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -90.28 108.01 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 172.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.4 m -83.08 105.36 14.0 Favored 'General case' 0 CA--C 1.567 1.609 0 CA-C-O 121.674 0.75 . . . . 0.0 112.164 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -85.59 97.35 10.03 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 122.053 0.93 . . . . 0.0 112.298 -175.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 53.9 p-90 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 123.108 1.432 . . . . 0.0 112.087 179.537 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 m . . . . . 0 CA--C 1.575 1.919 0 N-CA-C 120.431 3.493 . . . . 0.0 120.431 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.255 0.3 OUTLIER -89.99 169.26 11.36 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-N 122.247 2.294 . . . . 0.0 116.066 -172.449 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.01 51.83 0.68 Allowed Glycine 0 N--CA 1.5 2.932 0 N-CA-C 117.032 1.573 . . . . 0.0 117.032 177.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.07 -56.66 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 C-N-CA 123.883 0.873 . . . . 0.0 110.228 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -69.75 175.91 33.45 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 118.712 2.245 . . . . 0.0 118.712 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 p -114.24 56.23 0.72 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 115.499 1.666 . . . . 0.0 115.499 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.269 11.7 p -164.59 -129.38 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.194 -0.941 . . . . 0.0 110.98 176.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -144.92 142.42 29.85 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 121.143 1.792 . . . . 0.0 111.74 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -91.9 -73.54 0.54 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-N 114.254 -1.339 . . . . 0.0 110.118 172.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -137.72 76.42 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -172.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.22 80.9 0.05 OUTLIER 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 172.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.29 -23.98 6.7 Favored Glycine 0 N--CA 1.5 2.908 0 N-CA-C 119.016 2.367 . . . . 0.0 119.016 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -54.37 -46.41 73.0 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 117.024 2.231 . . . . 0.0 117.024 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.47 -132.6 2.36 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 124.053 0.835 . . . . 0.0 111.148 175.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -119.83 -178.63 3.68 Favored 'General case' 0 CA--C 1.567 1.604 0 CA-C-O 122.231 1.015 . . . . 0.0 112.353 -173.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.2 145.11 26.97 Favored 'General case' 0 CA--C 1.562 1.41 0 O-C-N 120.115 -1.616 . . . . 0.0 111.665 172.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.5 t -71.81 -45.77 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 O-C-N 121.185 -0.947 . . . . 0.0 112.044 172.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -91.0 119.31 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 167.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 97.7 m -80.51 95.54 6.51 Favored 'General case' 0 CA--C 1.568 1.65 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -106.23 92.58 4.2 Favored 'General case' 0 CA--C 1.563 1.46 0 C-N-CA 124.365 1.066 . . . . 0.0 109.305 175.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.388 51.8 p-90 . . . . . 0 N--CA 1.507 2.415 0 N-CA-C 118.693 2.849 . . . . 0.0 118.693 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 t . . . . . 0 CA--C 1.574 1.893 0 N-CA-C 119.056 2.984 . . . . 0.0 119.056 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.46 174.07 6.03 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 120.62 1.555 . . . . 0.0 114.489 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.86 56.35 0.64 Allowed Glycine 0 N--CA 1.501 2.969 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 175.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.19 -53.39 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 C-N-CA 124.579 1.152 . . . . 0.0 109.32 177.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.07 173.6 27.74 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 118.783 2.273 . . . . 0.0 118.783 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -115.82 50.09 1.05 Allowed 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 115.914 1.82 . . . . 0.0 115.914 -175.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.271 18.8 p -160.53 -124.26 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.884 -1.135 . . . . 0.0 110.782 175.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -146.05 138.08 25.17 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-N 121.149 1.795 . . . . 0.0 112.126 -179.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.7 p-10 -87.65 -61.85 1.63 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.108 171.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -146.83 128.38 15.08 Favored 'General case' 0 CA--C 1.568 1.637 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 174.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.85 106.29 0.1 Allowed 'General case' 0 CA--C 1.571 1.771 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.58 -46.55 1.07 Allowed Glycine 0 N--CA 1.491 2.363 0 CA-C-O 118.406 -1.219 . . . . 0.0 115.416 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -84.15 -61.93 1.69 Allowed 'General case' 0 CA--C 1.57 1.726 0 N-CA-C 116.291 1.959 . . . . 0.0 116.291 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.97 -121.47 0.77 Allowed Glycine 0 N--CA 1.489 2.174 0 CA-C-N 120.471 1.487 . . . . 0.0 115.752 -176.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -116.27 176.51 5.07 Favored 'General case' 0 CA--C 1.566 1.578 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -166.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.52 147.85 28.69 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.234 -1.541 . . . . 0.0 112.363 175.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -75.1 -46.24 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.627 -0.671 . . . . 0.0 111.263 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -87.43 111.31 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 169.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.1 m -76.26 108.7 9.38 Favored 'General case' 0 CA--C 1.566 1.573 0 O-C-N 121.343 -0.848 . . . . 0.0 112.296 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -80.01 106.1 11.78 Favored 'General case' 0 N--CA 1.492 1.64 0 CA-C-O 122.299 1.047 . . . . 0.0 113.485 -170.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.495 1.809 0 N-CA-C 115.915 1.821 . . . . 0.0 115.915 -178.013 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.576 1.957 0 N-CA-C 119.459 3.133 . . . . 0.0 119.459 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.3 0.2 OUTLIER -90.15 179.23 5.97 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 121.613 2.006 . . . . 0.0 115.004 -174.401 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -98.25 -42.78 2.92 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 118.707 2.243 . . . . 0.0 118.707 178.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -82.85 56.41 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 117.486 2.402 . . . . 0.0 117.486 -173.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -153.0 175.25 31.58 Favored Glycine 0 N--CA 1.49 2.255 0 O-C-N 120.902 -1.124 . . . . 0.0 115.302 172.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.6 p -122.03 54.7 1.15 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.267 12.4 p -164.49 -130.82 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 C-N-CA 123.875 0.87 . . . . 0.0 110.156 174.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -150.05 133.1 16.2 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 119.988 -1.695 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.13 -58.06 2.92 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -141.35 77.11 1.58 Allowed 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 118.845 0.748 . . . . 0.0 111.909 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 36.38 75.5 0.06 Allowed 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 119.036 2.976 . . . . 0.0 119.036 175.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.24 -17.95 57.26 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 119.16 2.424 . . . . 0.0 119.16 -173.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.7 t -60.68 -52.75 63.81 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 116.758 2.133 . . . . 0.0 116.758 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.1 -120.86 0.65 Allowed Glycine 0 N--CA 1.489 2.169 0 O-C-N 121.573 -0.705 . . . . 0.0 112.258 175.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -122.62 172.54 8.32 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.941 0.897 . . . . 0.0 112.319 -173.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.0 141.96 34.31 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.393 -1.442 . . . . 0.0 111.606 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.7 m -73.18 -35.21 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 175.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.24 91.75 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-N 120.027 1.285 . . . . 0.0 107.875 175.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.5 m -87.64 108.24 18.99 Favored 'General case' 0 CA--C 1.566 1.586 0 O-C-N 121.578 -0.701 . . . . 0.0 112.28 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -85.83 93.22 8.85 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.547 -0.72 . . . . 0.0 112.382 -178.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.372 29.0 p90 . . . . . 0 N--CA 1.507 2.422 0 N-CA-C 120.2 3.407 . . . . 0.0 120.2 175.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.2 m . . . . . 0 CA--C 1.577 1.982 0 N-CA-C 119.127 3.01 . . . . 0.0 119.127 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.259 0.3 OUTLIER -88.84 170.92 10.32 Favored 'General case' 0 N--CA 1.499 1.996 0 CA-C-N 122.024 2.193 . . . . 0.0 115.691 -172.741 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.9 50.12 0.8 Allowed Glycine 0 N--CA 1.5 2.921 0 N-CA-C 116.734 1.454 . . . . 0.0 116.734 176.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.53 -53.97 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 C-N-CA 124.193 0.997 . . . . 0.0 110.181 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.97 175.91 17.61 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 118.186 2.034 . . . . 0.0 118.186 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 t -116.67 48.03 1.35 Allowed 'General case' 0 N--CA 1.502 2.157 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -176.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 22.9 p -162.68 -120.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.787 -1.196 . . . . 0.0 111.426 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -148.13 138.61 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 CA-C-N 121.477 1.944 . . . . 0.0 112.966 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.41 -68.33 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 114.514 -1.221 . . . . 0.0 111.934 174.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.69 81.43 1.65 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 123.1 0.56 . . . . 0.0 112.057 -172.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.9 77.86 0.09 Allowed 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 117.991 2.589 . . . . 0.0 117.991 174.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.47 -16.76 22.88 Favored Glycine 0 N--CA 1.499 2.883 0 N-CA-C 119.876 2.71 . . . . 0.0 119.876 -176.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.2 t -56.83 -47.0 81.31 Favored 'General case' 0 N--CA 1.501 2.09 0 N-CA-C 117.447 2.388 . . . . 0.0 117.447 -178.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.66 -129.71 1.49 Allowed Glycine 0 N--CA 1.486 1.981 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -118.17 179.67 4.03 Favored 'General case' 0 CA--C 1.564 1.491 0 CA-C-O 122.01 0.909 . . . . 0.0 113.1 -174.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -158.79 148.97 19.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.342 -1.474 . . . . 0.0 112.287 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -70.76 -42.88 77.61 Favored 'Isoleucine or valine' 0 CA--C 1.581 2.162 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 165.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -91.08 115.5 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 168.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.0 m -78.55 106.27 10.4 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -98.39 103.97 15.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.374 19.5 p90 . . . . . 0 N--CA 1.507 2.376 0 N-CA-C 118.921 2.934 . . . . 0.0 118.921 179.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.573 1.859 0 N-CA-C 119.43 3.122 . . . . 0.0 119.43 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.324 0.9 OUTLIER -110.42 -161.89 0.77 Allowed 'General case' 0 CA--C 1.58 2.105 0 CA-C-N 120.843 1.656 . . . . 0.0 114.871 -176.107 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.33 63.19 0.42 Allowed Glycine 0 N--CA 1.502 3.041 0 N-CA-C 117.89 1.916 . . . . 0.0 117.89 -175.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.575 1.927 0 C-N-CA 124.343 1.057 . . . . 0.0 108.948 172.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -73.35 177.53 43.02 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 119.766 2.667 . . . . 0.0 119.766 -177.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 p -114.68 54.01 0.79 Allowed 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 115.165 1.543 . . . . 0.0 115.165 -175.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.4 p -169.22 134.27 1.51 Allowed 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 124.332 1.053 . . . . 0.0 109.546 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -70.12 129.25 38.91 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 37.8 p-10 -75.19 -60.29 2.36 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 177.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -144.01 85.76 1.82 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 123.448 0.699 . . . . 0.0 109.476 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 11.19 74.87 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.207 0 N-CA-C 121.024 3.713 . . . . 0.0 121.024 175.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.58 -38.8 2.53 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 117.008 1.563 . . . . 0.0 117.008 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.4 t -63.91 -56.98 11.24 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 116.873 2.175 . . . . 0.0 116.873 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.91 -122.31 0.87 Allowed Glycine 0 N--CA 1.488 2.104 0 O-C-N 121.269 -0.894 . . . . 0.0 113.921 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -136.55 150.37 48.58 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 124.031 0.932 . . . . 0.0 113.487 -170.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.31 141.13 39.14 Favored 'General case' 0 CA--C 1.563 1.447 0 C-N-CA 123.768 0.827 . . . . 0.0 110.984 175.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -73.54 -40.49 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 120.94 -1.1 . . . . 0.0 112.645 171.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -89.52 104.52 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 171.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 89.1 m -77.41 112.93 14.68 Favored 'General case' 0 CA--C 1.568 1.647 0 CA-C-O 122.198 0.999 . . . . 0.0 113.206 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -84.52 91.27 7.82 Favored 'General case' 0 CA--C 1.57 1.743 0 C-N-CA 124.422 1.089 . . . . 0.0 113.424 -177.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.1 t90 . . . . . 0 N--CA 1.503 2.179 0 CA-C-O 125.2 2.429 . . . . 0.0 113.669 -179.143 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.576 1.943 0 N-CA-C 119.995 3.331 . . . . 0.0 119.995 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -78.48 178.45 7.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 121.859 2.118 . . . . 0.0 113.933 177.469 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -123.51 56.13 0.68 Allowed Glycine 0 N--CA 1.501 3.012 0 O-C-N 120.297 -1.502 . . . . 0.0 116.725 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.86 -53.45 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.576 1.961 0 C-N-CA 124.411 1.084 . . . . 0.0 109.54 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -63.63 158.89 39.41 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 119.137 2.415 . . . . 0.0 119.137 -177.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -99.47 44.77 1.01 Allowed 'General case' 0 N--CA 1.5 2.075 0 N-CA-C 116.239 1.941 . . . . 0.0 116.239 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.5 p -175.62 152.42 1.3 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 125.156 1.383 . . . . 0.0 109.676 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -67.38 144.81 55.6 Favored 'General case' 0 CA--C 1.58 2.111 0 N-CA-C 116.708 2.114 . . . . 0.0 116.708 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -76.14 -70.03 0.47 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 118.002 -0.999 . . . . 0.0 112.139 172.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -153.48 100.96 2.46 Favored 'General case' 0 CA--C 1.563 1.476 0 CA-C-N 120.012 1.278 . . . . 0.0 109.39 -173.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 45.62 67.81 0.68 Allowed 'General case' 0 CA--C 1.574 1.889 0 N-CA-C 119.005 2.965 . . . . 0.0 119.005 173.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.65 -11.97 57.71 Favored Glycine 0 N--CA 1.499 2.874 0 N-CA-C 120.93 3.132 . . . . 0.0 120.93 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.14 -39.26 93.64 Favored 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 117.975 2.583 . . . . 0.0 117.975 -176.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.95 -123.02 1.08 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 124.277 0.942 . . . . 0.0 111.126 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -131.21 171.73 12.95 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.89 151.71 29.79 Favored 'General case' 0 CA--C 1.562 1.434 0 O-C-N 120.344 -1.472 . . . . 0.0 111.738 174.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.67 -46.46 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.389 0 O-C-N 121.027 -1.046 . . . . 0.0 111.686 166.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.9 t -88.38 117.95 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 169.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.0 m -80.16 106.59 12.29 Favored 'General case' 0 CA--C 1.571 1.784 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -174.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.4 p90 -123.53 72.31 1.13 Allowed 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 122.526 1.155 . . . . 0.0 114.096 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.341 21.9 p90 . . . . . 0 N--CA 1.508 2.454 0 N-CA-C 117.648 2.462 . . . . 0.0 117.648 178.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 t . . . . . 0 N--CA 1.498 1.938 0 N-CA-C 119.609 3.189 . . . . 0.0 119.609 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.36 171.47 13.48 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-N 121.583 1.992 . . . . 0.0 114.57 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -119.75 55.21 0.62 Allowed Glycine 0 N--CA 1.502 3.038 0 N-CA-C 116.149 1.22 . . . . 0.0 116.149 175.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.11 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 124.61 1.164 . . . . 0.0 109.099 177.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.28 170.55 34.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 118.631 2.212 . . . . 0.0 118.631 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.2 p -114.63 55.73 0.74 Allowed 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 115.184 1.55 . . . . 0.0 115.184 -175.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 25.2 p -162.92 -129.05 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.14 -0.975 . . . . 0.0 110.967 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -145.24 138.3 26.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 119.983 -1.698 . . . . 0.0 111.301 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -85.79 -58.17 2.76 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 123.926 0.89 . . . . 0.0 111.303 172.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -150.14 134.48 17.25 Favored 'General case' 0 CA--C 1.571 1.762 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 172.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -44.9 113.12 0.51 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.802 2.149 . . . . 0.0 116.802 -177.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.65 -27.96 16.88 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 118.358 2.103 . . . . 0.0 118.358 -171.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.49 -53.78 5.44 Favored 'General case' 0 CA--C 1.573 1.845 0 CA-C-N 119.806 1.803 . . . . 0.0 115.687 -177.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.5 -133.08 2.71 Favored Glycine 0 N--CA 1.49 2.266 0 O-C-N 121.09 -1.006 . . . . 0.0 113.939 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -113.09 175.73 5.32 Favored 'General case' 0 CA--C 1.566 1.589 0 CA-C-O 122.02 0.914 . . . . 0.0 113.383 -170.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.2 146.54 31.78 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.106 -1.621 . . . . 0.0 112.542 176.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.5 t -77.87 -43.23 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.578 -0.701 . . . . 0.0 111.874 170.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.29 95.95 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 95.0 m -83.9 110.5 18.44 Favored 'General case' 0 CA--C 1.565 1.54 0 N-CA-C 113.999 1.111 . . . . 0.0 113.999 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -91.44 77.2 5.81 Favored 'General case' 0 CA--C 1.57 1.743 0 CA-C-O 122.7 1.238 . . . . 0.0 114.299 -178.107 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 66.1 p-90 . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 123.051 1.405 . . . . 0.0 112.036 178.752 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.574 1.885 0 N-CA-C 119.561 3.171 . . . . 0.0 119.561 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.365 1.3 pt? -98.35 -161.02 0.84 Allowed 'General case' 0 CA--C 1.577 2.016 0 CA-C-N 121.647 2.021 . . . . 0.0 115.397 -173.096 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.44 64.57 0.41 Allowed Glycine 0 N--CA 1.5 2.938 0 O-C-N 119.758 -1.839 . . . . 0.0 117.647 -175.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.11 -54.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.899 0 C-N-CA 124.227 1.011 . . . . 0.0 108.941 172.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.81 179.12 47.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 119.674 2.63 . . . . 0.0 119.674 -177.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.6 p -115.21 53.06 0.84 Allowed 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 -177.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.0 p -167.61 134.49 2.22 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 124.342 1.057 . . . . 0.0 109.695 -179.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -69.37 132.33 46.21 Favored 'General case' 0 CA--C 1.573 1.831 0 N-CA-C 115.462 1.653 . . . . 0.0 115.462 -173.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.2 p-10 -73.68 -67.44 0.59 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 113.455 0.909 . . . . 0.0 113.455 176.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -139.42 76.43 1.56 Allowed 'General case' 0 N--CA 1.494 1.767 0 CA-C-N 118.634 0.652 . . . . 0.0 112.007 -171.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 41.7 79.08 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 118.392 2.738 . . . . 0.0 118.392 175.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.22 -22.93 20.66 Favored Glycine 0 N--CA 1.498 2.81 0 N-CA-C 119.164 2.425 . . . . 0.0 119.164 -174.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -58.22 -49.66 76.31 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 117.552 2.427 . . . . 0.0 117.552 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.37 -125.92 1.15 Allowed Glycine 0 N--CA 1.487 2.036 0 O-C-N 121.547 -0.721 . . . . 0.0 112.332 177.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -140.72 146.94 38.42 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -173.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -109.38 142.85 39.74 Favored 'General case' 0 CA--C 1.563 1.443 0 C-N-CA 123.558 0.743 . . . . 0.0 111.366 174.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -71.42 -43.8 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 120.797 -1.189 . . . . 0.0 112.423 170.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t -90.61 113.8 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 169.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.5 m -77.0 98.2 4.88 Favored 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 -175.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -97.2 -14.95 21.11 Favored 'General case' 0 N--CA 1.498 1.952 0 N-CA-C 118.995 2.961 . . . . 0.0 118.995 -178.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.737 0 N-CA-C 117.615 2.45 . . . . 0.0 117.615 -176.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 t . . . . . 0 CA--C 1.574 1.868 0 N-CA-C 119.36 3.096 . . . . 0.0 119.36 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.13 173.19 6.41 Favored 'General case' 0 CA--C 1.576 1.959 0 CA-C-N 120.618 1.554 . . . . 0.0 114.452 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.52 56.29 0.63 Allowed Glycine 0 N--CA 1.501 3.026 0 N-CA-C 116.127 1.211 . . . . 0.0 116.127 175.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.5 -52.91 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 C-N-CA 124.488 1.115 . . . . 0.0 109.418 177.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.91 178.44 25.48 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 119.064 2.385 . . . . 0.0 119.064 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -119.82 50.41 1.28 Allowed 'General case' 0 N--CA 1.5 2.05 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 -175.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.253 22.4 p -157.25 -129.31 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.84 -1.162 . . . . 0.0 110.821 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -144.42 135.67 25.4 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.765 1.621 . . . . 0.0 111.071 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.4 p-10 -86.82 -60.41 1.99 Allowed 'General case' 0 N--CA 1.491 1.608 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.336 173.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -147.16 127.42 13.88 Favored 'General case' 0 CA--C 1.566 1.595 0 N-CA-C 105.364 -2.087 . . . . 0.0 105.364 173.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.85 106.8 0.1 Allowed 'General case' 0 CA--C 1.574 1.868 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.1 -46.03 1.1 Allowed Glycine 0 N--CA 1.492 2.406 0 CA-C-O 118.436 -1.202 . . . . 0.0 115.497 -169.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.4 t -83.57 -61.62 1.79 Allowed 'General case' 0 CA--C 1.569 1.677 0 N-CA-C 116.282 1.956 . . . . 0.0 116.282 -178.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.53 -121.19 0.76 Allowed Glycine 0 N--CA 1.488 2.133 0 CA-C-N 120.504 1.502 . . . . 0.0 115.803 -177.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.43 174.72 5.91 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -166.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.89 147.03 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 120.348 -1.47 . . . . 0.0 112.113 174.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.7 t -76.93 -44.0 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.575 -0.703 . . . . 0.0 112.61 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.5 t -88.54 95.69 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 CA-C-N 119.668 1.122 . . . . 0.0 108.095 175.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.8 m -85.44 96.26 9.53 Favored 'General case' 0 CA--C 1.565 1.553 0 CA-C-O 121.911 0.862 . . . . 0.0 112.266 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -142.49 151.35 41.6 Favored 'General case' 0 CA--C 1.569 1.677 0 CA-C-O 122.798 1.285 . . . . 0.0 112.321 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 51.4 p-90 . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 124.629 2.157 . . . . 0.0 114.52 173.506 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.574 1.887 0 N-CA-C 120.325 3.454 . . . . 0.0 120.325 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.3 179.55 4.55 Favored 'General case' 0 CA--C 1.579 2.073 0 CA-C-N 121.093 1.77 . . . . 0.0 114.088 178.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -124.21 58.46 0.64 Allowed Glycine 0 N--CA 1.501 3.005 0 O-C-N 120.259 -1.525 . . . . 0.0 116.697 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -131.54 -54.75 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 124.403 1.081 . . . . 0.0 109.391 176.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.58 -179.97 28.76 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 119.232 2.453 . . . . 0.0 119.232 -177.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -121.29 43.79 2.71 Favored 'General case' 0 N--CA 1.504 2.272 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -175.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 21.1 p -163.56 139.81 6.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.79 -1.194 . . . . 0.0 109.821 177.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -63.5 137.81 58.27 Favored 'General case' 0 CA--C 1.577 2.014 0 N-CA-C 116.266 1.95 . . . . 0.0 116.266 -174.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.277 39.1 p-10 -80.68 -80.86 0.13 Allowed 'General case' 0 N--CA 1.489 1.512 0 CA-C-O 118.237 -0.887 . . . . 0.0 113.223 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -121.29 55.42 1.07 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -173.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . 0.264 . . 57.65 7.56 0.56 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 121.762 3.986 . . . . 0.0 121.762 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.61 64.02 0.03 OUTLIER Glycine 0 N--CA 1.491 2.322 0 O-C-N 120.866 -1.146 . . . . 0.0 115.152 -177.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 54.0 t -156.84 -64.68 0.1 Allowed 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 123.589 0.756 . . . . 0.0 111.464 177.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.77 -117.83 0.46 Allowed Glycine 0 N--CA 1.483 1.788 0 O-C-N 121.633 -0.667 . . . . 0.0 112.391 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -129.23 172.23 11.66 Favored 'General case' 0 CA--C 1.566 1.591 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -168.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.45 143.87 47.78 Favored 'General case' 0 CA--C 1.563 1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 110.705 173.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.1 t -74.06 -43.92 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.106 -0.996 . . . . 0.0 112.326 171.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.6 t -93.76 112.24 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 172.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 78.6 m -80.31 96.24 6.59 Favored 'General case' 0 CA--C 1.568 1.645 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -178.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.1 t80 -128.88 93.92 3.72 Favored 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 123.679 1.704 . . . . 0.0 110.199 179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 48.3 p90 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 124.462 2.077 . . . . 0.0 113.964 -178.511 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 120.275 3.435 . . . . 0.0 120.275 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.43 166.75 18.11 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 121.859 2.118 . . . . 0.0 115.161 -178.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.37 49.96 0.81 Allowed Glycine 0 N--CA 1.5 2.9 0 N-CA-C 116.701 1.441 . . . . 0.0 116.701 176.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -133.58 -55.23 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 124.334 1.054 . . . . 0.0 109.991 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.71 169.35 38.09 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 118.311 2.084 . . . . 0.0 118.311 -178.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.8 p -109.77 56.15 0.63 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 115.526 1.676 . . . . 0.0 115.526 -174.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.254 22.5 p -164.26 -131.71 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.124 -0.985 . . . . 0.0 111.111 176.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -146.36 136.26 23.4 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 119.933 -1.73 . . . . 0.0 111.295 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.0 p30 -82.84 -63.32 1.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.012 -0.995 . . . . 0.0 111.136 174.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -145.24 124.0 12.61 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.956 -2.239 . . . . 0.0 104.956 174.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -38.36 111.18 0.16 Allowed 'General case' 0 CA--C 1.573 1.839 0 N-CA-C 117.892 2.553 . . . . 0.0 117.892 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.05 -32.25 7.04 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 117.917 1.927 . . . . 0.0 117.917 -171.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -80.31 -51.67 8.62 Favored 'General case' 0 CA--C 1.574 1.867 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 -176.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.14 -135.13 3.46 Favored Glycine 0 N--CA 1.49 2.295 0 O-C-N 121.203 -0.936 . . . . 0.0 113.243 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -114.23 178.98 4.09 Favored 'General case' 0 CA--C 1.567 1.607 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -171.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.96 145.3 30.6 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.058 -1.651 . . . . 0.0 112.262 175.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.4 t -75.82 -45.34 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 O-C-N 121.393 -0.817 . . . . 0.0 111.691 171.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -90.84 107.23 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 171.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.2 m -81.99 96.71 7.8 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -144.45 108.73 4.81 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.907 0.86 . . . . 0.0 109.346 177.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.7 t-105 . . . . . 0 N--CA 1.489 1.483 0 CA-C-O 123.917 1.818 . . . . 0.0 110.59 -179.491 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.497 1.898 0 N-CA-C 119.781 3.252 . . . . 0.0 119.781 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.41 171.6 13.3 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 121.59 1.996 . . . . 0.0 114.571 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.48 55.57 0.63 Allowed Glycine 0 N--CA 1.5 2.955 0 N-CA-C 116.015 1.166 . . . . 0.0 116.015 175.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.58 -52.55 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.89 0 C-N-CA 124.737 1.215 . . . . 0.0 109.055 177.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.16 173.92 31.18 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 118.673 2.229 . . . . 0.0 118.673 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -117.8 51.16 1.07 Allowed 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 115.317 1.599 . . . . 0.0 115.317 -175.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.256 25.6 p -157.48 -128.63 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.83 -1.169 . . . . 0.0 110.963 174.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -145.66 135.87 23.87 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-N 120.903 1.683 . . . . 0.0 111.533 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p-10 -83.34 -60.6 2.09 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.988 172.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -147.53 135.3 21.08 Favored 'General case' 0 CA--C 1.572 1.816 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 171.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.17 113.69 0.61 Allowed 'General case' 0 CA--C 1.573 1.842 0 N-CA-C 116.795 2.146 . . . . 0.0 116.795 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.26 -26.88 22.28 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 118.431 2.132 . . . . 0.0 118.431 -171.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.57 -54.02 5.24 Favored 'General case' 0 CA--C 1.573 1.849 0 CA-C-N 119.809 1.805 . . . . 0.0 115.606 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.46 -133.0 2.69 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 121.079 -1.013 . . . . 0.0 113.942 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -112.86 175.32 5.49 Favored 'General case' 0 CA--C 1.567 1.605 0 CA-C-O 122.121 0.962 . . . . 0.0 113.354 -170.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.09 147.01 33.19 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.159 -1.588 . . . . 0.0 112.092 175.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 66.2 t -77.77 -42.52 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 O-C-N 121.544 -0.722 . . . . 0.0 112.493 172.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -86.66 95.29 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 CA-C-N 119.839 1.2 . . . . 0.0 108.12 175.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.9 m -87.02 113.85 23.13 Favored 'General case' 0 CA--C 1.567 1.603 0 O-C-N 121.707 -0.621 . . . . 0.0 112.505 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 62.2 t80 -84.42 141.84 30.54 Favored 'General case' 0 CA--C 1.571 1.774 0 CA-C-O 121.892 0.853 . . . . 0.0 113.122 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.1 t-105 . . . . . 0 N--CA 1.488 1.443 0 CA-C-O 123.884 1.802 . . . . 0.0 109.868 175.804 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 t . . . . . 0 N--CA 1.498 1.97 0 N-CA-C 119.886 3.291 . . . . 0.0 119.886 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.77 166.04 17.29 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 121.615 2.007 . . . . 0.0 114.861 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -110.85 48.77 0.9 Allowed Glycine 0 N--CA 1.501 2.984 0 N-CA-C 116.957 1.543 . . . . 0.0 116.957 177.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.53 -55.67 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 C-N-CA 124.168 0.987 . . . . 0.0 110.267 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.52 34.84 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 118.612 2.205 . . . . 0.0 118.612 -177.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.7 p -112.99 58.15 0.66 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 19.4 p -165.71 -132.7 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 110.868 175.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -144.03 139.3 28.91 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 119.877 -1.765 . . . . 0.0 111.313 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.4 p-10 -90.65 -65.61 1.0 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.95 176.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -139.82 77.44 1.61 Allowed 'General case' 0 N--CA 1.494 1.744 0 CA-C-N 119.06 0.845 . . . . 0.0 111.254 -175.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 32.64 80.68 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 119.403 3.112 . . . . 0.0 119.403 174.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.48 -28.45 14.13 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 118.391 2.116 . . . . 0.0 118.391 -173.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.4 t -59.93 -41.37 91.63 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 117.298 2.333 . . . . 0.0 117.298 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.35 -135.94 3.93 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 124.024 0.821 . . . . 0.0 111.814 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -115.36 176.65 4.97 Favored 'General case' 0 CA--C 1.565 1.533 0 CA-C-O 122.084 0.945 . . . . 0.0 113.257 -173.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.0 144.92 37.22 Favored 'General case' 0 CA--C 1.562 1.432 0 O-C-N 120.258 -1.526 . . . . 0.0 111.776 175.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -74.75 -42.26 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 174.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -88.81 94.67 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 CA-C-N 119.883 1.22 . . . . 0.0 108.033 175.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.7 m -85.88 105.8 16.63 Favored 'General case' 0 CA--C 1.565 1.538 0 CA-C-O 121.716 0.769 . . . . 0.0 112.454 -179.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -83.74 97.15 8.98 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 122.007 0.908 . . . . 0.0 111.556 -178.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 72.4 t90 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 123.831 1.777 . . . . 0.0 110.569 -178.095 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 119.08 2.993 . . . . 0.0 119.08 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.85 169.15 14.43 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 121.34 1.882 . . . . 0.0 114.585 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -112.48 48.17 0.97 Allowed Glycine 0 N--CA 1.499 2.878 0 N-CA-C 117.097 1.599 . . . . 0.0 117.097 177.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -131.5 -54.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 124.156 0.982 . . . . 0.0 110.179 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.8 172.67 23.93 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 p -114.34 54.06 0.78 Allowed 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 115.53 1.678 . . . . 0.0 115.53 -175.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.262 22.0 p -165.99 -124.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.18 -0.95 . . . . 0.0 110.841 176.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -147.85 140.44 24.6 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-N 120.94 1.7 . . . . 0.0 111.717 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -82.47 -71.67 0.48 Allowed 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.469 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -145.26 85.91 1.75 Allowed 'General case' 0 CA--C 1.566 1.585 0 CA-C-N 119.548 1.067 . . . . 0.0 111.736 -179.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 50.89 81.66 0.07 Allowed 'General case' 0 CA--C 1.571 1.782 0 N-CA-C 118.017 2.599 . . . . 0.0 118.017 173.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.52 -21.97 8.19 Favored Glycine 0 N--CA 1.5 2.929 0 N-CA-C 120.31 2.884 . . . . 0.0 120.31 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.1 t -59.43 -39.55 83.9 Favored 'General case' 0 N--CA 1.5 2.074 0 N-CA-C 117.689 2.477 . . . . 0.0 117.689 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.5 -132.85 2.61 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 124.108 0.861 . . . . 0.0 111.239 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -117.95 178.47 4.41 Favored 'General case' 0 CA--C 1.565 1.548 0 CA-C-O 122.127 0.965 . . . . 0.0 113.446 -173.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -155.73 146.28 21.96 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.371 -1.456 . . . . 0.0 112.594 175.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . 0.253 9.4 p -69.15 -45.95 78.79 Favored 'Isoleucine or valine' 0 CA--C 1.58 2.096 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 166.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.2 112.75 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.571 1.757 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 69.5 m -78.47 115.04 17.9 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -71.52 134.32 46.42 Favored 'General case' 0 CA--C 1.575 1.929 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.45 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 58.2 p-90 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 125.281 2.467 . . . . 0.0 112.699 -178.989 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.498 1.927 0 N-CA-C 120.815 3.635 . . . . 0.0 120.815 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.252 0.3 OUTLIER -80.77 174.32 11.73 Favored 'General case' 0 CA--C 1.578 2.025 0 CA-C-N 122.136 2.244 . . . . 0.0 114.381 178.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.49 57.74 0.6 Allowed Glycine 0 N--CA 1.501 2.981 0 O-C-N 120.404 -1.435 . . . . 0.0 116.455 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.29 -53.91 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 C-N-CA 124.513 1.125 . . . . 0.0 108.981 176.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.46 168.67 42.12 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 118.417 2.127 . . . . 0.0 118.417 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -112.66 43.11 1.71 Allowed 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.8 p -164.83 142.77 6.43 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 124.546 1.138 . . . . 0.0 109.729 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.7 140.23 58.85 Favored 'General case' 0 CA--C 1.579 2.085 0 N-CA-C 118.006 2.595 . . . . 0.0 118.006 -171.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p30 -79.7 -60.99 2.13 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 123.444 0.698 . . . . 0.0 111.637 172.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -151.7 94.0 1.93 Allowed 'General case' 0 CA--C 1.566 1.595 0 CA-C-N 119.732 1.151 . . . . 0.0 109.202 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 13.42 83.28 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 121.438 3.866 . . . . 0.0 121.438 175.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.42 -35.74 4.2 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 117.648 1.819 . . . . 0.0 117.648 -174.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.7 t -68.88 -45.04 72.0 Favored 'General case' 0 CA--C 1.577 2.005 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 -177.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 160.47 -130.88 2.49 Favored Glycine 0 N--CA 1.489 2.203 0 O-C-N 121.359 -0.838 . . . . 0.0 112.745 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -125.09 171.66 10.1 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -170.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.23 140.96 37.88 Favored 'General case' 0 CA--C 1.564 1.49 0 O-C-N 120.364 -1.46 . . . . 0.0 110.615 175.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.1 m -69.03 -39.56 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.058 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.1 t -96.3 118.09 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 168.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.3 m -76.89 100.93 5.72 Favored 'General case' 0 CA--C 1.569 1.681 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -107.64 -30.69 8.44 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 118.002 2.593 . . . . 0.0 118.002 -178.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.497 1.894 0 CA-C-O 124.664 2.174 . . . . 0.0 110.778 -175.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.573 1.865 0 N-CA-C 119.177 3.029 . . . . 0.0 119.177 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.43 169.47 8.68 Favored 'General case' 0 CA--C 1.575 1.906 0 CA-C-N 120.664 1.575 . . . . 0.0 114.703 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.26 52.26 0.66 Allowed Glycine 0 N--CA 1.5 2.937 0 N-CA-C 116.669 1.428 . . . . 0.0 116.669 177.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.23 -54.83 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 C-N-CA 124.112 0.965 . . . . 0.0 110.211 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.53 177.73 25.27 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 118.825 2.29 . . . . 0.0 118.825 -177.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.7 t -116.43 53.46 0.88 Allowed 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 115.047 1.499 . . . . 0.0 115.047 -175.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -162.16 -129.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.92 -1.113 . . . . 0.0 110.974 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -144.1 139.89 29.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.932 -1.73 . . . . 0.0 110.832 178.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -90.97 -60.06 2.01 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 123.637 0.775 . . . . 0.0 111.256 172.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -147.22 127.25 13.67 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 174.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.84 106.56 0.09 Allowed 'General case' 0 CA--C 1.572 1.81 0 N-CA-C 116.001 1.852 . . . . 0.0 116.001 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.39 -46.02 1.1 Allowed Glycine 0 N--CA 1.492 2.381 0 CA-C-O 118.509 -1.162 . . . . 0.0 115.687 -169.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.3 t -83.46 -60.71 2.05 Favored 'General case' 0 CA--C 1.569 1.698 0 N-CA-C 116.611 2.078 . . . . 0.0 116.611 -178.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 178.24 -124.9 0.95 Allowed Glycine 0 N--CA 1.49 2.284 0 CA-C-N 120.314 1.416 . . . . 0.0 115.356 -176.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -115.05 178.19 4.38 Favored 'General case' 0 CA--C 1.566 1.577 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -168.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.6 141.29 33.47 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.346 -1.472 . . . . 0.0 112.087 175.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.86 -39.8 52.39 Favored 'Isoleucine or valine' 0 CA--C 1.576 1.951 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 170.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.1 t -90.77 97.14 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 170.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 68.6 m -82.41 110.83 17.89 Favored 'General case' 0 CA--C 1.564 1.485 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -175.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -82.84 88.47 6.78 Favored 'General case' 0 CA--C 1.571 1.761 0 CA-C-O 122.693 1.235 . . . . 0.0 110.807 173.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 40.8 t-105 . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 124.585 2.136 . . . . 0.0 111.303 -173.987 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.498 1.955 0 N-CA-C 118.742 2.868 . . . . 0.0 118.742 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.3 173.51 11.53 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 121.056 1.753 . . . . 0.0 114.203 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.1 55.11 0.65 Allowed Glycine 0 N--CA 1.501 3.005 0 N-CA-C 116.217 1.247 . . . . 0.0 116.217 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.86 -52.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 C-N-CA 124.662 1.185 . . . . 0.0 109.195 177.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.82 172.87 23.65 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 118.506 2.163 . . . . 0.0 118.506 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -117.61 49.08 1.26 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 115.185 1.55 . . . . 0.0 115.185 -177.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.25 26.2 p -159.23 -122.8 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.85 -1.156 . . . . 0.0 110.961 175.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -147.56 142.35 26.78 Favored 'General case' 0 N--CA 1.491 1.625 0 CA-C-N 120.934 1.697 . . . . 0.0 111.999 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -91.01 -63.21 1.3 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 124.515 1.126 . . . . 0.0 113.343 176.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 94.4 m-85 -140.77 78.13 1.63 Allowed 'General case' 0 N--CA 1.495 1.808 0 CA-C-N 119.079 0.854 . . . . 0.0 111.237 -173.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 38.79 75.24 0.08 Allowed 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 118.717 2.858 . . . . 0.0 118.717 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.14 -19.83 51.09 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 119.545 2.578 . . . . 0.0 119.545 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.9 t -61.49 -41.35 97.14 Favored 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 117.766 2.506 . . . . 0.0 117.766 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.34 -128.04 1.49 Allowed Glycine 0 N--CA 1.489 2.198 0 O-C-N 121.361 -0.837 . . . . 0.0 111.726 177.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -120.04 174.25 6.59 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-O 122.058 0.932 . . . . 0.0 113.242 -173.194 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.26 147.36 25.59 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.403 -1.435 . . . . 0.0 112.787 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -73.4 -42.14 56.86 Favored 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 165.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.6 t . . . . . 0 N--CA 1.495 1.786 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 170.183 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.499 1.977 0 N-CA-C 120.745 3.609 . . . . 0.0 120.745 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.254 0.2 OUTLIER -80.56 176.18 10.01 Favored 'General case' 0 CA--C 1.579 2.075 0 CA-C-N 122.044 2.202 . . . . 0.0 114.139 177.942 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.45 56.27 0.61 Allowed Glycine 0 N--CA 1.501 3.013 0 O-C-N 120.206 -1.558 . . . . 0.0 116.828 176.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.0 mt -129.48 -59.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 C-N-CA 124.273 1.029 . . . . 0.0 109.455 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.31 172.02 42.26 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 119.836 2.694 . . . . 0.0 119.836 -175.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.8 p -110.74 51.23 0.78 Allowed 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -175.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.4 p -169.9 140.01 1.99 Allowed 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.44 1.096 . . . . 0.0 109.627 178.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -66.48 133.67 50.87 Favored 'General case' 0 CA--C 1.576 1.964 0 N-CA-C 115.652 1.723 . . . . 0.0 115.652 -176.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.254 26.3 p30 -71.54 -72.34 0.23 Allowed 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 123.77 0.828 . . . . 0.0 112.884 177.027 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -144.21 87.75 1.91 Allowed 'General case' 0 CA--C 1.566 1.588 0 CA-C-N 119.42 1.009 . . . . 0.0 110.923 -178.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.79 82.72 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 118.366 2.728 . . . . 0.0 118.366 173.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.94 -23.94 5.58 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 120.097 2.799 . . . . 0.0 120.097 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.9 t -58.82 -40.78 85.17 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 117.907 2.558 . . . . 0.0 117.907 -176.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.15 -126.11 1.47 Allowed Glycine 0 N--CA 1.488 2.137 0 C-N-CA 124.003 0.811 . . . . 0.0 111.368 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -131.18 169.1 16.38 Favored 'General case' 0 CA--C 1.569 1.694 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -172.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.61 142.75 49.96 Favored 'General case' 0 CA--C 1.564 1.507 0 O-C-N 120.569 -1.332 . . . . 0.0 110.796 174.231 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.2 t -75.03 -38.53 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.294 0 O-C-N 120.954 -1.091 . . . . 0.0 113.57 173.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t . . . . . 0 N--CA 1.495 1.791 0 O-C-N 120.802 -1.186 . . . . 0.0 108.307 176.3 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.575 1.917 0 N-CA-C 120.421 3.489 . . . . 0.0 120.421 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.04 173.76 6.16 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 121.006 1.73 . . . . 0.0 113.882 177.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -117.81 54.03 0.62 Allowed Glycine 0 N--CA 1.501 2.976 0 O-C-N 120.306 -1.496 . . . . 0.0 116.595 176.251 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.25 -54.94 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 124.274 1.03 . . . . 0.0 109.631 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.88 173.86 30.27 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 118.09 1.996 . . . . 0.0 118.09 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.8 t -116.04 43.83 2.06 Favored 'General case' 0 N--CA 1.504 2.249 0 N-CA-C 116.083 1.882 . . . . 0.0 116.083 -175.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 18.5 p -166.77 142.55 4.43 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.752 -1.218 . . . . 0.0 110.367 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -57.55 133.78 55.55 Favored 'General case' 0 CA--C 1.581 2.173 0 N-CA-C 117.616 2.45 . . . . 0.0 117.616 -174.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -81.85 -64.14 1.24 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 123.041 0.536 . . . . 0.0 112.406 171.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -148.59 120.98 8.45 Favored 'General case' 0 CA--C 1.566 1.565 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.46 105.64 0.06 Allowed 'General case' 0 CA--C 1.573 1.828 0 N-CA-C 116.834 2.161 . . . . 0.0 116.834 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.68 -45.59 1.13 Allowed Glycine 0 N--CA 1.491 2.354 0 CA-C-O 118.548 -1.14 . . . . 0.0 115.816 -170.314 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 31.2 t -83.52 -59.01 2.58 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 116.809 2.151 . . . . 0.0 116.809 -178.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.62 -121.64 0.9 Allowed Glycine 0 N--CA 1.487 2.07 0 CA-C-N 119.918 1.236 . . . . 0.0 114.242 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -124.37 172.37 9.19 Favored 'General case' 0 CA--C 1.566 1.573 0 N-CA-C 115.248 1.573 . . . . 0.0 115.248 -167.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.22 144.48 48.46 Favored 'General case' 0 CA--C 1.561 1.381 0 O-C-N 120.542 -1.349 . . . . 0.0 111.073 174.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -72.31 -43.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 121.0 -1.063 . . . . 0.0 111.57 168.133 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t . . . . . 0 N--CA 1.495 1.778 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 168.732 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.4 t . . . . . 0 CA--C 1.575 1.937 0 N-CA-C 121.185 3.772 . . . . 0.0 121.185 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 173.36 6.34 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-N 121.364 1.893 . . . . 0.0 113.806 177.034 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.71 51.21 0.73 Allowed Glycine 0 N--CA 1.502 3.034 0 O-C-N 119.971 -1.706 . . . . 0.0 117.326 176.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -132.53 -56.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 C-N-CA 123.938 0.895 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.97 168.13 41.2 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 119.283 2.473 . . . . 0.0 119.283 -174.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.7 p -105.99 55.13 0.68 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -174.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 19.2 p -178.15 140.62 0.23 Allowed 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 125.021 1.329 . . . . 0.0 109.263 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -69.64 136.25 50.93 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 116.274 1.953 . . . . 0.0 116.274 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 49.7 p30 -78.2 -63.66 1.34 Allowed 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 123.194 0.597 . . . . 0.0 112.104 175.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -147.93 124.41 11.01 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.653 -2.351 . . . . 0.0 104.653 175.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.08 105.81 0.06 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.386 1.995 . . . . 0.0 116.386 179.056 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.89 -47.23 1.03 Allowed Glycine 0 N--CA 1.491 2.329 0 CA-C-O 118.366 -1.241 . . . . 0.0 115.335 -169.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 t -86.08 -61.95 1.63 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.37 -119.98 0.78 Allowed Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.942 1.246 . . . . 0.0 114.351 -175.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -126.89 172.83 10.08 Favored 'General case' 0 CA--C 1.571 1.754 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -167.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -130.5 141.56 50.5 Favored 'General case' 0 CA--C 1.563 1.473 0 O-C-N 120.281 -1.512 . . . . 0.0 110.855 174.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 -41.8 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.02 -1.05 . . . . 0.0 112.628 171.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t . . . . . 0 N--CA 1.495 1.799 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 172.625 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 m . . . . . 0 CA--C 1.575 1.919 0 N-CA-C 120.431 3.493 . . . . 0.0 120.431 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.255 0.3 OUTLIER -89.99 169.26 11.36 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-N 122.247 2.294 . . . . 0.0 116.066 -172.449 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.01 51.83 0.68 Allowed Glycine 0 N--CA 1.5 2.932 0 N-CA-C 117.032 1.573 . . . . 0.0 117.032 177.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.07 -56.66 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 C-N-CA 123.883 0.873 . . . . 0.0 110.228 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -69.75 175.91 33.45 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 118.712 2.245 . . . . 0.0 118.712 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 p -114.24 56.23 0.72 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 115.499 1.666 . . . . 0.0 115.499 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.269 11.7 p -164.59 -129.38 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.194 -0.941 . . . . 0.0 110.98 176.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -144.92 142.42 29.85 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 121.143 1.792 . . . . 0.0 111.74 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -91.9 -73.54 0.54 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-N 114.254 -1.339 . . . . 0.0 110.118 172.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -137.72 76.42 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -172.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.22 80.9 0.05 OUTLIER 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 172.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.29 -23.98 6.7 Favored Glycine 0 N--CA 1.5 2.908 0 N-CA-C 119.016 2.367 . . . . 0.0 119.016 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -54.37 -46.41 73.0 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 117.024 2.231 . . . . 0.0 117.024 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.47 -132.6 2.36 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 124.053 0.835 . . . . 0.0 111.148 175.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -119.83 -178.63 3.68 Favored 'General case' 0 CA--C 1.567 1.604 0 CA-C-O 122.231 1.015 . . . . 0.0 112.353 -173.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.2 145.11 26.97 Favored 'General case' 0 CA--C 1.562 1.41 0 O-C-N 120.115 -1.616 . . . . 0.0 111.665 172.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.5 t -71.81 -45.77 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 O-C-N 121.185 -0.947 . . . . 0.0 112.044 172.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t . . . . . 0 N--CA 1.495 1.792 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 167.561 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 t . . . . . 0 CA--C 1.574 1.893 0 N-CA-C 119.056 2.984 . . . . 0.0 119.056 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.46 174.07 6.03 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 120.62 1.555 . . . . 0.0 114.489 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.86 56.35 0.64 Allowed Glycine 0 N--CA 1.501 2.969 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 175.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.19 -53.39 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 C-N-CA 124.579 1.152 . . . . 0.0 109.32 177.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.07 173.6 27.74 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 118.783 2.273 . . . . 0.0 118.783 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -115.82 50.09 1.05 Allowed 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 115.914 1.82 . . . . 0.0 115.914 -175.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.271 18.8 p -160.53 -124.26 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.884 -1.135 . . . . 0.0 110.782 175.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -146.05 138.08 25.17 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-N 121.149 1.795 . . . . 0.0 112.126 -179.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.7 p-10 -87.65 -61.85 1.63 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.108 171.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -146.83 128.38 15.08 Favored 'General case' 0 CA--C 1.568 1.637 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 174.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.85 106.29 0.1 Allowed 'General case' 0 CA--C 1.571 1.771 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.58 -46.55 1.07 Allowed Glycine 0 N--CA 1.491 2.363 0 CA-C-O 118.406 -1.219 . . . . 0.0 115.416 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -84.15 -61.93 1.69 Allowed 'General case' 0 CA--C 1.57 1.726 0 N-CA-C 116.291 1.959 . . . . 0.0 116.291 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.97 -121.47 0.77 Allowed Glycine 0 N--CA 1.489 2.174 0 CA-C-N 120.471 1.487 . . . . 0.0 115.752 -176.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -116.27 176.51 5.07 Favored 'General case' 0 CA--C 1.566 1.578 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -166.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.52 147.85 28.69 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.234 -1.541 . . . . 0.0 112.363 175.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -75.1 -46.24 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.627 -0.671 . . . . 0.0 111.263 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t . . . . . 0 N--CA 1.495 1.781 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 169.5 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.576 1.957 0 N-CA-C 119.459 3.133 . . . . 0.0 119.459 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.3 0.2 OUTLIER -90.15 179.23 5.97 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 121.613 2.006 . . . . 0.0 115.004 -174.401 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -98.25 -42.78 2.92 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 118.707 2.243 . . . . 0.0 118.707 178.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -82.85 56.41 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 117.486 2.402 . . . . 0.0 117.486 -173.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -153.0 175.25 31.58 Favored Glycine 0 N--CA 1.49 2.255 0 O-C-N 120.902 -1.124 . . . . 0.0 115.302 172.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.6 p -122.03 54.7 1.15 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.267 12.4 p -164.49 -130.82 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 C-N-CA 123.875 0.87 . . . . 0.0 110.156 174.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -150.05 133.1 16.2 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 119.988 -1.695 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.13 -58.06 2.92 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -141.35 77.11 1.58 Allowed 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 118.845 0.748 . . . . 0.0 111.909 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 36.38 75.5 0.06 Allowed 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 119.036 2.976 . . . . 0.0 119.036 175.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.24 -17.95 57.26 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 119.16 2.424 . . . . 0.0 119.16 -173.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.7 t -60.68 -52.75 63.81 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 116.758 2.133 . . . . 0.0 116.758 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.1 -120.86 0.65 Allowed Glycine 0 N--CA 1.489 2.169 0 O-C-N 121.573 -0.705 . . . . 0.0 112.258 175.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -122.62 172.54 8.32 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.941 0.897 . . . . 0.0 112.319 -173.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.0 141.96 34.31 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.393 -1.442 . . . . 0.0 111.606 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.7 m -73.18 -35.21 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 175.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t . . . . . 0 N--CA 1.497 1.911 0 CA-C-N 120.027 1.285 . . . . 0.0 107.875 175.239 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.2 m . . . . . 0 CA--C 1.577 1.982 0 N-CA-C 119.127 3.01 . . . . 0.0 119.127 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.259 0.3 OUTLIER -88.84 170.92 10.32 Favored 'General case' 0 N--CA 1.499 1.996 0 CA-C-N 122.024 2.193 . . . . 0.0 115.691 -172.741 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.9 50.12 0.8 Allowed Glycine 0 N--CA 1.5 2.921 0 N-CA-C 116.734 1.454 . . . . 0.0 116.734 176.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.53 -53.97 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 C-N-CA 124.193 0.997 . . . . 0.0 110.181 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.97 175.91 17.61 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 118.186 2.034 . . . . 0.0 118.186 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 t -116.67 48.03 1.35 Allowed 'General case' 0 N--CA 1.502 2.157 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -176.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 22.9 p -162.68 -120.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.787 -1.196 . . . . 0.0 111.426 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -148.13 138.61 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 CA-C-N 121.477 1.944 . . . . 0.0 112.966 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.41 -68.33 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 114.514 -1.221 . . . . 0.0 111.934 174.11 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.69 81.43 1.65 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 123.1 0.56 . . . . 0.0 112.057 -172.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.9 77.86 0.09 Allowed 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 117.991 2.589 . . . . 0.0 117.991 174.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.47 -16.76 22.88 Favored Glycine 0 N--CA 1.499 2.883 0 N-CA-C 119.876 2.71 . . . . 0.0 119.876 -176.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.2 t -56.83 -47.0 81.31 Favored 'General case' 0 N--CA 1.501 2.09 0 N-CA-C 117.447 2.388 . . . . 0.0 117.447 -178.438 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.66 -129.71 1.49 Allowed Glycine 0 N--CA 1.486 1.981 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -118.17 179.67 4.03 Favored 'General case' 0 CA--C 1.564 1.491 0 CA-C-O 122.01 0.909 . . . . 0.0 113.1 -174.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -158.79 148.97 19.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.342 -1.474 . . . . 0.0 112.287 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -70.76 -42.88 77.61 Favored 'Isoleucine or valine' 0 CA--C 1.581 2.162 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 165.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t . . . . . 0 N--CA 1.497 1.886 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 168.373 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.573 1.859 0 N-CA-C 119.43 3.122 . . . . 0.0 119.43 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.324 0.9 OUTLIER -110.42 -161.89 0.77 Allowed 'General case' 0 CA--C 1.58 2.105 0 CA-C-N 120.843 1.656 . . . . 0.0 114.871 -176.107 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.33 63.19 0.42 Allowed Glycine 0 N--CA 1.502 3.041 0 N-CA-C 117.89 1.916 . . . . 0.0 117.89 -175.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.575 1.927 0 C-N-CA 124.343 1.057 . . . . 0.0 108.948 172.398 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -73.35 177.53 43.02 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 119.766 2.667 . . . . 0.0 119.766 -177.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 p -114.68 54.01 0.79 Allowed 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 115.165 1.543 . . . . 0.0 115.165 -175.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.4 p -169.22 134.27 1.51 Allowed 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 124.332 1.053 . . . . 0.0 109.546 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -70.12 129.25 38.91 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 37.8 p-10 -75.19 -60.29 2.36 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 177.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -144.01 85.76 1.82 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 123.448 0.699 . . . . 0.0 109.476 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 11.19 74.87 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.207 0 N-CA-C 121.024 3.713 . . . . 0.0 121.024 175.663 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.58 -38.8 2.53 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 117.008 1.563 . . . . 0.0 117.008 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.4 t -63.91 -56.98 11.24 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 116.873 2.175 . . . . 0.0 116.873 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.91 -122.31 0.87 Allowed Glycine 0 N--CA 1.488 2.104 0 O-C-N 121.269 -0.894 . . . . 0.0 113.921 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -136.55 150.37 48.58 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 124.031 0.932 . . . . 0.0 113.487 -170.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.31 141.13 39.14 Favored 'General case' 0 CA--C 1.563 1.447 0 C-N-CA 123.768 0.827 . . . . 0.0 110.984 175.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -73.54 -40.49 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 120.94 -1.1 . . . . 0.0 112.645 171.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t . . . . . 0 N--CA 1.495 1.819 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 171.825 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.576 1.943 0 N-CA-C 119.995 3.331 . . . . 0.0 119.995 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -78.48 178.45 7.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 121.859 2.118 . . . . 0.0 113.933 177.469 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -123.51 56.13 0.68 Allowed Glycine 0 N--CA 1.501 3.012 0 O-C-N 120.297 -1.502 . . . . 0.0 116.725 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.86 -53.45 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.576 1.961 0 C-N-CA 124.411 1.084 . . . . 0.0 109.54 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -63.63 158.89 39.41 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 119.137 2.415 . . . . 0.0 119.137 -177.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -99.47 44.77 1.01 Allowed 'General case' 0 N--CA 1.5 2.075 0 N-CA-C 116.239 1.941 . . . . 0.0 116.239 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.5 p -175.62 152.42 1.3 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 125.156 1.383 . . . . 0.0 109.676 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -67.38 144.81 55.6 Favored 'General case' 0 CA--C 1.58 2.111 0 N-CA-C 116.708 2.114 . . . . 0.0 116.708 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -76.14 -70.03 0.47 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 118.002 -0.999 . . . . 0.0 112.139 172.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -153.48 100.96 2.46 Favored 'General case' 0 CA--C 1.563 1.476 0 CA-C-N 120.012 1.278 . . . . 0.0 109.39 -173.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 45.62 67.81 0.68 Allowed 'General case' 0 CA--C 1.574 1.889 0 N-CA-C 119.005 2.965 . . . . 0.0 119.005 173.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.65 -11.97 57.71 Favored Glycine 0 N--CA 1.499 2.874 0 N-CA-C 120.93 3.132 . . . . 0.0 120.93 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.14 -39.26 93.64 Favored 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 117.975 2.583 . . . . 0.0 117.975 -176.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.95 -123.02 1.08 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 124.277 0.942 . . . . 0.0 111.126 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -131.21 171.73 12.95 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.065 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.89 151.71 29.79 Favored 'General case' 0 CA--C 1.562 1.434 0 O-C-N 120.344 -1.472 . . . . 0.0 111.738 174.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.67 -46.46 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.389 0 O-C-N 121.027 -1.046 . . . . 0.0 111.686 166.263 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.9 t . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 169.342 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 t . . . . . 0 N--CA 1.498 1.938 0 N-CA-C 119.609 3.189 . . . . 0.0 119.609 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.36 171.47 13.48 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-N 121.583 1.992 . . . . 0.0 114.57 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -119.75 55.21 0.62 Allowed Glycine 0 N--CA 1.502 3.038 0 N-CA-C 116.149 1.22 . . . . 0.0 116.149 175.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.11 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 124.61 1.164 . . . . 0.0 109.099 177.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.28 170.55 34.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 118.631 2.212 . . . . 0.0 118.631 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.2 p -114.63 55.73 0.74 Allowed 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 115.184 1.55 . . . . 0.0 115.184 -175.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 25.2 p -162.92 -129.05 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.14 -0.975 . . . . 0.0 110.967 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -145.24 138.3 26.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 119.983 -1.698 . . . . 0.0 111.301 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -85.79 -58.17 2.76 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 123.926 0.89 . . . . 0.0 111.303 172.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -150.14 134.48 17.25 Favored 'General case' 0 CA--C 1.571 1.762 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 172.102 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -44.9 113.12 0.51 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.802 2.149 . . . . 0.0 116.802 -177.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.65 -27.96 16.88 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 118.358 2.103 . . . . 0.0 118.358 -171.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.49 -53.78 5.44 Favored 'General case' 0 CA--C 1.573 1.845 0 CA-C-N 119.806 1.803 . . . . 0.0 115.687 -177.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.5 -133.08 2.71 Favored Glycine 0 N--CA 1.49 2.266 0 O-C-N 121.09 -1.006 . . . . 0.0 113.939 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -113.09 175.73 5.32 Favored 'General case' 0 CA--C 1.566 1.589 0 CA-C-O 122.02 0.914 . . . . 0.0 113.383 -170.303 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.2 146.54 31.78 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.106 -1.621 . . . . 0.0 112.542 176.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.5 t -77.87 -43.23 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.578 -0.701 . . . . 0.0 111.874 170.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t . . . . . 0 N--CA 1.497 1.88 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 172.758 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.574 1.885 0 N-CA-C 119.561 3.171 . . . . 0.0 119.561 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.365 1.3 pt? -98.35 -161.02 0.84 Allowed 'General case' 0 CA--C 1.577 2.016 0 CA-C-N 121.647 2.021 . . . . 0.0 115.397 -173.096 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.44 64.57 0.41 Allowed Glycine 0 N--CA 1.5 2.938 0 O-C-N 119.758 -1.839 . . . . 0.0 117.647 -175.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.11 -54.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.899 0 C-N-CA 124.227 1.011 . . . . 0.0 108.941 172.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.81 179.12 47.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 119.674 2.63 . . . . 0.0 119.674 -177.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.6 p -115.21 53.06 0.84 Allowed 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 -177.323 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.0 p -167.61 134.49 2.22 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 124.342 1.057 . . . . 0.0 109.695 -179.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -69.37 132.33 46.21 Favored 'General case' 0 CA--C 1.573 1.831 0 N-CA-C 115.462 1.653 . . . . 0.0 115.462 -173.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.2 p-10 -73.68 -67.44 0.59 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 113.455 0.909 . . . . 0.0 113.455 176.294 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -139.42 76.43 1.56 Allowed 'General case' 0 N--CA 1.494 1.767 0 CA-C-N 118.634 0.652 . . . . 0.0 112.007 -171.167 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 41.7 79.08 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 118.392 2.738 . . . . 0.0 118.392 175.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.22 -22.93 20.66 Favored Glycine 0 N--CA 1.498 2.81 0 N-CA-C 119.164 2.425 . . . . 0.0 119.164 -174.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -58.22 -49.66 76.31 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 117.552 2.427 . . . . 0.0 117.552 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.37 -125.92 1.15 Allowed Glycine 0 N--CA 1.487 2.036 0 O-C-N 121.547 -0.721 . . . . 0.0 112.332 177.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -140.72 146.94 38.42 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -173.269 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -109.38 142.85 39.74 Favored 'General case' 0 CA--C 1.563 1.443 0 C-N-CA 123.558 0.743 . . . . 0.0 111.366 174.335 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -71.42 -43.8 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 120.797 -1.189 . . . . 0.0 112.423 170.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t . . . . . 0 N--CA 1.496 1.848 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 169.934 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 t . . . . . 0 CA--C 1.574 1.868 0 N-CA-C 119.36 3.096 . . . . 0.0 119.36 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.13 173.19 6.41 Favored 'General case' 0 CA--C 1.576 1.959 0 CA-C-N 120.618 1.554 . . . . 0.0 114.452 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.52 56.29 0.63 Allowed Glycine 0 N--CA 1.501 3.026 0 N-CA-C 116.127 1.211 . . . . 0.0 116.127 175.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.5 -52.91 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 C-N-CA 124.488 1.115 . . . . 0.0 109.418 177.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.91 178.44 25.48 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 119.064 2.385 . . . . 0.0 119.064 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -119.82 50.41 1.28 Allowed 'General case' 0 N--CA 1.5 2.05 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 -175.523 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.253 22.4 p -157.25 -129.31 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.84 -1.162 . . . . 0.0 110.821 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -144.42 135.67 25.4 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.765 1.621 . . . . 0.0 111.071 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.4 p-10 -86.82 -60.41 1.99 Allowed 'General case' 0 N--CA 1.491 1.608 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.336 173.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -147.16 127.42 13.88 Favored 'General case' 0 CA--C 1.566 1.595 0 N-CA-C 105.364 -2.087 . . . . 0.0 105.364 173.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.85 106.8 0.1 Allowed 'General case' 0 CA--C 1.574 1.868 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.1 -46.03 1.1 Allowed Glycine 0 N--CA 1.492 2.406 0 CA-C-O 118.436 -1.202 . . . . 0.0 115.497 -169.5 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.4 t -83.57 -61.62 1.79 Allowed 'General case' 0 CA--C 1.569 1.677 0 N-CA-C 116.282 1.956 . . . . 0.0 116.282 -178.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.53 -121.19 0.76 Allowed Glycine 0 N--CA 1.488 2.133 0 CA-C-N 120.504 1.502 . . . . 0.0 115.803 -177.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.43 174.72 5.91 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -166.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.89 147.03 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 120.348 -1.47 . . . . 0.0 112.113 174.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.7 t -76.93 -44.0 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.575 -0.703 . . . . 0.0 112.61 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.5 t . . . . . 0 N--CA 1.496 1.861 0 CA-C-N 119.668 1.122 . . . . 0.0 108.095 175.613 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.574 1.887 0 N-CA-C 120.325 3.454 . . . . 0.0 120.325 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.3 179.55 4.55 Favored 'General case' 0 CA--C 1.579 2.073 0 CA-C-N 121.093 1.77 . . . . 0.0 114.088 178.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -124.21 58.46 0.64 Allowed Glycine 0 N--CA 1.501 3.005 0 O-C-N 120.259 -1.525 . . . . 0.0 116.697 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -131.54 -54.75 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 124.403 1.081 . . . . 0.0 109.391 176.128 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.58 -179.97 28.76 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 119.232 2.453 . . . . 0.0 119.232 -177.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -121.29 43.79 2.71 Favored 'General case' 0 N--CA 1.504 2.272 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -175.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 21.1 p -163.56 139.81 6.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.79 -1.194 . . . . 0.0 109.821 177.586 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -63.5 137.81 58.27 Favored 'General case' 0 CA--C 1.577 2.014 0 N-CA-C 116.266 1.95 . . . . 0.0 116.266 -174.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.277 39.1 p-10 -80.68 -80.86 0.13 Allowed 'General case' 0 N--CA 1.489 1.512 0 CA-C-O 118.237 -0.887 . . . . 0.0 113.223 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -121.29 55.42 1.07 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -173.408 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . 0.264 . . 57.65 7.56 0.56 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 121.762 3.986 . . . . 0.0 121.762 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.61 64.02 0.03 OUTLIER Glycine 0 N--CA 1.491 2.322 0 O-C-N 120.866 -1.146 . . . . 0.0 115.152 -177.448 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 54.0 t -156.84 -64.68 0.1 Allowed 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 123.589 0.756 . . . . 0.0 111.464 177.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.77 -117.83 0.46 Allowed Glycine 0 N--CA 1.483 1.788 0 O-C-N 121.633 -0.667 . . . . 0.0 112.391 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -129.23 172.23 11.66 Favored 'General case' 0 CA--C 1.566 1.591 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -168.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.45 143.87 47.78 Favored 'General case' 0 CA--C 1.563 1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 110.705 173.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.1 t -74.06 -43.92 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.106 -0.996 . . . . 0.0 112.326 171.055 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.6 t . . . . . 0 N--CA 1.495 1.804 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 172.035 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 120.275 3.435 . . . . 0.0 120.275 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.43 166.75 18.11 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 121.859 2.118 . . . . 0.0 115.161 -178.145 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.37 49.96 0.81 Allowed Glycine 0 N--CA 1.5 2.9 0 N-CA-C 116.701 1.441 . . . . 0.0 116.701 176.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -133.58 -55.23 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 124.334 1.054 . . . . 0.0 109.991 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.71 169.35 38.09 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 118.311 2.084 . . . . 0.0 118.311 -178.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.8 p -109.77 56.15 0.63 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 115.526 1.676 . . . . 0.0 115.526 -174.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.254 22.5 p -164.26 -131.71 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.124 -0.985 . . . . 0.0 111.111 176.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -146.36 136.26 23.4 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 119.933 -1.73 . . . . 0.0 111.295 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.0 p30 -82.84 -63.32 1.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.012 -0.995 . . . . 0.0 111.136 174.084 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -145.24 124.0 12.61 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.956 -2.239 . . . . 0.0 104.956 174.507 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -38.36 111.18 0.16 Allowed 'General case' 0 CA--C 1.573 1.839 0 N-CA-C 117.892 2.553 . . . . 0.0 117.892 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.05 -32.25 7.04 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 117.917 1.927 . . . . 0.0 117.917 -171.463 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -80.31 -51.67 8.62 Favored 'General case' 0 CA--C 1.574 1.867 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 -176.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.14 -135.13 3.46 Favored Glycine 0 N--CA 1.49 2.295 0 O-C-N 121.203 -0.936 . . . . 0.0 113.243 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -114.23 178.98 4.09 Favored 'General case' 0 CA--C 1.567 1.607 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -171.252 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.96 145.3 30.6 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.058 -1.651 . . . . 0.0 112.262 175.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.4 t -75.82 -45.34 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 O-C-N 121.393 -0.817 . . . . 0.0 111.691 171.096 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t . . . . . 0 N--CA 1.496 1.842 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 171.576 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.497 1.898 0 N-CA-C 119.781 3.252 . . . . 0.0 119.781 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.41 171.6 13.3 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 121.59 1.996 . . . . 0.0 114.571 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.48 55.57 0.63 Allowed Glycine 0 N--CA 1.5 2.955 0 N-CA-C 116.015 1.166 . . . . 0.0 116.015 175.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.58 -52.55 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.89 0 C-N-CA 124.737 1.215 . . . . 0.0 109.055 177.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.16 173.92 31.18 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 118.673 2.229 . . . . 0.0 118.673 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -117.8 51.16 1.07 Allowed 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 115.317 1.599 . . . . 0.0 115.317 -175.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.256 25.6 p -157.48 -128.63 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.83 -1.169 . . . . 0.0 110.963 174.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -145.66 135.87 23.87 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-N 120.903 1.683 . . . . 0.0 111.533 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p-10 -83.34 -60.6 2.09 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.988 172.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -147.53 135.3 21.08 Favored 'General case' 0 CA--C 1.572 1.816 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 171.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.17 113.69 0.61 Allowed 'General case' 0 CA--C 1.573 1.842 0 N-CA-C 116.795 2.146 . . . . 0.0 116.795 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.26 -26.88 22.28 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 118.431 2.132 . . . . 0.0 118.431 -171.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.57 -54.02 5.24 Favored 'General case' 0 CA--C 1.573 1.849 0 CA-C-N 119.809 1.805 . . . . 0.0 115.606 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.46 -133.0 2.69 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 121.079 -1.013 . . . . 0.0 113.942 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -112.86 175.32 5.49 Favored 'General case' 0 CA--C 1.567 1.605 0 CA-C-O 122.121 0.962 . . . . 0.0 113.354 -170.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.09 147.01 33.19 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.159 -1.588 . . . . 0.0 112.092 175.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 66.2 t -77.77 -42.52 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 O-C-N 121.544 -0.722 . . . . 0.0 112.493 172.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t . . . . . 0 N--CA 1.497 1.901 0 CA-C-N 119.839 1.2 . . . . 0.0 108.12 175.105 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 t . . . . . 0 N--CA 1.498 1.97 0 N-CA-C 119.886 3.291 . . . . 0.0 119.886 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.77 166.04 17.29 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 121.615 2.007 . . . . 0.0 114.861 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -110.85 48.77 0.9 Allowed Glycine 0 N--CA 1.501 2.984 0 N-CA-C 116.957 1.543 . . . . 0.0 116.957 177.184 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.53 -55.67 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 C-N-CA 124.168 0.987 . . . . 0.0 110.267 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.52 34.84 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 118.612 2.205 . . . . 0.0 118.612 -177.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.7 p -112.99 58.15 0.66 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 19.4 p -165.71 -132.7 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 110.868 175.592 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -144.03 139.3 28.91 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 119.877 -1.765 . . . . 0.0 111.313 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.4 p-10 -90.65 -65.61 1.0 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.95 176.056 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -139.82 77.44 1.61 Allowed 'General case' 0 N--CA 1.494 1.744 0 CA-C-N 119.06 0.845 . . . . 0.0 111.254 -175.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 32.64 80.68 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 119.403 3.112 . . . . 0.0 119.403 174.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.48 -28.45 14.13 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 118.391 2.116 . . . . 0.0 118.391 -173.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.4 t -59.93 -41.37 91.63 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 117.298 2.333 . . . . 0.0 117.298 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.35 -135.94 3.93 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 124.024 0.821 . . . . 0.0 111.814 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -115.36 176.65 4.97 Favored 'General case' 0 CA--C 1.565 1.533 0 CA-C-O 122.084 0.945 . . . . 0.0 113.257 -173.115 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.0 144.92 37.22 Favored 'General case' 0 CA--C 1.562 1.432 0 O-C-N 120.258 -1.526 . . . . 0.0 111.776 175.282 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -74.75 -42.26 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 174.522 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 N--CA 1.496 1.845 0 CA-C-N 119.883 1.22 . . . . 0.0 108.033 175.712 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 119.08 2.993 . . . . 0.0 119.08 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.85 169.15 14.43 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 121.34 1.882 . . . . 0.0 114.585 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -112.48 48.17 0.97 Allowed Glycine 0 N--CA 1.499 2.878 0 N-CA-C 117.097 1.599 . . . . 0.0 117.097 177.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -131.5 -54.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 124.156 0.982 . . . . 0.0 110.179 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.8 172.67 23.93 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 p -114.34 54.06 0.78 Allowed 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 115.53 1.678 . . . . 0.0 115.53 -175.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.262 22.0 p -165.99 -124.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.18 -0.95 . . . . 0.0 110.841 176.218 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -147.85 140.44 24.6 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-N 120.94 1.7 . . . . 0.0 111.717 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -82.47 -71.67 0.48 Allowed 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.469 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -145.26 85.91 1.75 Allowed 'General case' 0 CA--C 1.566 1.585 0 CA-C-N 119.548 1.067 . . . . 0.0 111.736 -179.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 50.89 81.66 0.07 Allowed 'General case' 0 CA--C 1.571 1.782 0 N-CA-C 118.017 2.599 . . . . 0.0 118.017 173.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.52 -21.97 8.19 Favored Glycine 0 N--CA 1.5 2.929 0 N-CA-C 120.31 2.884 . . . . 0.0 120.31 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.1 t -59.43 -39.55 83.9 Favored 'General case' 0 N--CA 1.5 2.074 0 N-CA-C 117.689 2.477 . . . . 0.0 117.689 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.5 -132.85 2.61 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 124.108 0.861 . . . . 0.0 111.239 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -117.95 178.47 4.41 Favored 'General case' 0 CA--C 1.565 1.548 0 CA-C-O 122.127 0.965 . . . . 0.0 113.446 -173.26 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -155.73 146.28 21.96 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.371 -1.456 . . . . 0.0 112.594 175.608 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . 0.253 9.4 p -69.15 -45.95 78.79 Favored 'Isoleucine or valine' 0 CA--C 1.58 2.096 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 166.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.5 t . . . . . 0 CA--C 1.571 1.757 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 169.317 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.498 1.927 0 N-CA-C 120.815 3.635 . . . . 0.0 120.815 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.252 0.3 OUTLIER -80.77 174.32 11.73 Favored 'General case' 0 CA--C 1.578 2.025 0 CA-C-N 122.136 2.244 . . . . 0.0 114.381 178.984 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.49 57.74 0.6 Allowed Glycine 0 N--CA 1.501 2.981 0 O-C-N 120.404 -1.435 . . . . 0.0 116.455 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.29 -53.91 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 C-N-CA 124.513 1.125 . . . . 0.0 108.981 176.205 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.46 168.67 42.12 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 118.417 2.127 . . . . 0.0 118.417 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -112.66 43.11 1.71 Allowed 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.8 p -164.83 142.77 6.43 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 124.546 1.138 . . . . 0.0 109.729 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.7 140.23 58.85 Favored 'General case' 0 CA--C 1.579 2.085 0 N-CA-C 118.006 2.595 . . . . 0.0 118.006 -171.458 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p30 -79.7 -60.99 2.13 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 123.444 0.698 . . . . 0.0 111.637 172.782 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -151.7 94.0 1.93 Allowed 'General case' 0 CA--C 1.566 1.595 0 CA-C-N 119.732 1.151 . . . . 0.0 109.202 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 13.42 83.28 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 121.438 3.866 . . . . 0.0 121.438 175.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.42 -35.74 4.2 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 117.648 1.819 . . . . 0.0 117.648 -174.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.7 t -68.88 -45.04 72.0 Favored 'General case' 0 CA--C 1.577 2.005 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 -177.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 160.47 -130.88 2.49 Favored Glycine 0 N--CA 1.489 2.203 0 O-C-N 121.359 -0.838 . . . . 0.0 112.745 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -125.09 171.66 10.1 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -170.744 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.23 140.96 37.88 Favored 'General case' 0 CA--C 1.564 1.49 0 O-C-N 120.364 -1.46 . . . . 0.0 110.615 175.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.1 m -69.03 -39.56 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.058 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.1 t . . . . . 0 N--CA 1.494 1.756 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 168.714 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.573 1.865 0 N-CA-C 119.177 3.029 . . . . 0.0 119.177 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.43 169.47 8.68 Favored 'General case' 0 CA--C 1.575 1.906 0 CA-C-N 120.664 1.575 . . . . 0.0 114.703 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.26 52.26 0.66 Allowed Glycine 0 N--CA 1.5 2.937 0 N-CA-C 116.669 1.428 . . . . 0.0 116.669 177.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.23 -54.83 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 C-N-CA 124.112 0.965 . . . . 0.0 110.211 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.53 177.73 25.27 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 118.825 2.29 . . . . 0.0 118.825 -177.269 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.7 t -116.43 53.46 0.88 Allowed 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 115.047 1.499 . . . . 0.0 115.047 -175.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -162.16 -129.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.92 -1.113 . . . . 0.0 110.974 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -144.1 139.89 29.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.932 -1.73 . . . . 0.0 110.832 178.442 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -90.97 -60.06 2.01 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 123.637 0.775 . . . . 0.0 111.256 172.719 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -147.22 127.25 13.67 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 174.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.84 106.56 0.09 Allowed 'General case' 0 CA--C 1.572 1.81 0 N-CA-C 116.001 1.852 . . . . 0.0 116.001 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.39 -46.02 1.1 Allowed Glycine 0 N--CA 1.492 2.381 0 CA-C-O 118.509 -1.162 . . . . 0.0 115.687 -169.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.3 t -83.46 -60.71 2.05 Favored 'General case' 0 CA--C 1.569 1.698 0 N-CA-C 116.611 2.078 . . . . 0.0 116.611 -178.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 178.24 -124.9 0.95 Allowed Glycine 0 N--CA 1.49 2.284 0 CA-C-N 120.314 1.416 . . . . 0.0 115.356 -176.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -115.05 178.19 4.38 Favored 'General case' 0 CA--C 1.566 1.577 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -168.687 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.6 141.29 33.47 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.346 -1.472 . . . . 0.0 112.087 175.234 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.86 -39.8 52.39 Favored 'Isoleucine or valine' 0 CA--C 1.576 1.951 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 170.127 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.1 t . . . . . 0 N--CA 1.496 1.848 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 170.94 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.498 1.955 0 N-CA-C 118.742 2.868 . . . . 0.0 118.742 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.3 173.51 11.53 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 121.056 1.753 . . . . 0.0 114.203 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.1 55.11 0.65 Allowed Glycine 0 N--CA 1.501 3.005 0 N-CA-C 116.217 1.247 . . . . 0.0 116.217 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.86 -52.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 C-N-CA 124.662 1.185 . . . . 0.0 109.195 177.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.82 172.87 23.65 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 118.506 2.163 . . . . 0.0 118.506 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -117.61 49.08 1.26 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 115.185 1.55 . . . . 0.0 115.185 -177.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.25 26.2 p -159.23 -122.8 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.85 -1.156 . . . . 0.0 110.961 175.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -147.56 142.35 26.78 Favored 'General case' 0 N--CA 1.491 1.625 0 CA-C-N 120.934 1.697 . . . . 0.0 111.999 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -91.01 -63.21 1.3 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 124.515 1.126 . . . . 0.0 113.343 176.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 94.4 m-85 -140.77 78.13 1.63 Allowed 'General case' 0 N--CA 1.495 1.808 0 CA-C-N 119.079 0.854 . . . . 0.0 111.237 -173.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 38.79 75.24 0.08 Allowed 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 118.717 2.858 . . . . 0.0 118.717 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.14 -19.83 51.09 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 119.545 2.578 . . . . 0.0 119.545 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.9 t -61.49 -41.35 97.14 Favored 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 117.766 2.506 . . . . 0.0 117.766 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.34 -128.04 1.49 Allowed Glycine 0 N--CA 1.489 2.198 0 O-C-N 121.361 -0.837 . . . . 0.0 111.726 177.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -120.04 174.25 6.59 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-O 122.058 0.932 . . . . 0.0 113.242 -173.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.26 147.36 25.59 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.403 -1.435 . . . . 0.0 112.787 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -73.4 -42.14 56.86 Favored 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 165.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.6 t -91.74 110.92 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 170.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 63.6 m -84.62 122.94 29.76 Favored 'General case' 0 CA--C 1.568 1.641 0 O-C-N 121.534 -0.729 . . . . 0.0 112.714 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -73.62 97.83 2.73 Favored 'General case' 0 CA--C 1.573 1.862 0 CA-C-O 122.991 1.377 . . . . 0.0 113.884 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 60.9 p-90 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 124.719 2.199 . . . . 0.0 114.064 -177.577 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.499 1.977 0 N-CA-C 120.745 3.609 . . . . 0.0 120.745 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.254 0.2 OUTLIER -80.56 176.18 10.01 Favored 'General case' 0 CA--C 1.579 2.075 0 CA-C-N 122.044 2.202 . . . . 0.0 114.139 177.942 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.45 56.27 0.61 Allowed Glycine 0 N--CA 1.501 3.013 0 O-C-N 120.206 -1.558 . . . . 0.0 116.828 176.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.0 mt -129.48 -59.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 C-N-CA 124.273 1.029 . . . . 0.0 109.455 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.31 172.02 42.26 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 119.836 2.694 . . . . 0.0 119.836 -175.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.8 p -110.74 51.23 0.78 Allowed 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -175.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.4 p -169.9 140.01 1.99 Allowed 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.44 1.096 . . . . 0.0 109.627 178.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -66.48 133.67 50.87 Favored 'General case' 0 CA--C 1.576 1.964 0 N-CA-C 115.652 1.723 . . . . 0.0 115.652 -176.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.254 26.3 p30 -71.54 -72.34 0.23 Allowed 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 123.77 0.828 . . . . 0.0 112.884 177.027 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -144.21 87.75 1.91 Allowed 'General case' 0 CA--C 1.566 1.588 0 CA-C-N 119.42 1.009 . . . . 0.0 110.923 -178.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.79 82.72 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 118.366 2.728 . . . . 0.0 118.366 173.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.94 -23.94 5.58 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 120.097 2.799 . . . . 0.0 120.097 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.9 t -58.82 -40.78 85.17 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 117.907 2.558 . . . . 0.0 117.907 -176.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.15 -126.11 1.47 Allowed Glycine 0 N--CA 1.488 2.137 0 C-N-CA 124.003 0.811 . . . . 0.0 111.368 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -131.18 169.1 16.38 Favored 'General case' 0 CA--C 1.569 1.694 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -172.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.61 142.75 49.96 Favored 'General case' 0 CA--C 1.564 1.507 0 O-C-N 120.569 -1.332 . . . . 0.0 110.796 174.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.2 t -75.03 -38.53 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.294 0 O-C-N 120.954 -1.091 . . . . 0.0 113.57 173.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -87.82 96.5 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.802 -1.186 . . . . 0.0 108.307 176.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 82.1 m -91.25 83.24 5.49 Favored 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 114.079 1.141 . . . . 0.0 114.079 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.58 108.91 4.82 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 122.205 1.002 . . . . 0.0 108.878 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 59.8 m95 . . . . . 0 N--CA 1.495 1.824 0 CA-C-O 124.355 2.026 . . . . 0.0 113.871 -175.329 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.575 1.917 0 N-CA-C 120.421 3.489 . . . . 0.0 120.421 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.04 173.76 6.16 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 121.006 1.73 . . . . 0.0 113.882 177.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -117.81 54.03 0.62 Allowed Glycine 0 N--CA 1.501 2.976 0 O-C-N 120.306 -1.496 . . . . 0.0 116.595 176.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.25 -54.94 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 124.274 1.03 . . . . 0.0 109.631 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.88 173.86 30.27 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 118.09 1.996 . . . . 0.0 118.09 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.8 t -116.04 43.83 2.06 Favored 'General case' 0 N--CA 1.504 2.249 0 N-CA-C 116.083 1.882 . . . . 0.0 116.083 -175.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 18.5 p -166.77 142.55 4.43 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.752 -1.218 . . . . 0.0 110.367 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -57.55 133.78 55.55 Favored 'General case' 0 CA--C 1.581 2.173 0 N-CA-C 117.616 2.45 . . . . 0.0 117.616 -174.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -81.85 -64.14 1.24 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 123.041 0.536 . . . . 0.0 112.406 171.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -148.59 120.98 8.45 Favored 'General case' 0 CA--C 1.566 1.565 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.46 105.64 0.06 Allowed 'General case' 0 CA--C 1.573 1.828 0 N-CA-C 116.834 2.161 . . . . 0.0 116.834 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.68 -45.59 1.13 Allowed Glycine 0 N--CA 1.491 2.354 0 CA-C-O 118.548 -1.14 . . . . 0.0 115.816 -170.314 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 31.2 t -83.52 -59.01 2.58 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 116.809 2.151 . . . . 0.0 116.809 -178.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.62 -121.64 0.9 Allowed Glycine 0 N--CA 1.487 2.07 0 CA-C-N 119.918 1.236 . . . . 0.0 114.242 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -124.37 172.37 9.19 Favored 'General case' 0 CA--C 1.566 1.573 0 N-CA-C 115.248 1.573 . . . . 0.0 115.248 -167.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.22 144.48 48.46 Favored 'General case' 0 CA--C 1.561 1.381 0 O-C-N 120.542 -1.349 . . . . 0.0 111.073 174.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -72.31 -43.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 121.0 -1.063 . . . . 0.0 111.57 168.133 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -86.12 110.98 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 168.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 97.3 m -73.0 115.59 12.49 Favored 'General case' 0 CA--C 1.567 1.62 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -82.79 97.05 8.4 Favored 'General case' 0 CA--C 1.569 1.687 0 CA-C-O 122.155 0.979 . . . . 0.0 112.988 -173.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 57.1 p-90 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 123.091 1.425 . . . . 0.0 111.969 179.712 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.4 t . . . . . 0 CA--C 1.575 1.937 0 N-CA-C 121.185 3.772 . . . . 0.0 121.185 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 173.36 6.34 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-N 121.364 1.893 . . . . 0.0 113.806 177.034 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.71 51.21 0.73 Allowed Glycine 0 N--CA 1.502 3.034 0 O-C-N 119.971 -1.706 . . . . 0.0 117.326 176.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -132.53 -56.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 C-N-CA 123.938 0.895 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.97 168.13 41.2 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 119.283 2.473 . . . . 0.0 119.283 -174.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.7 p -105.99 55.13 0.68 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -174.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 19.2 p -178.15 140.62 0.23 Allowed 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 125.021 1.329 . . . . 0.0 109.263 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -69.64 136.25 50.93 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 116.274 1.953 . . . . 0.0 116.274 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 49.7 p30 -78.2 -63.66 1.34 Allowed 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 123.194 0.597 . . . . 0.0 112.104 175.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -147.93 124.41 11.01 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.653 -2.351 . . . . 0.0 104.653 175.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.08 105.81 0.06 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.386 1.995 . . . . 0.0 116.386 179.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.89 -47.23 1.03 Allowed Glycine 0 N--CA 1.491 2.329 0 CA-C-O 118.366 -1.241 . . . . 0.0 115.335 -169.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 t -86.08 -61.95 1.63 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.37 -119.98 0.78 Allowed Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.942 1.246 . . . . 0.0 114.351 -175.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -126.89 172.83 10.08 Favored 'General case' 0 CA--C 1.571 1.754 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -167.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -130.5 141.56 50.5 Favored 'General case' 0 CA--C 1.563 1.473 0 O-C-N 120.281 -1.512 . . . . 0.0 110.855 174.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 -41.8 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.02 -1.05 . . . . 0.0 112.628 171.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -90.28 108.01 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 172.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.4 m -83.08 105.36 14.0 Favored 'General case' 0 CA--C 1.567 1.609 0 CA-C-O 121.674 0.75 . . . . 0.0 112.164 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -85.59 97.35 10.03 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 122.053 0.93 . . . . 0.0 112.298 -175.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 53.9 p-90 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 123.108 1.432 . . . . 0.0 112.087 179.537 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 m . . . . . 0 CA--C 1.575 1.919 0 N-CA-C 120.431 3.493 . . . . 0.0 120.431 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.255 0.3 OUTLIER -89.99 169.26 11.36 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-N 122.247 2.294 . . . . 0.0 116.066 -172.449 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.01 51.83 0.68 Allowed Glycine 0 N--CA 1.5 2.932 0 N-CA-C 117.032 1.573 . . . . 0.0 117.032 177.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.07 -56.66 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 C-N-CA 123.883 0.873 . . . . 0.0 110.228 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -69.75 175.91 33.45 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 118.712 2.245 . . . . 0.0 118.712 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 p -114.24 56.23 0.72 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 115.499 1.666 . . . . 0.0 115.499 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.269 11.7 p -164.59 -129.38 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.194 -0.941 . . . . 0.0 110.98 176.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -144.92 142.42 29.85 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 121.143 1.792 . . . . 0.0 111.74 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -91.9 -73.54 0.54 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-N 114.254 -1.339 . . . . 0.0 110.118 172.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -137.72 76.42 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -172.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.22 80.9 0.05 OUTLIER 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 172.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.29 -23.98 6.7 Favored Glycine 0 N--CA 1.5 2.908 0 N-CA-C 119.016 2.367 . . . . 0.0 119.016 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -54.37 -46.41 73.0 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 117.024 2.231 . . . . 0.0 117.024 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.47 -132.6 2.36 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 124.053 0.835 . . . . 0.0 111.148 175.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -119.83 -178.63 3.68 Favored 'General case' 0 CA--C 1.567 1.604 0 CA-C-O 122.231 1.015 . . . . 0.0 112.353 -173.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.2 145.11 26.97 Favored 'General case' 0 CA--C 1.562 1.41 0 O-C-N 120.115 -1.616 . . . . 0.0 111.665 172.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.5 t -71.81 -45.77 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 O-C-N 121.185 -0.947 . . . . 0.0 112.044 172.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -91.0 119.31 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 167.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 97.7 m -80.51 95.54 6.51 Favored 'General case' 0 CA--C 1.568 1.65 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -106.23 92.58 4.2 Favored 'General case' 0 CA--C 1.563 1.46 0 C-N-CA 124.365 1.066 . . . . 0.0 109.305 175.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.388 51.8 p-90 . . . . . 0 N--CA 1.507 2.415 0 N-CA-C 118.693 2.849 . . . . 0.0 118.693 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 t . . . . . 0 CA--C 1.574 1.893 0 N-CA-C 119.056 2.984 . . . . 0.0 119.056 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.46 174.07 6.03 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 120.62 1.555 . . . . 0.0 114.489 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.86 56.35 0.64 Allowed Glycine 0 N--CA 1.501 2.969 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 175.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.19 -53.39 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 C-N-CA 124.579 1.152 . . . . 0.0 109.32 177.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.07 173.6 27.74 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 118.783 2.273 . . . . 0.0 118.783 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -115.82 50.09 1.05 Allowed 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 115.914 1.82 . . . . 0.0 115.914 -175.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.271 18.8 p -160.53 -124.26 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.884 -1.135 . . . . 0.0 110.782 175.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -146.05 138.08 25.17 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-N 121.149 1.795 . . . . 0.0 112.126 -179.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.7 p-10 -87.65 -61.85 1.63 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.108 171.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -146.83 128.38 15.08 Favored 'General case' 0 CA--C 1.568 1.637 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 174.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.85 106.29 0.1 Allowed 'General case' 0 CA--C 1.571 1.771 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.58 -46.55 1.07 Allowed Glycine 0 N--CA 1.491 2.363 0 CA-C-O 118.406 -1.219 . . . . 0.0 115.416 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -84.15 -61.93 1.69 Allowed 'General case' 0 CA--C 1.57 1.726 0 N-CA-C 116.291 1.959 . . . . 0.0 116.291 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.97 -121.47 0.77 Allowed Glycine 0 N--CA 1.489 2.174 0 CA-C-N 120.471 1.487 . . . . 0.0 115.752 -176.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -116.27 176.51 5.07 Favored 'General case' 0 CA--C 1.566 1.578 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -166.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.52 147.85 28.69 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.234 -1.541 . . . . 0.0 112.363 175.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -75.1 -46.24 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.627 -0.671 . . . . 0.0 111.263 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -87.43 111.31 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 169.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.1 m -76.26 108.7 9.38 Favored 'General case' 0 CA--C 1.566 1.573 0 O-C-N 121.343 -0.848 . . . . 0.0 112.296 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -80.01 106.1 11.78 Favored 'General case' 0 N--CA 1.492 1.64 0 CA-C-O 122.299 1.047 . . . . 0.0 113.485 -170.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.495 1.809 0 N-CA-C 115.915 1.821 . . . . 0.0 115.915 -178.013 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.576 1.957 0 N-CA-C 119.459 3.133 . . . . 0.0 119.459 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.3 0.2 OUTLIER -90.15 179.23 5.97 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 121.613 2.006 . . . . 0.0 115.004 -174.401 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -98.25 -42.78 2.92 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 118.707 2.243 . . . . 0.0 118.707 178.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -82.85 56.41 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 117.486 2.402 . . . . 0.0 117.486 -173.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -153.0 175.25 31.58 Favored Glycine 0 N--CA 1.49 2.255 0 O-C-N 120.902 -1.124 . . . . 0.0 115.302 172.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.6 p -122.03 54.7 1.15 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.267 12.4 p -164.49 -130.82 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 C-N-CA 123.875 0.87 . . . . 0.0 110.156 174.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -150.05 133.1 16.2 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 119.988 -1.695 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.13 -58.06 2.92 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -141.35 77.11 1.58 Allowed 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 118.845 0.748 . . . . 0.0 111.909 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 36.38 75.5 0.06 Allowed 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 119.036 2.976 . . . . 0.0 119.036 175.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.24 -17.95 57.26 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 119.16 2.424 . . . . 0.0 119.16 -173.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.7 t -60.68 -52.75 63.81 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 116.758 2.133 . . . . 0.0 116.758 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.1 -120.86 0.65 Allowed Glycine 0 N--CA 1.489 2.169 0 O-C-N 121.573 -0.705 . . . . 0.0 112.258 175.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -122.62 172.54 8.32 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.941 0.897 . . . . 0.0 112.319 -173.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.0 141.96 34.31 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.393 -1.442 . . . . 0.0 111.606 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.7 m -73.18 -35.21 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 175.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.24 91.75 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-N 120.027 1.285 . . . . 0.0 107.875 175.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.5 m -87.64 108.24 18.99 Favored 'General case' 0 CA--C 1.566 1.586 0 O-C-N 121.578 -0.701 . . . . 0.0 112.28 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -85.83 93.22 8.85 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.547 -0.72 . . . . 0.0 112.382 -178.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.372 29.0 p90 . . . . . 0 N--CA 1.507 2.422 0 N-CA-C 120.2 3.407 . . . . 0.0 120.2 175.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.2 m . . . . . 0 CA--C 1.577 1.982 0 N-CA-C 119.127 3.01 . . . . 0.0 119.127 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.259 0.3 OUTLIER -88.84 170.92 10.32 Favored 'General case' 0 N--CA 1.499 1.996 0 CA-C-N 122.024 2.193 . . . . 0.0 115.691 -172.741 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.9 50.12 0.8 Allowed Glycine 0 N--CA 1.5 2.921 0 N-CA-C 116.734 1.454 . . . . 0.0 116.734 176.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.53 -53.97 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 C-N-CA 124.193 0.997 . . . . 0.0 110.181 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.97 175.91 17.61 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 118.186 2.034 . . . . 0.0 118.186 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 t -116.67 48.03 1.35 Allowed 'General case' 0 N--CA 1.502 2.157 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -176.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 22.9 p -162.68 -120.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.787 -1.196 . . . . 0.0 111.426 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -148.13 138.61 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 CA-C-N 121.477 1.944 . . . . 0.0 112.966 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.41 -68.33 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 114.514 -1.221 . . . . 0.0 111.934 174.11 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.69 81.43 1.65 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 123.1 0.56 . . . . 0.0 112.057 -172.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.9 77.86 0.09 Allowed 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 117.991 2.589 . . . . 0.0 117.991 174.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.47 -16.76 22.88 Favored Glycine 0 N--CA 1.499 2.883 0 N-CA-C 119.876 2.71 . . . . 0.0 119.876 -176.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.2 t -56.83 -47.0 81.31 Favored 'General case' 0 N--CA 1.501 2.09 0 N-CA-C 117.447 2.388 . . . . 0.0 117.447 -178.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.66 -129.71 1.49 Allowed Glycine 0 N--CA 1.486 1.981 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -118.17 179.67 4.03 Favored 'General case' 0 CA--C 1.564 1.491 0 CA-C-O 122.01 0.909 . . . . 0.0 113.1 -174.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -158.79 148.97 19.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.342 -1.474 . . . . 0.0 112.287 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -70.76 -42.88 77.61 Favored 'Isoleucine or valine' 0 CA--C 1.581 2.162 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 165.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -91.08 115.5 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 168.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.0 m -78.55 106.27 10.4 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -98.39 103.97 15.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.374 19.5 p90 . . . . . 0 N--CA 1.507 2.376 0 N-CA-C 118.921 2.934 . . . . 0.0 118.921 179.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.573 1.859 0 N-CA-C 119.43 3.122 . . . . 0.0 119.43 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.324 0.9 OUTLIER -110.42 -161.89 0.77 Allowed 'General case' 0 CA--C 1.58 2.105 0 CA-C-N 120.843 1.656 . . . . 0.0 114.871 -176.107 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.33 63.19 0.42 Allowed Glycine 0 N--CA 1.502 3.041 0 N-CA-C 117.89 1.916 . . . . 0.0 117.89 -175.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.575 1.927 0 C-N-CA 124.343 1.057 . . . . 0.0 108.948 172.398 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -73.35 177.53 43.02 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 119.766 2.667 . . . . 0.0 119.766 -177.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 p -114.68 54.01 0.79 Allowed 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 115.165 1.543 . . . . 0.0 115.165 -175.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.4 p -169.22 134.27 1.51 Allowed 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 124.332 1.053 . . . . 0.0 109.546 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -70.12 129.25 38.91 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 37.8 p-10 -75.19 -60.29 2.36 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 177.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -144.01 85.76 1.82 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 123.448 0.699 . . . . 0.0 109.476 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 11.19 74.87 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.207 0 N-CA-C 121.024 3.713 . . . . 0.0 121.024 175.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.58 -38.8 2.53 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 117.008 1.563 . . . . 0.0 117.008 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.4 t -63.91 -56.98 11.24 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 116.873 2.175 . . . . 0.0 116.873 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.91 -122.31 0.87 Allowed Glycine 0 N--CA 1.488 2.104 0 O-C-N 121.269 -0.894 . . . . 0.0 113.921 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -136.55 150.37 48.58 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 124.031 0.932 . . . . 0.0 113.487 -170.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.31 141.13 39.14 Favored 'General case' 0 CA--C 1.563 1.447 0 C-N-CA 123.768 0.827 . . . . 0.0 110.984 175.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -73.54 -40.49 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 120.94 -1.1 . . . . 0.0 112.645 171.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -89.52 104.52 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 171.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 89.1 m -77.41 112.93 14.68 Favored 'General case' 0 CA--C 1.568 1.647 0 CA-C-O 122.198 0.999 . . . . 0.0 113.206 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -84.52 91.27 7.82 Favored 'General case' 0 CA--C 1.57 1.743 0 C-N-CA 124.422 1.089 . . . . 0.0 113.424 -177.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.1 t90 . . . . . 0 N--CA 1.503 2.179 0 CA-C-O 125.2 2.429 . . . . 0.0 113.669 -179.143 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.576 1.943 0 N-CA-C 119.995 3.331 . . . . 0.0 119.995 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -78.48 178.45 7.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 121.859 2.118 . . . . 0.0 113.933 177.469 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -123.51 56.13 0.68 Allowed Glycine 0 N--CA 1.501 3.012 0 O-C-N 120.297 -1.502 . . . . 0.0 116.725 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.86 -53.45 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.576 1.961 0 C-N-CA 124.411 1.084 . . . . 0.0 109.54 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -63.63 158.89 39.41 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 119.137 2.415 . . . . 0.0 119.137 -177.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -99.47 44.77 1.01 Allowed 'General case' 0 N--CA 1.5 2.075 0 N-CA-C 116.239 1.941 . . . . 0.0 116.239 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.5 p -175.62 152.42 1.3 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 125.156 1.383 . . . . 0.0 109.676 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -67.38 144.81 55.6 Favored 'General case' 0 CA--C 1.58 2.111 0 N-CA-C 116.708 2.114 . . . . 0.0 116.708 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -76.14 -70.03 0.47 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 118.002 -0.999 . . . . 0.0 112.139 172.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -153.48 100.96 2.46 Favored 'General case' 0 CA--C 1.563 1.476 0 CA-C-N 120.012 1.278 . . . . 0.0 109.39 -173.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 45.62 67.81 0.68 Allowed 'General case' 0 CA--C 1.574 1.889 0 N-CA-C 119.005 2.965 . . . . 0.0 119.005 173.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.65 -11.97 57.71 Favored Glycine 0 N--CA 1.499 2.874 0 N-CA-C 120.93 3.132 . . . . 0.0 120.93 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.14 -39.26 93.64 Favored 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 117.975 2.583 . . . . 0.0 117.975 -176.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.95 -123.02 1.08 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 124.277 0.942 . . . . 0.0 111.126 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -131.21 171.73 12.95 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.065 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.89 151.71 29.79 Favored 'General case' 0 CA--C 1.562 1.434 0 O-C-N 120.344 -1.472 . . . . 0.0 111.738 174.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.67 -46.46 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.389 0 O-C-N 121.027 -1.046 . . . . 0.0 111.686 166.263 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.9 t -88.38 117.95 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 169.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.0 m -80.16 106.59 12.29 Favored 'General case' 0 CA--C 1.571 1.784 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -174.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.4 p90 -123.53 72.31 1.13 Allowed 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 122.526 1.155 . . . . 0.0 114.096 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.341 21.9 p90 . . . . . 0 N--CA 1.508 2.454 0 N-CA-C 117.648 2.462 . . . . 0.0 117.648 178.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 t . . . . . 0 N--CA 1.498 1.938 0 N-CA-C 119.609 3.189 . . . . 0.0 119.609 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.36 171.47 13.48 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-N 121.583 1.992 . . . . 0.0 114.57 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -119.75 55.21 0.62 Allowed Glycine 0 N--CA 1.502 3.038 0 N-CA-C 116.149 1.22 . . . . 0.0 116.149 175.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.11 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 124.61 1.164 . . . . 0.0 109.099 177.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.28 170.55 34.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 118.631 2.212 . . . . 0.0 118.631 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.2 p -114.63 55.73 0.74 Allowed 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 115.184 1.55 . . . . 0.0 115.184 -175.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 25.2 p -162.92 -129.05 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.14 -0.975 . . . . 0.0 110.967 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -145.24 138.3 26.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 119.983 -1.698 . . . . 0.0 111.301 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -85.79 -58.17 2.76 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 123.926 0.89 . . . . 0.0 111.303 172.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -150.14 134.48 17.25 Favored 'General case' 0 CA--C 1.571 1.762 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 172.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -44.9 113.12 0.51 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.802 2.149 . . . . 0.0 116.802 -177.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.65 -27.96 16.88 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 118.358 2.103 . . . . 0.0 118.358 -171.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.49 -53.78 5.44 Favored 'General case' 0 CA--C 1.573 1.845 0 CA-C-N 119.806 1.803 . . . . 0.0 115.687 -177.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.5 -133.08 2.71 Favored Glycine 0 N--CA 1.49 2.266 0 O-C-N 121.09 -1.006 . . . . 0.0 113.939 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -113.09 175.73 5.32 Favored 'General case' 0 CA--C 1.566 1.589 0 CA-C-O 122.02 0.914 . . . . 0.0 113.383 -170.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.2 146.54 31.78 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.106 -1.621 . . . . 0.0 112.542 176.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.5 t -77.87 -43.23 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.578 -0.701 . . . . 0.0 111.874 170.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.29 95.95 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 95.0 m -83.9 110.5 18.44 Favored 'General case' 0 CA--C 1.565 1.54 0 N-CA-C 113.999 1.111 . . . . 0.0 113.999 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -91.44 77.2 5.81 Favored 'General case' 0 CA--C 1.57 1.743 0 CA-C-O 122.7 1.238 . . . . 0.0 114.299 -178.107 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 66.1 p-90 . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 123.051 1.405 . . . . 0.0 112.036 178.752 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.574 1.885 0 N-CA-C 119.561 3.171 . . . . 0.0 119.561 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.365 1.3 pt? -98.35 -161.02 0.84 Allowed 'General case' 0 CA--C 1.577 2.016 0 CA-C-N 121.647 2.021 . . . . 0.0 115.397 -173.096 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.44 64.57 0.41 Allowed Glycine 0 N--CA 1.5 2.938 0 O-C-N 119.758 -1.839 . . . . 0.0 117.647 -175.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.11 -54.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.899 0 C-N-CA 124.227 1.011 . . . . 0.0 108.941 172.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.81 179.12 47.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 119.674 2.63 . . . . 0.0 119.674 -177.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.6 p -115.21 53.06 0.84 Allowed 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 -177.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.0 p -167.61 134.49 2.22 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 124.342 1.057 . . . . 0.0 109.695 -179.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -69.37 132.33 46.21 Favored 'General case' 0 CA--C 1.573 1.831 0 N-CA-C 115.462 1.653 . . . . 0.0 115.462 -173.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.2 p-10 -73.68 -67.44 0.59 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 113.455 0.909 . . . . 0.0 113.455 176.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -139.42 76.43 1.56 Allowed 'General case' 0 N--CA 1.494 1.767 0 CA-C-N 118.634 0.652 . . . . 0.0 112.007 -171.167 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 41.7 79.08 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 118.392 2.738 . . . . 0.0 118.392 175.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.22 -22.93 20.66 Favored Glycine 0 N--CA 1.498 2.81 0 N-CA-C 119.164 2.425 . . . . 0.0 119.164 -174.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -58.22 -49.66 76.31 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 117.552 2.427 . . . . 0.0 117.552 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.37 -125.92 1.15 Allowed Glycine 0 N--CA 1.487 2.036 0 O-C-N 121.547 -0.721 . . . . 0.0 112.332 177.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -140.72 146.94 38.42 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -173.269 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -109.38 142.85 39.74 Favored 'General case' 0 CA--C 1.563 1.443 0 C-N-CA 123.558 0.743 . . . . 0.0 111.366 174.335 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -71.42 -43.8 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 120.797 -1.189 . . . . 0.0 112.423 170.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t -90.61 113.8 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 169.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.5 m -77.0 98.2 4.88 Favored 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 -175.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -97.2 -14.95 21.11 Favored 'General case' 0 N--CA 1.498 1.952 0 N-CA-C 118.995 2.961 . . . . 0.0 118.995 -178.062 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.737 0 N-CA-C 117.615 2.45 . . . . 0.0 117.615 -176.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 t . . . . . 0 CA--C 1.574 1.868 0 N-CA-C 119.36 3.096 . . . . 0.0 119.36 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.13 173.19 6.41 Favored 'General case' 0 CA--C 1.576 1.959 0 CA-C-N 120.618 1.554 . . . . 0.0 114.452 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.52 56.29 0.63 Allowed Glycine 0 N--CA 1.501 3.026 0 N-CA-C 116.127 1.211 . . . . 0.0 116.127 175.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.5 -52.91 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 C-N-CA 124.488 1.115 . . . . 0.0 109.418 177.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.91 178.44 25.48 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 119.064 2.385 . . . . 0.0 119.064 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -119.82 50.41 1.28 Allowed 'General case' 0 N--CA 1.5 2.05 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 -175.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.253 22.4 p -157.25 -129.31 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.84 -1.162 . . . . 0.0 110.821 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -144.42 135.67 25.4 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.765 1.621 . . . . 0.0 111.071 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.4 p-10 -86.82 -60.41 1.99 Allowed 'General case' 0 N--CA 1.491 1.608 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.336 173.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -147.16 127.42 13.88 Favored 'General case' 0 CA--C 1.566 1.595 0 N-CA-C 105.364 -2.087 . . . . 0.0 105.364 173.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.85 106.8 0.1 Allowed 'General case' 0 CA--C 1.574 1.868 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.1 -46.03 1.1 Allowed Glycine 0 N--CA 1.492 2.406 0 CA-C-O 118.436 -1.202 . . . . 0.0 115.497 -169.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.4 t -83.57 -61.62 1.79 Allowed 'General case' 0 CA--C 1.569 1.677 0 N-CA-C 116.282 1.956 . . . . 0.0 116.282 -178.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.53 -121.19 0.76 Allowed Glycine 0 N--CA 1.488 2.133 0 CA-C-N 120.504 1.502 . . . . 0.0 115.803 -177.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.43 174.72 5.91 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -166.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.89 147.03 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 120.348 -1.47 . . . . 0.0 112.113 174.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.7 t -76.93 -44.0 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.575 -0.703 . . . . 0.0 112.61 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.5 t -88.54 95.69 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 CA-C-N 119.668 1.122 . . . . 0.0 108.095 175.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.8 m -85.44 96.26 9.53 Favored 'General case' 0 CA--C 1.565 1.553 0 CA-C-O 121.911 0.862 . . . . 0.0 112.266 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -142.49 151.35 41.6 Favored 'General case' 0 CA--C 1.569 1.677 0 CA-C-O 122.798 1.285 . . . . 0.0 112.321 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 51.4 p-90 . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 124.629 2.157 . . . . 0.0 114.52 173.506 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.574 1.887 0 N-CA-C 120.325 3.454 . . . . 0.0 120.325 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.3 179.55 4.55 Favored 'General case' 0 CA--C 1.579 2.073 0 CA-C-N 121.093 1.77 . . . . 0.0 114.088 178.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -124.21 58.46 0.64 Allowed Glycine 0 N--CA 1.501 3.005 0 O-C-N 120.259 -1.525 . . . . 0.0 116.697 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -131.54 -54.75 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 124.403 1.081 . . . . 0.0 109.391 176.128 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.58 -179.97 28.76 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 119.232 2.453 . . . . 0.0 119.232 -177.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -121.29 43.79 2.71 Favored 'General case' 0 N--CA 1.504 2.272 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -175.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 21.1 p -163.56 139.81 6.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.79 -1.194 . . . . 0.0 109.821 177.586 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -63.5 137.81 58.27 Favored 'General case' 0 CA--C 1.577 2.014 0 N-CA-C 116.266 1.95 . . . . 0.0 116.266 -174.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.277 39.1 p-10 -80.68 -80.86 0.13 Allowed 'General case' 0 N--CA 1.489 1.512 0 CA-C-O 118.237 -0.887 . . . . 0.0 113.223 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -121.29 55.42 1.07 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -173.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . 0.264 . . 57.65 7.56 0.56 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 121.762 3.986 . . . . 0.0 121.762 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.61 64.02 0.03 OUTLIER Glycine 0 N--CA 1.491 2.322 0 O-C-N 120.866 -1.146 . . . . 0.0 115.152 -177.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 54.0 t -156.84 -64.68 0.1 Allowed 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 123.589 0.756 . . . . 0.0 111.464 177.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.77 -117.83 0.46 Allowed Glycine 0 N--CA 1.483 1.788 0 O-C-N 121.633 -0.667 . . . . 0.0 112.391 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -129.23 172.23 11.66 Favored 'General case' 0 CA--C 1.566 1.591 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -168.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.45 143.87 47.78 Favored 'General case' 0 CA--C 1.563 1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 110.705 173.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.1 t -74.06 -43.92 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.106 -0.996 . . . . 0.0 112.326 171.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.6 t -93.76 112.24 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 172.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 78.6 m -80.31 96.24 6.59 Favored 'General case' 0 CA--C 1.568 1.645 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -178.05 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.1 t80 -128.88 93.92 3.72 Favored 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 123.679 1.704 . . . . 0.0 110.199 179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 48.3 p90 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 124.462 2.077 . . . . 0.0 113.964 -178.511 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 120.275 3.435 . . . . 0.0 120.275 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.43 166.75 18.11 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 121.859 2.118 . . . . 0.0 115.161 -178.145 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.37 49.96 0.81 Allowed Glycine 0 N--CA 1.5 2.9 0 N-CA-C 116.701 1.441 . . . . 0.0 116.701 176.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -133.58 -55.23 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 124.334 1.054 . . . . 0.0 109.991 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.71 169.35 38.09 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 118.311 2.084 . . . . 0.0 118.311 -178.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.8 p -109.77 56.15 0.63 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 115.526 1.676 . . . . 0.0 115.526 -174.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.254 22.5 p -164.26 -131.71 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.124 -0.985 . . . . 0.0 111.111 176.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -146.36 136.26 23.4 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 119.933 -1.73 . . . . 0.0 111.295 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.0 p30 -82.84 -63.32 1.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.012 -0.995 . . . . 0.0 111.136 174.084 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -145.24 124.0 12.61 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.956 -2.239 . . . . 0.0 104.956 174.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -38.36 111.18 0.16 Allowed 'General case' 0 CA--C 1.573 1.839 0 N-CA-C 117.892 2.553 . . . . 0.0 117.892 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.05 -32.25 7.04 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 117.917 1.927 . . . . 0.0 117.917 -171.463 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -80.31 -51.67 8.62 Favored 'General case' 0 CA--C 1.574 1.867 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 -176.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.14 -135.13 3.46 Favored Glycine 0 N--CA 1.49 2.295 0 O-C-N 121.203 -0.936 . . . . 0.0 113.243 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -114.23 178.98 4.09 Favored 'General case' 0 CA--C 1.567 1.607 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -171.252 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.96 145.3 30.6 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.058 -1.651 . . . . 0.0 112.262 175.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.4 t -75.82 -45.34 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 O-C-N 121.393 -0.817 . . . . 0.0 111.691 171.096 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -90.84 107.23 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 171.576 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.2 m -81.99 96.71 7.8 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.049 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -144.45 108.73 4.81 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.907 0.86 . . . . 0.0 109.346 177.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.7 t-105 . . . . . 0 N--CA 1.489 1.483 0 CA-C-O 123.917 1.818 . . . . 0.0 110.59 -179.491 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.497 1.898 0 N-CA-C 119.781 3.252 . . . . 0.0 119.781 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.41 171.6 13.3 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 121.59 1.996 . . . . 0.0 114.571 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.48 55.57 0.63 Allowed Glycine 0 N--CA 1.5 2.955 0 N-CA-C 116.015 1.166 . . . . 0.0 116.015 175.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.58 -52.55 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.89 0 C-N-CA 124.737 1.215 . . . . 0.0 109.055 177.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.16 173.92 31.18 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 118.673 2.229 . . . . 0.0 118.673 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -117.8 51.16 1.07 Allowed 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 115.317 1.599 . . . . 0.0 115.317 -175.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.256 25.6 p -157.48 -128.63 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.83 -1.169 . . . . 0.0 110.963 174.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -145.66 135.87 23.87 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-N 120.903 1.683 . . . . 0.0 111.533 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p-10 -83.34 -60.6 2.09 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.988 172.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -147.53 135.3 21.08 Favored 'General case' 0 CA--C 1.572 1.816 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 171.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.17 113.69 0.61 Allowed 'General case' 0 CA--C 1.573 1.842 0 N-CA-C 116.795 2.146 . . . . 0.0 116.795 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.26 -26.88 22.28 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 118.431 2.132 . . . . 0.0 118.431 -171.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.57 -54.02 5.24 Favored 'General case' 0 CA--C 1.573 1.849 0 CA-C-N 119.809 1.805 . . . . 0.0 115.606 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.46 -133.0 2.69 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 121.079 -1.013 . . . . 0.0 113.942 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -112.86 175.32 5.49 Favored 'General case' 0 CA--C 1.567 1.605 0 CA-C-O 122.121 0.962 . . . . 0.0 113.354 -170.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.09 147.01 33.19 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.159 -1.588 . . . . 0.0 112.092 175.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 66.2 t -77.77 -42.52 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 O-C-N 121.544 -0.722 . . . . 0.0 112.493 172.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -86.66 95.29 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 CA-C-N 119.839 1.2 . . . . 0.0 108.12 175.105 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.9 m -87.02 113.85 23.13 Favored 'General case' 0 CA--C 1.567 1.603 0 O-C-N 121.707 -0.621 . . . . 0.0 112.505 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 62.2 t80 -84.42 141.84 30.54 Favored 'General case' 0 CA--C 1.571 1.774 0 CA-C-O 121.892 0.853 . . . . 0.0 113.122 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.1 t-105 . . . . . 0 N--CA 1.488 1.443 0 CA-C-O 123.884 1.802 . . . . 0.0 109.868 175.804 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 t . . . . . 0 N--CA 1.498 1.97 0 N-CA-C 119.886 3.291 . . . . 0.0 119.886 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.77 166.04 17.29 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 121.615 2.007 . . . . 0.0 114.861 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -110.85 48.77 0.9 Allowed Glycine 0 N--CA 1.501 2.984 0 N-CA-C 116.957 1.543 . . . . 0.0 116.957 177.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.53 -55.67 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 C-N-CA 124.168 0.987 . . . . 0.0 110.267 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.52 34.84 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 118.612 2.205 . . . . 0.0 118.612 -177.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.7 p -112.99 58.15 0.66 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 19.4 p -165.71 -132.7 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 110.868 175.592 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -144.03 139.3 28.91 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 119.877 -1.765 . . . . 0.0 111.313 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.4 p-10 -90.65 -65.61 1.0 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.95 176.056 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -139.82 77.44 1.61 Allowed 'General case' 0 N--CA 1.494 1.744 0 CA-C-N 119.06 0.845 . . . . 0.0 111.254 -175.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 32.64 80.68 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 119.403 3.112 . . . . 0.0 119.403 174.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.48 -28.45 14.13 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 118.391 2.116 . . . . 0.0 118.391 -173.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.4 t -59.93 -41.37 91.63 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 117.298 2.333 . . . . 0.0 117.298 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.35 -135.94 3.93 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 124.024 0.821 . . . . 0.0 111.814 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -115.36 176.65 4.97 Favored 'General case' 0 CA--C 1.565 1.533 0 CA-C-O 122.084 0.945 . . . . 0.0 113.257 -173.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.0 144.92 37.22 Favored 'General case' 0 CA--C 1.562 1.432 0 O-C-N 120.258 -1.526 . . . . 0.0 111.776 175.282 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -74.75 -42.26 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 174.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -88.81 94.67 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 CA-C-N 119.883 1.22 . . . . 0.0 108.033 175.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.7 m -85.88 105.8 16.63 Favored 'General case' 0 CA--C 1.565 1.538 0 CA-C-O 121.716 0.769 . . . . 0.0 112.454 -179.329 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -83.74 97.15 8.98 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 122.007 0.908 . . . . 0.0 111.556 -178.286 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 72.4 t90 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 123.831 1.777 . . . . 0.0 110.569 -178.095 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 119.08 2.993 . . . . 0.0 119.08 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.85 169.15 14.43 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 121.34 1.882 . . . . 0.0 114.585 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -112.48 48.17 0.97 Allowed Glycine 0 N--CA 1.499 2.878 0 N-CA-C 117.097 1.599 . . . . 0.0 117.097 177.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -131.5 -54.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 124.156 0.982 . . . . 0.0 110.179 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.8 172.67 23.93 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 p -114.34 54.06 0.78 Allowed 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 115.53 1.678 . . . . 0.0 115.53 -175.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.262 22.0 p -165.99 -124.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.18 -0.95 . . . . 0.0 110.841 176.218 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -147.85 140.44 24.6 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-N 120.94 1.7 . . . . 0.0 111.717 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -82.47 -71.67 0.48 Allowed 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.469 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -145.26 85.91 1.75 Allowed 'General case' 0 CA--C 1.566 1.585 0 CA-C-N 119.548 1.067 . . . . 0.0 111.736 -179.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 50.89 81.66 0.07 Allowed 'General case' 0 CA--C 1.571 1.782 0 N-CA-C 118.017 2.599 . . . . 0.0 118.017 173.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.52 -21.97 8.19 Favored Glycine 0 N--CA 1.5 2.929 0 N-CA-C 120.31 2.884 . . . . 0.0 120.31 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.1 t -59.43 -39.55 83.9 Favored 'General case' 0 N--CA 1.5 2.074 0 N-CA-C 117.689 2.477 . . . . 0.0 117.689 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.5 -132.85 2.61 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 124.108 0.861 . . . . 0.0 111.239 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -117.95 178.47 4.41 Favored 'General case' 0 CA--C 1.565 1.548 0 CA-C-O 122.127 0.965 . . . . 0.0 113.446 -173.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -155.73 146.28 21.96 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.371 -1.456 . . . . 0.0 112.594 175.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . 0.253 9.4 p -69.15 -45.95 78.79 Favored 'Isoleucine or valine' 0 CA--C 1.58 2.096 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 166.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.2 112.75 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.571 1.757 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 69.5 m -78.47 115.04 17.9 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -71.52 134.32 46.42 Favored 'General case' 0 CA--C 1.575 1.929 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.45 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 58.2 p-90 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 125.281 2.467 . . . . 0.0 112.699 -178.989 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.498 1.927 0 N-CA-C 120.815 3.635 . . . . 0.0 120.815 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.252 0.3 OUTLIER -80.77 174.32 11.73 Favored 'General case' 0 CA--C 1.578 2.025 0 CA-C-N 122.136 2.244 . . . . 0.0 114.381 178.984 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.49 57.74 0.6 Allowed Glycine 0 N--CA 1.501 2.981 0 O-C-N 120.404 -1.435 . . . . 0.0 116.455 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.29 -53.91 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 C-N-CA 124.513 1.125 . . . . 0.0 108.981 176.205 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.46 168.67 42.12 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 118.417 2.127 . . . . 0.0 118.417 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -112.66 43.11 1.71 Allowed 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.8 p -164.83 142.77 6.43 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 124.546 1.138 . . . . 0.0 109.729 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -64.7 140.23 58.85 Favored 'General case' 0 CA--C 1.579 2.085 0 N-CA-C 118.006 2.595 . . . . 0.0 118.006 -171.458 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p30 -79.7 -60.99 2.13 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 123.444 0.698 . . . . 0.0 111.637 172.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -151.7 94.0 1.93 Allowed 'General case' 0 CA--C 1.566 1.595 0 CA-C-N 119.732 1.151 . . . . 0.0 109.202 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 13.42 83.28 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 121.438 3.866 . . . . 0.0 121.438 175.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.42 -35.74 4.2 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 117.648 1.819 . . . . 0.0 117.648 -174.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.7 t -68.88 -45.04 72.0 Favored 'General case' 0 CA--C 1.577 2.005 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 -177.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 160.47 -130.88 2.49 Favored Glycine 0 N--CA 1.489 2.203 0 O-C-N 121.359 -0.838 . . . . 0.0 112.745 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -125.09 171.66 10.1 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -170.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.23 140.96 37.88 Favored 'General case' 0 CA--C 1.564 1.49 0 O-C-N 120.364 -1.46 . . . . 0.0 110.615 175.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.1 m -69.03 -39.56 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.058 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.1 t -96.3 118.09 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 168.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.3 m -76.89 100.93 5.72 Favored 'General case' 0 CA--C 1.569 1.681 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -107.64 -30.69 8.44 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 118.002 2.593 . . . . 0.0 118.002 -178.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.497 1.894 0 CA-C-O 124.664 2.174 . . . . 0.0 110.778 -175.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.573 1.865 0 N-CA-C 119.177 3.029 . . . . 0.0 119.177 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.43 169.47 8.68 Favored 'General case' 0 CA--C 1.575 1.906 0 CA-C-N 120.664 1.575 . . . . 0.0 114.703 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.26 52.26 0.66 Allowed Glycine 0 N--CA 1.5 2.937 0 N-CA-C 116.669 1.428 . . . . 0.0 116.669 177.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.23 -54.83 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 C-N-CA 124.112 0.965 . . . . 0.0 110.211 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.53 177.73 25.27 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 118.825 2.29 . . . . 0.0 118.825 -177.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.7 t -116.43 53.46 0.88 Allowed 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 115.047 1.499 . . . . 0.0 115.047 -175.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -162.16 -129.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.92 -1.113 . . . . 0.0 110.974 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -144.1 139.89 29.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.932 -1.73 . . . . 0.0 110.832 178.442 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -90.97 -60.06 2.01 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 123.637 0.775 . . . . 0.0 111.256 172.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -147.22 127.25 13.67 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 174.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.84 106.56 0.09 Allowed 'General case' 0 CA--C 1.572 1.81 0 N-CA-C 116.001 1.852 . . . . 0.0 116.001 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.39 -46.02 1.1 Allowed Glycine 0 N--CA 1.492 2.381 0 CA-C-O 118.509 -1.162 . . . . 0.0 115.687 -169.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.3 t -83.46 -60.71 2.05 Favored 'General case' 0 CA--C 1.569 1.698 0 N-CA-C 116.611 2.078 . . . . 0.0 116.611 -178.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 178.24 -124.9 0.95 Allowed Glycine 0 N--CA 1.49 2.284 0 CA-C-N 120.314 1.416 . . . . 0.0 115.356 -176.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -115.05 178.19 4.38 Favored 'General case' 0 CA--C 1.566 1.577 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -168.687 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.6 141.29 33.47 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.346 -1.472 . . . . 0.0 112.087 175.234 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.86 -39.8 52.39 Favored 'Isoleucine or valine' 0 CA--C 1.576 1.951 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 170.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.1 t -90.77 97.14 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 170.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 68.6 m -82.41 110.83 17.89 Favored 'General case' 0 CA--C 1.564 1.485 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -175.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -82.84 88.47 6.78 Favored 'General case' 0 CA--C 1.571 1.761 0 CA-C-O 122.693 1.235 . . . . 0.0 110.807 173.161 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 40.8 t-105 . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 124.585 2.136 . . . . 0.0 111.303 -173.987 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.498 1.955 0 N-CA-C 118.742 2.868 . . . . 0.0 118.742 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.3 173.51 11.53 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 121.056 1.753 . . . . 0.0 114.203 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.1 55.11 0.65 Allowed Glycine 0 N--CA 1.501 3.005 0 N-CA-C 116.217 1.247 . . . . 0.0 116.217 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.86 -52.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 C-N-CA 124.662 1.185 . . . . 0.0 109.195 177.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.82 172.87 23.65 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 118.506 2.163 . . . . 0.0 118.506 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -117.61 49.08 1.26 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 115.185 1.55 . . . . 0.0 115.185 -177.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.25 26.2 p -159.23 -122.8 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.85 -1.156 . . . . 0.0 110.961 175.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -147.56 142.35 26.78 Favored 'General case' 0 N--CA 1.491 1.625 0 CA-C-N 120.934 1.697 . . . . 0.0 111.999 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -91.01 -63.21 1.3 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 124.515 1.126 . . . . 0.0 113.343 176.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 94.4 m-85 -140.77 78.13 1.63 Allowed 'General case' 0 N--CA 1.495 1.808 0 CA-C-N 119.079 0.854 . . . . 0.0 111.237 -173.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 38.79 75.24 0.08 Allowed 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 118.717 2.858 . . . . 0.0 118.717 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.14 -19.83 51.09 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 119.545 2.578 . . . . 0.0 119.545 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.9 t -61.49 -41.35 97.14 Favored 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 117.766 2.506 . . . . 0.0 117.766 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.34 -128.04 1.49 Allowed Glycine 0 N--CA 1.489 2.198 0 O-C-N 121.361 -0.837 . . . . 0.0 111.726 177.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -120.04 174.25 6.59 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-O 122.058 0.932 . . . . 0.0 113.242 -173.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.26 147.36 25.59 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.403 -1.435 . . . . 0.0 112.787 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -73.4 -42.14 56.86 Favored 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 165.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.6 t . . . . . 0 N--CA 1.495 1.786 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 170.183 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.499 1.977 0 N-CA-C 120.745 3.609 . . . . 0.0 120.745 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.254 0.2 OUTLIER -80.56 176.18 10.01 Favored 'General case' 0 CA--C 1.579 2.075 0 CA-C-N 122.044 2.202 . . . . 0.0 114.139 177.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.45 56.27 0.61 Allowed Glycine 0 N--CA 1.501 3.013 0 O-C-N 120.206 -1.558 . . . . 0.0 116.828 176.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.0 mt -129.48 -59.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 C-N-CA 124.273 1.029 . . . . 0.0 109.455 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.31 172.02 42.26 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 119.836 2.694 . . . . 0.0 119.836 -175.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.8 p -110.74 51.23 0.78 Allowed 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -175.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.4 p -169.9 140.01 1.99 Allowed 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.44 1.096 . . . . 0.0 109.627 178.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -66.48 133.67 50.87 Favored 'General case' 0 CA--C 1.576 1.964 0 N-CA-C 115.652 1.723 . . . . 0.0 115.652 -176.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.254 26.3 p30 -71.54 -72.34 0.23 Allowed 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 123.77 0.828 . . . . 0.0 112.884 177.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -144.21 87.75 1.91 Allowed 'General case' 0 CA--C 1.566 1.588 0 CA-C-N 119.42 1.009 . . . . 0.0 110.923 -178.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.79 82.72 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 118.366 2.728 . . . . 0.0 118.366 173.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.94 -23.94 5.58 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 120.097 2.799 . . . . 0.0 120.097 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.9 t -58.82 -40.78 85.17 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 117.907 2.558 . . . . 0.0 117.907 -176.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.15 -126.11 1.47 Allowed Glycine 0 N--CA 1.488 2.137 0 C-N-CA 124.003 0.811 . . . . 0.0 111.368 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -131.18 169.1 16.38 Favored 'General case' 0 CA--C 1.569 1.694 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -172.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.61 142.75 49.96 Favored 'General case' 0 CA--C 1.564 1.507 0 O-C-N 120.569 -1.332 . . . . 0.0 110.796 174.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.2 t -75.03 -38.53 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.294 0 O-C-N 120.954 -1.091 . . . . 0.0 113.57 173.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t . . . . . 0 N--CA 1.495 1.791 0 O-C-N 120.802 -1.186 . . . . 0.0 108.307 176.3 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.575 1.917 0 N-CA-C 120.421 3.489 . . . . 0.0 120.421 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.04 173.76 6.16 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 121.006 1.73 . . . . 0.0 113.882 177.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -117.81 54.03 0.62 Allowed Glycine 0 N--CA 1.501 2.976 0 O-C-N 120.306 -1.496 . . . . 0.0 116.595 176.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.25 -54.94 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 124.274 1.03 . . . . 0.0 109.631 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.88 173.86 30.27 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 118.09 1.996 . . . . 0.0 118.09 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.8 t -116.04 43.83 2.06 Favored 'General case' 0 N--CA 1.504 2.249 0 N-CA-C 116.083 1.882 . . . . 0.0 116.083 -175.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 18.5 p -166.77 142.55 4.43 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.752 -1.218 . . . . 0.0 110.367 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -57.55 133.78 55.55 Favored 'General case' 0 CA--C 1.581 2.173 0 N-CA-C 117.616 2.45 . . . . 0.0 117.616 -174.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -81.85 -64.14 1.24 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 123.041 0.536 . . . . 0.0 112.406 171.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -148.59 120.98 8.45 Favored 'General case' 0 CA--C 1.566 1.565 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.46 105.64 0.06 Allowed 'General case' 0 CA--C 1.573 1.828 0 N-CA-C 116.834 2.161 . . . . 0.0 116.834 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.68 -45.59 1.13 Allowed Glycine 0 N--CA 1.491 2.354 0 CA-C-O 118.548 -1.14 . . . . 0.0 115.816 -170.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 31.2 t -83.52 -59.01 2.58 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 116.809 2.151 . . . . 0.0 116.809 -178.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.62 -121.64 0.9 Allowed Glycine 0 N--CA 1.487 2.07 0 CA-C-N 119.918 1.236 . . . . 0.0 114.242 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -124.37 172.37 9.19 Favored 'General case' 0 CA--C 1.566 1.573 0 N-CA-C 115.248 1.573 . . . . 0.0 115.248 -167.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.22 144.48 48.46 Favored 'General case' 0 CA--C 1.561 1.381 0 O-C-N 120.542 -1.349 . . . . 0.0 111.073 174.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -72.31 -43.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 121.0 -1.063 . . . . 0.0 111.57 168.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t . . . . . 0 N--CA 1.495 1.778 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 168.732 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.4 t . . . . . 0 CA--C 1.575 1.937 0 N-CA-C 121.185 3.772 . . . . 0.0 121.185 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 173.36 6.34 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-N 121.364 1.893 . . . . 0.0 113.806 177.034 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.71 51.21 0.73 Allowed Glycine 0 N--CA 1.502 3.034 0 O-C-N 119.971 -1.706 . . . . 0.0 117.326 176.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -132.53 -56.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 C-N-CA 123.938 0.895 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.97 168.13 41.2 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 119.283 2.473 . . . . 0.0 119.283 -174.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.7 p -105.99 55.13 0.68 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -174.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 19.2 p -178.15 140.62 0.23 Allowed 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 125.021 1.329 . . . . 0.0 109.263 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -69.64 136.25 50.93 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 116.274 1.953 . . . . 0.0 116.274 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 49.7 p30 -78.2 -63.66 1.34 Allowed 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 123.194 0.597 . . . . 0.0 112.104 175.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -147.93 124.41 11.01 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.653 -2.351 . . . . 0.0 104.653 175.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.08 105.81 0.06 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.386 1.995 . . . . 0.0 116.386 179.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.89 -47.23 1.03 Allowed Glycine 0 N--CA 1.491 2.329 0 CA-C-O 118.366 -1.241 . . . . 0.0 115.335 -169.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 t -86.08 -61.95 1.63 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.37 -119.98 0.78 Allowed Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.942 1.246 . . . . 0.0 114.351 -175.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -126.89 172.83 10.08 Favored 'General case' 0 CA--C 1.571 1.754 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -167.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -130.5 141.56 50.5 Favored 'General case' 0 CA--C 1.563 1.473 0 O-C-N 120.281 -1.512 . . . . 0.0 110.855 174.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 -41.8 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.02 -1.05 . . . . 0.0 112.628 171.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t . . . . . 0 N--CA 1.495 1.799 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 172.625 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 m . . . . . 0 CA--C 1.575 1.919 0 N-CA-C 120.431 3.493 . . . . 0.0 120.431 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.255 0.3 OUTLIER -89.99 169.26 11.36 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-N 122.247 2.294 . . . . 0.0 116.066 -172.449 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.01 51.83 0.68 Allowed Glycine 0 N--CA 1.5 2.932 0 N-CA-C 117.032 1.573 . . . . 0.0 117.032 177.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.07 -56.66 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 C-N-CA 123.883 0.873 . . . . 0.0 110.228 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -69.75 175.91 33.45 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 118.712 2.245 . . . . 0.0 118.712 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 p -114.24 56.23 0.72 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 115.499 1.666 . . . . 0.0 115.499 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.269 11.7 p -164.59 -129.38 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.194 -0.941 . . . . 0.0 110.98 176.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -144.92 142.42 29.85 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 121.143 1.792 . . . . 0.0 111.74 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -91.9 -73.54 0.54 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-N 114.254 -1.339 . . . . 0.0 110.118 172.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -137.72 76.42 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -172.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.22 80.9 0.05 OUTLIER 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 172.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.29 -23.98 6.7 Favored Glycine 0 N--CA 1.5 2.908 0 N-CA-C 119.016 2.367 . . . . 0.0 119.016 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -54.37 -46.41 73.0 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 117.024 2.231 . . . . 0.0 117.024 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.47 -132.6 2.36 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 124.053 0.835 . . . . 0.0 111.148 175.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -119.83 -178.63 3.68 Favored 'General case' 0 CA--C 1.567 1.604 0 CA-C-O 122.231 1.015 . . . . 0.0 112.353 -173.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.2 145.11 26.97 Favored 'General case' 0 CA--C 1.562 1.41 0 O-C-N 120.115 -1.616 . . . . 0.0 111.665 172.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.5 t -71.81 -45.77 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 O-C-N 121.185 -0.947 . . . . 0.0 112.044 172.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t . . . . . 0 N--CA 1.495 1.792 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 167.561 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 t . . . . . 0 CA--C 1.574 1.893 0 N-CA-C 119.056 2.984 . . . . 0.0 119.056 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.46 174.07 6.03 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 120.62 1.555 . . . . 0.0 114.489 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.86 56.35 0.64 Allowed Glycine 0 N--CA 1.501 2.969 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 175.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.19 -53.39 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 C-N-CA 124.579 1.152 . . . . 0.0 109.32 177.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.07 173.6 27.74 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 118.783 2.273 . . . . 0.0 118.783 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -115.82 50.09 1.05 Allowed 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 115.914 1.82 . . . . 0.0 115.914 -175.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.271 18.8 p -160.53 -124.26 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.884 -1.135 . . . . 0.0 110.782 175.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -146.05 138.08 25.17 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-N 121.149 1.795 . . . . 0.0 112.126 -179.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.7 p-10 -87.65 -61.85 1.63 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.108 171.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -146.83 128.38 15.08 Favored 'General case' 0 CA--C 1.568 1.637 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 174.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.85 106.29 0.1 Allowed 'General case' 0 CA--C 1.571 1.771 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.58 -46.55 1.07 Allowed Glycine 0 N--CA 1.491 2.363 0 CA-C-O 118.406 -1.219 . . . . 0.0 115.416 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -84.15 -61.93 1.69 Allowed 'General case' 0 CA--C 1.57 1.726 0 N-CA-C 116.291 1.959 . . . . 0.0 116.291 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.97 -121.47 0.77 Allowed Glycine 0 N--CA 1.489 2.174 0 CA-C-N 120.471 1.487 . . . . 0.0 115.752 -176.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -116.27 176.51 5.07 Favored 'General case' 0 CA--C 1.566 1.578 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -166.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.52 147.85 28.69 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.234 -1.541 . . . . 0.0 112.363 175.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -75.1 -46.24 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.627 -0.671 . . . . 0.0 111.263 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t . . . . . 0 N--CA 1.495 1.781 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 169.5 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.576 1.957 0 N-CA-C 119.459 3.133 . . . . 0.0 119.459 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.3 0.2 OUTLIER -90.15 179.23 5.97 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 121.613 2.006 . . . . 0.0 115.004 -174.401 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -98.25 -42.78 2.92 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 118.707 2.243 . . . . 0.0 118.707 178.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -82.85 56.41 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 117.486 2.402 . . . . 0.0 117.486 -173.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -153.0 175.25 31.58 Favored Glycine 0 N--CA 1.49 2.255 0 O-C-N 120.902 -1.124 . . . . 0.0 115.302 172.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.6 p -122.03 54.7 1.15 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.267 12.4 p -164.49 -130.82 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 C-N-CA 123.875 0.87 . . . . 0.0 110.156 174.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -150.05 133.1 16.2 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 119.988 -1.695 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.13 -58.06 2.92 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -141.35 77.11 1.58 Allowed 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 118.845 0.748 . . . . 0.0 111.909 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 36.38 75.5 0.06 Allowed 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 119.036 2.976 . . . . 0.0 119.036 175.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.24 -17.95 57.26 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 119.16 2.424 . . . . 0.0 119.16 -173.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.7 t -60.68 -52.75 63.81 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 116.758 2.133 . . . . 0.0 116.758 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.1 -120.86 0.65 Allowed Glycine 0 N--CA 1.489 2.169 0 O-C-N 121.573 -0.705 . . . . 0.0 112.258 175.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -122.62 172.54 8.32 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.941 0.897 . . . . 0.0 112.319 -173.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.0 141.96 34.31 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.393 -1.442 . . . . 0.0 111.606 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.7 m -73.18 -35.21 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 175.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t . . . . . 0 N--CA 1.497 1.911 0 CA-C-N 120.027 1.285 . . . . 0.0 107.875 175.239 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.2 m . . . . . 0 CA--C 1.577 1.982 0 N-CA-C 119.127 3.01 . . . . 0.0 119.127 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.259 0.3 OUTLIER -88.84 170.92 10.32 Favored 'General case' 0 N--CA 1.499 1.996 0 CA-C-N 122.024 2.193 . . . . 0.0 115.691 -172.741 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.9 50.12 0.8 Allowed Glycine 0 N--CA 1.5 2.921 0 N-CA-C 116.734 1.454 . . . . 0.0 116.734 176.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.53 -53.97 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 C-N-CA 124.193 0.997 . . . . 0.0 110.181 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.97 175.91 17.61 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 118.186 2.034 . . . . 0.0 118.186 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 t -116.67 48.03 1.35 Allowed 'General case' 0 N--CA 1.502 2.157 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -176.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 22.9 p -162.68 -120.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.787 -1.196 . . . . 0.0 111.426 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -148.13 138.61 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 CA-C-N 121.477 1.944 . . . . 0.0 112.966 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.41 -68.33 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 114.514 -1.221 . . . . 0.0 111.934 174.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.69 81.43 1.65 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 123.1 0.56 . . . . 0.0 112.057 -172.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.9 77.86 0.09 Allowed 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 117.991 2.589 . . . . 0.0 117.991 174.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.47 -16.76 22.88 Favored Glycine 0 N--CA 1.499 2.883 0 N-CA-C 119.876 2.71 . . . . 0.0 119.876 -176.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.2 t -56.83 -47.0 81.31 Favored 'General case' 0 N--CA 1.501 2.09 0 N-CA-C 117.447 2.388 . . . . 0.0 117.447 -178.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.66 -129.71 1.49 Allowed Glycine 0 N--CA 1.486 1.981 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -118.17 179.67 4.03 Favored 'General case' 0 CA--C 1.564 1.491 0 CA-C-O 122.01 0.909 . . . . 0.0 113.1 -174.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -158.79 148.97 19.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.342 -1.474 . . . . 0.0 112.287 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -70.76 -42.88 77.61 Favored 'Isoleucine or valine' 0 CA--C 1.581 2.162 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 165.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t . . . . . 0 N--CA 1.497 1.886 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 168.373 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.573 1.859 0 N-CA-C 119.43 3.122 . . . . 0.0 119.43 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.324 0.9 OUTLIER -110.42 -161.89 0.77 Allowed 'General case' 0 CA--C 1.58 2.105 0 CA-C-N 120.843 1.656 . . . . 0.0 114.871 -176.107 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.33 63.19 0.42 Allowed Glycine 0 N--CA 1.502 3.041 0 N-CA-C 117.89 1.916 . . . . 0.0 117.89 -175.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.575 1.927 0 C-N-CA 124.343 1.057 . . . . 0.0 108.948 172.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -73.35 177.53 43.02 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 119.766 2.667 . . . . 0.0 119.766 -177.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 p -114.68 54.01 0.79 Allowed 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 115.165 1.543 . . . . 0.0 115.165 -175.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.4 p -169.22 134.27 1.51 Allowed 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 124.332 1.053 . . . . 0.0 109.546 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -70.12 129.25 38.91 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 37.8 p-10 -75.19 -60.29 2.36 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 177.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -144.01 85.76 1.82 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 123.448 0.699 . . . . 0.0 109.476 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 11.19 74.87 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.207 0 N-CA-C 121.024 3.713 . . . . 0.0 121.024 175.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.58 -38.8 2.53 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 117.008 1.563 . . . . 0.0 117.008 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.4 t -63.91 -56.98 11.24 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 116.873 2.175 . . . . 0.0 116.873 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.91 -122.31 0.87 Allowed Glycine 0 N--CA 1.488 2.104 0 O-C-N 121.269 -0.894 . . . . 0.0 113.921 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -136.55 150.37 48.58 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 124.031 0.932 . . . . 0.0 113.487 -170.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.31 141.13 39.14 Favored 'General case' 0 CA--C 1.563 1.447 0 C-N-CA 123.768 0.827 . . . . 0.0 110.984 175.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -73.54 -40.49 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 120.94 -1.1 . . . . 0.0 112.645 171.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t . . . . . 0 N--CA 1.495 1.819 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 171.825 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.576 1.943 0 N-CA-C 119.995 3.331 . . . . 0.0 119.995 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -78.48 178.45 7.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 121.859 2.118 . . . . 0.0 113.933 177.469 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -123.51 56.13 0.68 Allowed Glycine 0 N--CA 1.501 3.012 0 O-C-N 120.297 -1.502 . . . . 0.0 116.725 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.86 -53.45 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.576 1.961 0 C-N-CA 124.411 1.084 . . . . 0.0 109.54 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -63.63 158.89 39.41 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 119.137 2.415 . . . . 0.0 119.137 -177.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -99.47 44.77 1.01 Allowed 'General case' 0 N--CA 1.5 2.075 0 N-CA-C 116.239 1.941 . . . . 0.0 116.239 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.5 p -175.62 152.42 1.3 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 125.156 1.383 . . . . 0.0 109.676 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -67.38 144.81 55.6 Favored 'General case' 0 CA--C 1.58 2.111 0 N-CA-C 116.708 2.114 . . . . 0.0 116.708 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -76.14 -70.03 0.47 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 118.002 -0.999 . . . . 0.0 112.139 172.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -153.48 100.96 2.46 Favored 'General case' 0 CA--C 1.563 1.476 0 CA-C-N 120.012 1.278 . . . . 0.0 109.39 -173.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 45.62 67.81 0.68 Allowed 'General case' 0 CA--C 1.574 1.889 0 N-CA-C 119.005 2.965 . . . . 0.0 119.005 173.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.65 -11.97 57.71 Favored Glycine 0 N--CA 1.499 2.874 0 N-CA-C 120.93 3.132 . . . . 0.0 120.93 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.14 -39.26 93.64 Favored 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 117.975 2.583 . . . . 0.0 117.975 -176.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.95 -123.02 1.08 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 124.277 0.942 . . . . 0.0 111.126 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -131.21 171.73 12.95 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.89 151.71 29.79 Favored 'General case' 0 CA--C 1.562 1.434 0 O-C-N 120.344 -1.472 . . . . 0.0 111.738 174.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.67 -46.46 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.389 0 O-C-N 121.027 -1.046 . . . . 0.0 111.686 166.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.9 t . . . . . 0 N--CA 1.498 1.931 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 169.342 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 t . . . . . 0 N--CA 1.498 1.938 0 N-CA-C 119.609 3.189 . . . . 0.0 119.609 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.36 171.47 13.48 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-N 121.583 1.992 . . . . 0.0 114.57 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -119.75 55.21 0.62 Allowed Glycine 0 N--CA 1.502 3.038 0 N-CA-C 116.149 1.22 . . . . 0.0 116.149 175.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.11 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 124.61 1.164 . . . . 0.0 109.099 177.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.28 170.55 34.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 118.631 2.212 . . . . 0.0 118.631 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.2 p -114.63 55.73 0.74 Allowed 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 115.184 1.55 . . . . 0.0 115.184 -175.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 25.2 p -162.92 -129.05 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.14 -0.975 . . . . 0.0 110.967 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -145.24 138.3 26.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 119.983 -1.698 . . . . 0.0 111.301 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -85.79 -58.17 2.76 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 123.926 0.89 . . . . 0.0 111.303 172.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -150.14 134.48 17.25 Favored 'General case' 0 CA--C 1.571 1.762 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 172.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -44.9 113.12 0.51 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.802 2.149 . . . . 0.0 116.802 -177.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.65 -27.96 16.88 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 118.358 2.103 . . . . 0.0 118.358 -171.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.49 -53.78 5.44 Favored 'General case' 0 CA--C 1.573 1.845 0 CA-C-N 119.806 1.803 . . . . 0.0 115.687 -177.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.5 -133.08 2.71 Favored Glycine 0 N--CA 1.49 2.266 0 O-C-N 121.09 -1.006 . . . . 0.0 113.939 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -113.09 175.73 5.32 Favored 'General case' 0 CA--C 1.566 1.589 0 CA-C-O 122.02 0.914 . . . . 0.0 113.383 -170.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.2 146.54 31.78 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.106 -1.621 . . . . 0.0 112.542 176.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.5 t -77.87 -43.23 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.578 -0.701 . . . . 0.0 111.874 170.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t . . . . . 0 N--CA 1.497 1.88 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 172.758 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.574 1.885 0 N-CA-C 119.561 3.171 . . . . 0.0 119.561 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.365 1.3 pt? -98.35 -161.02 0.84 Allowed 'General case' 0 CA--C 1.577 2.016 0 CA-C-N 121.647 2.021 . . . . 0.0 115.397 -173.096 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.44 64.57 0.41 Allowed Glycine 0 N--CA 1.5 2.938 0 O-C-N 119.758 -1.839 . . . . 0.0 117.647 -175.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.11 -54.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.899 0 C-N-CA 124.227 1.011 . . . . 0.0 108.941 172.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.81 179.12 47.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 119.674 2.63 . . . . 0.0 119.674 -177.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.6 p -115.21 53.06 0.84 Allowed 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 -177.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.0 p -167.61 134.49 2.22 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 124.342 1.057 . . . . 0.0 109.695 -179.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -69.37 132.33 46.21 Favored 'General case' 0 CA--C 1.573 1.831 0 N-CA-C 115.462 1.653 . . . . 0.0 115.462 -173.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.2 p-10 -73.68 -67.44 0.59 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 113.455 0.909 . . . . 0.0 113.455 176.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -139.42 76.43 1.56 Allowed 'General case' 0 N--CA 1.494 1.767 0 CA-C-N 118.634 0.652 . . . . 0.0 112.007 -171.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 41.7 79.08 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 118.392 2.738 . . . . 0.0 118.392 175.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.22 -22.93 20.66 Favored Glycine 0 N--CA 1.498 2.81 0 N-CA-C 119.164 2.425 . . . . 0.0 119.164 -174.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -58.22 -49.66 76.31 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 117.552 2.427 . . . . 0.0 117.552 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.37 -125.92 1.15 Allowed Glycine 0 N--CA 1.487 2.036 0 O-C-N 121.547 -0.721 . . . . 0.0 112.332 177.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -140.72 146.94 38.42 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -173.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -109.38 142.85 39.74 Favored 'General case' 0 CA--C 1.563 1.443 0 C-N-CA 123.558 0.743 . . . . 0.0 111.366 174.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -71.42 -43.8 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 120.797 -1.189 . . . . 0.0 112.423 170.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t . . . . . 0 N--CA 1.496 1.848 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 169.934 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 t . . . . . 0 CA--C 1.574 1.868 0 N-CA-C 119.36 3.096 . . . . 0.0 119.36 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.13 173.19 6.41 Favored 'General case' 0 CA--C 1.576 1.959 0 CA-C-N 120.618 1.554 . . . . 0.0 114.452 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.52 56.29 0.63 Allowed Glycine 0 N--CA 1.501 3.026 0 N-CA-C 116.127 1.211 . . . . 0.0 116.127 175.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.5 -52.91 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 C-N-CA 124.488 1.115 . . . . 0.0 109.418 177.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.91 178.44 25.48 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 119.064 2.385 . . . . 0.0 119.064 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -119.82 50.41 1.28 Allowed 'General case' 0 N--CA 1.5 2.05 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 -175.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.253 22.4 p -157.25 -129.31 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.84 -1.162 . . . . 0.0 110.821 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -144.42 135.67 25.4 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.765 1.621 . . . . 0.0 111.071 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.4 p-10 -86.82 -60.41 1.99 Allowed 'General case' 0 N--CA 1.491 1.608 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.336 173.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -147.16 127.42 13.88 Favored 'General case' 0 CA--C 1.566 1.595 0 N-CA-C 105.364 -2.087 . . . . 0.0 105.364 173.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.85 106.8 0.1 Allowed 'General case' 0 CA--C 1.574 1.868 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.1 -46.03 1.1 Allowed Glycine 0 N--CA 1.492 2.406 0 CA-C-O 118.436 -1.202 . . . . 0.0 115.497 -169.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.4 t -83.57 -61.62 1.79 Allowed 'General case' 0 CA--C 1.569 1.677 0 N-CA-C 116.282 1.956 . . . . 0.0 116.282 -178.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.53 -121.19 0.76 Allowed Glycine 0 N--CA 1.488 2.133 0 CA-C-N 120.504 1.502 . . . . 0.0 115.803 -177.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.43 174.72 5.91 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -166.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.89 147.03 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 120.348 -1.47 . . . . 0.0 112.113 174.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.7 t -76.93 -44.0 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.575 -0.703 . . . . 0.0 112.61 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.5 t . . . . . 0 N--CA 1.496 1.861 0 CA-C-N 119.668 1.122 . . . . 0.0 108.095 175.613 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.574 1.887 0 N-CA-C 120.325 3.454 . . . . 0.0 120.325 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.3 179.55 4.55 Favored 'General case' 0 CA--C 1.579 2.073 0 CA-C-N 121.093 1.77 . . . . 0.0 114.088 178.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -124.21 58.46 0.64 Allowed Glycine 0 N--CA 1.501 3.005 0 O-C-N 120.259 -1.525 . . . . 0.0 116.697 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -131.54 -54.75 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 124.403 1.081 . . . . 0.0 109.391 176.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.58 -179.97 28.76 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 119.232 2.453 . . . . 0.0 119.232 -177.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -121.29 43.79 2.71 Favored 'General case' 0 N--CA 1.504 2.272 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -175.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 21.1 p -163.56 139.81 6.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.79 -1.194 . . . . 0.0 109.821 177.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -63.5 137.81 58.27 Favored 'General case' 0 CA--C 1.577 2.014 0 N-CA-C 116.266 1.95 . . . . 0.0 116.266 -174.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.277 39.1 p-10 -80.68 -80.86 0.13 Allowed 'General case' 0 N--CA 1.489 1.512 0 CA-C-O 118.237 -0.887 . . . . 0.0 113.223 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -121.29 55.42 1.07 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -173.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . 0.264 . . 57.65 7.56 0.56 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 121.762 3.986 . . . . 0.0 121.762 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.61 64.02 0.03 OUTLIER Glycine 0 N--CA 1.491 2.322 0 O-C-N 120.866 -1.146 . . . . 0.0 115.152 -177.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 54.0 t -156.84 -64.68 0.1 Allowed 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 123.589 0.756 . . . . 0.0 111.464 177.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.77 -117.83 0.46 Allowed Glycine 0 N--CA 1.483 1.788 0 O-C-N 121.633 -0.667 . . . . 0.0 112.391 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -129.23 172.23 11.66 Favored 'General case' 0 CA--C 1.566 1.591 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -168.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.45 143.87 47.78 Favored 'General case' 0 CA--C 1.563 1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 110.705 173.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.1 t -74.06 -43.92 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.106 -0.996 . . . . 0.0 112.326 171.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.6 t . . . . . 0 N--CA 1.495 1.804 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 172.035 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 120.275 3.435 . . . . 0.0 120.275 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.43 166.75 18.11 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 121.859 2.118 . . . . 0.0 115.161 -178.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.37 49.96 0.81 Allowed Glycine 0 N--CA 1.5 2.9 0 N-CA-C 116.701 1.441 . . . . 0.0 116.701 176.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -133.58 -55.23 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 124.334 1.054 . . . . 0.0 109.991 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.71 169.35 38.09 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 118.311 2.084 . . . . 0.0 118.311 -178.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.8 p -109.77 56.15 0.63 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 115.526 1.676 . . . . 0.0 115.526 -174.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.254 22.5 p -164.26 -131.71 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.124 -0.985 . . . . 0.0 111.111 176.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -146.36 136.26 23.4 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 119.933 -1.73 . . . . 0.0 111.295 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.0 p30 -82.84 -63.32 1.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.012 -0.995 . . . . 0.0 111.136 174.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -145.24 124.0 12.61 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.956 -2.239 . . . . 0.0 104.956 174.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -38.36 111.18 0.16 Allowed 'General case' 0 CA--C 1.573 1.839 0 N-CA-C 117.892 2.553 . . . . 0.0 117.892 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.05 -32.25 7.04 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 117.917 1.927 . . . . 0.0 117.917 -171.463 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -80.31 -51.67 8.62 Favored 'General case' 0 CA--C 1.574 1.867 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 -176.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.14 -135.13 3.46 Favored Glycine 0 N--CA 1.49 2.295 0 O-C-N 121.203 -0.936 . . . . 0.0 113.243 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -114.23 178.98 4.09 Favored 'General case' 0 CA--C 1.567 1.607 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -171.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.96 145.3 30.6 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.058 -1.651 . . . . 0.0 112.262 175.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.4 t -75.82 -45.34 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 O-C-N 121.393 -0.817 . . . . 0.0 111.691 171.096 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t . . . . . 0 N--CA 1.496 1.842 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 171.576 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.497 1.898 0 N-CA-C 119.781 3.252 . . . . 0.0 119.781 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.41 171.6 13.3 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 121.59 1.996 . . . . 0.0 114.571 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.48 55.57 0.63 Allowed Glycine 0 N--CA 1.5 2.955 0 N-CA-C 116.015 1.166 . . . . 0.0 116.015 175.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.58 -52.55 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.89 0 C-N-CA 124.737 1.215 . . . . 0.0 109.055 177.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.16 173.92 31.18 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 118.673 2.229 . . . . 0.0 118.673 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -117.8 51.16 1.07 Allowed 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 115.317 1.599 . . . . 0.0 115.317 -175.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.256 25.6 p -157.48 -128.63 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.83 -1.169 . . . . 0.0 110.963 174.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -145.66 135.87 23.87 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-N 120.903 1.683 . . . . 0.0 111.533 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p-10 -83.34 -60.6 2.09 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.988 172.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -147.53 135.3 21.08 Favored 'General case' 0 CA--C 1.572 1.816 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 171.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.17 113.69 0.61 Allowed 'General case' 0 CA--C 1.573 1.842 0 N-CA-C 116.795 2.146 . . . . 0.0 116.795 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.26 -26.88 22.28 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 118.431 2.132 . . . . 0.0 118.431 -171.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.57 -54.02 5.24 Favored 'General case' 0 CA--C 1.573 1.849 0 CA-C-N 119.809 1.805 . . . . 0.0 115.606 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.46 -133.0 2.69 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 121.079 -1.013 . . . . 0.0 113.942 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -112.86 175.32 5.49 Favored 'General case' 0 CA--C 1.567 1.605 0 CA-C-O 122.121 0.962 . . . . 0.0 113.354 -170.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.09 147.01 33.19 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.159 -1.588 . . . . 0.0 112.092 175.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 66.2 t -77.77 -42.52 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 O-C-N 121.544 -0.722 . . . . 0.0 112.493 172.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t . . . . . 0 N--CA 1.497 1.901 0 CA-C-N 119.839 1.2 . . . . 0.0 108.12 175.105 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 t . . . . . 0 N--CA 1.498 1.97 0 N-CA-C 119.886 3.291 . . . . 0.0 119.886 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.77 166.04 17.29 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 121.615 2.007 . . . . 0.0 114.861 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -110.85 48.77 0.9 Allowed Glycine 0 N--CA 1.501 2.984 0 N-CA-C 116.957 1.543 . . . . 0.0 116.957 177.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.53 -55.67 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 C-N-CA 124.168 0.987 . . . . 0.0 110.267 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.52 34.84 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 118.612 2.205 . . . . 0.0 118.612 -177.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.7 p -112.99 58.15 0.66 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 19.4 p -165.71 -132.7 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 110.868 175.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -144.03 139.3 28.91 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 119.877 -1.765 . . . . 0.0 111.313 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.4 p-10 -90.65 -65.61 1.0 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.95 176.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -139.82 77.44 1.61 Allowed 'General case' 0 N--CA 1.494 1.744 0 CA-C-N 119.06 0.845 . . . . 0.0 111.254 -175.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 32.64 80.68 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 119.403 3.112 . . . . 0.0 119.403 174.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.48 -28.45 14.13 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 118.391 2.116 . . . . 0.0 118.391 -173.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.4 t -59.93 -41.37 91.63 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 117.298 2.333 . . . . 0.0 117.298 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.35 -135.94 3.93 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 124.024 0.821 . . . . 0.0 111.814 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -115.36 176.65 4.97 Favored 'General case' 0 CA--C 1.565 1.533 0 CA-C-O 122.084 0.945 . . . . 0.0 113.257 -173.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.0 144.92 37.22 Favored 'General case' 0 CA--C 1.562 1.432 0 O-C-N 120.258 -1.526 . . . . 0.0 111.776 175.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -74.75 -42.26 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 174.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 N--CA 1.496 1.845 0 CA-C-N 119.883 1.22 . . . . 0.0 108.033 175.712 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 119.08 2.993 . . . . 0.0 119.08 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.85 169.15 14.43 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 121.34 1.882 . . . . 0.0 114.585 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -112.48 48.17 0.97 Allowed Glycine 0 N--CA 1.499 2.878 0 N-CA-C 117.097 1.599 . . . . 0.0 117.097 177.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -131.5 -54.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 124.156 0.982 . . . . 0.0 110.179 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.8 172.67 23.93 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 p -114.34 54.06 0.78 Allowed 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 115.53 1.678 . . . . 0.0 115.53 -175.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.262 22.0 p -165.99 -124.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.18 -0.95 . . . . 0.0 110.841 176.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -147.85 140.44 24.6 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-N 120.94 1.7 . . . . 0.0 111.717 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -82.47 -71.67 0.48 Allowed 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.469 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -145.26 85.91 1.75 Allowed 'General case' 0 CA--C 1.566 1.585 0 CA-C-N 119.548 1.067 . . . . 0.0 111.736 -179.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 50.89 81.66 0.07 Allowed 'General case' 0 CA--C 1.571 1.782 0 N-CA-C 118.017 2.599 . . . . 0.0 118.017 173.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.52 -21.97 8.19 Favored Glycine 0 N--CA 1.5 2.929 0 N-CA-C 120.31 2.884 . . . . 0.0 120.31 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.1 t -59.43 -39.55 83.9 Favored 'General case' 0 N--CA 1.5 2.074 0 N-CA-C 117.689 2.477 . . . . 0.0 117.689 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.5 -132.85 2.61 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 124.108 0.861 . . . . 0.0 111.239 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -117.95 178.47 4.41 Favored 'General case' 0 CA--C 1.565 1.548 0 CA-C-O 122.127 0.965 . . . . 0.0 113.446 -173.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -155.73 146.28 21.96 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.371 -1.456 . . . . 0.0 112.594 175.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . 0.253 9.4 p -69.15 -45.95 78.79 Favored 'Isoleucine or valine' 0 CA--C 1.58 2.096 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 166.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.5 t . . . . . 0 CA--C 1.571 1.757 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 169.317 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.498 1.927 0 N-CA-C 120.815 3.635 . . . . 0.0 120.815 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.252 0.3 OUTLIER -80.77 174.32 11.73 Favored 'General case' 0 CA--C 1.578 2.025 0 CA-C-N 122.136 2.244 . . . . 0.0 114.381 178.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.49 57.74 0.6 Allowed Glycine 0 N--CA 1.501 2.981 0 O-C-N 120.404 -1.435 . . . . 0.0 116.455 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.29 -53.91 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 C-N-CA 124.513 1.125 . . . . 0.0 108.981 176.205 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.46 168.67 42.12 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 118.417 2.127 . . . . 0.0 118.417 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -112.66 43.11 1.71 Allowed 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.8 p -164.83 142.77 6.43 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 124.546 1.138 . . . . 0.0 109.729 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.7 140.23 58.85 Favored 'General case' 0 CA--C 1.579 2.085 0 N-CA-C 118.006 2.595 . . . . 0.0 118.006 -171.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p30 -79.7 -60.99 2.13 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 123.444 0.698 . . . . 0.0 111.637 172.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -151.7 94.0 1.93 Allowed 'General case' 0 CA--C 1.566 1.595 0 CA-C-N 119.732 1.151 . . . . 0.0 109.202 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 13.42 83.28 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 121.438 3.866 . . . . 0.0 121.438 175.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.42 -35.74 4.2 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 117.648 1.819 . . . . 0.0 117.648 -174.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.7 t -68.88 -45.04 72.0 Favored 'General case' 0 CA--C 1.577 2.005 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 -177.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 160.47 -130.88 2.49 Favored Glycine 0 N--CA 1.489 2.203 0 O-C-N 121.359 -0.838 . . . . 0.0 112.745 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -125.09 171.66 10.1 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -170.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.23 140.96 37.88 Favored 'General case' 0 CA--C 1.564 1.49 0 O-C-N 120.364 -1.46 . . . . 0.0 110.615 175.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.1 m -69.03 -39.56 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.058 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.1 t . . . . . 0 N--CA 1.494 1.756 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 168.714 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.573 1.865 0 N-CA-C 119.177 3.029 . . . . 0.0 119.177 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.43 169.47 8.68 Favored 'General case' 0 CA--C 1.575 1.906 0 CA-C-N 120.664 1.575 . . . . 0.0 114.703 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.26 52.26 0.66 Allowed Glycine 0 N--CA 1.5 2.937 0 N-CA-C 116.669 1.428 . . . . 0.0 116.669 177.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.23 -54.83 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 C-N-CA 124.112 0.965 . . . . 0.0 110.211 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.53 177.73 25.27 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 118.825 2.29 . . . . 0.0 118.825 -177.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.7 t -116.43 53.46 0.88 Allowed 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 115.047 1.499 . . . . 0.0 115.047 -175.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -162.16 -129.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.92 -1.113 . . . . 0.0 110.974 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -144.1 139.89 29.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.932 -1.73 . . . . 0.0 110.832 178.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -90.97 -60.06 2.01 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 123.637 0.775 . . . . 0.0 111.256 172.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -147.22 127.25 13.67 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 174.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.84 106.56 0.09 Allowed 'General case' 0 CA--C 1.572 1.81 0 N-CA-C 116.001 1.852 . . . . 0.0 116.001 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.39 -46.02 1.1 Allowed Glycine 0 N--CA 1.492 2.381 0 CA-C-O 118.509 -1.162 . . . . 0.0 115.687 -169.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.3 t -83.46 -60.71 2.05 Favored 'General case' 0 CA--C 1.569 1.698 0 N-CA-C 116.611 2.078 . . . . 0.0 116.611 -178.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 178.24 -124.9 0.95 Allowed Glycine 0 N--CA 1.49 2.284 0 CA-C-N 120.314 1.416 . . . . 0.0 115.356 -176.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -115.05 178.19 4.38 Favored 'General case' 0 CA--C 1.566 1.577 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -168.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.6 141.29 33.47 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.346 -1.472 . . . . 0.0 112.087 175.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.86 -39.8 52.39 Favored 'Isoleucine or valine' 0 CA--C 1.576 1.951 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 170.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.1 t . . . . . 0 N--CA 1.496 1.848 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 170.94 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.498 1.955 0 N-CA-C 118.742 2.868 . . . . 0.0 118.742 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.3 173.51 11.53 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-N 121.056 1.753 . . . . 0.0 114.203 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.1 55.11 0.65 Allowed Glycine 0 N--CA 1.501 3.005 0 N-CA-C 116.217 1.247 . . . . 0.0 116.217 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.86 -52.1 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 C-N-CA 124.662 1.185 . . . . 0.0 109.195 177.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.82 172.87 23.65 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 118.506 2.163 . . . . 0.0 118.506 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -117.61 49.08 1.26 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 115.185 1.55 . . . . 0.0 115.185 -177.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.25 26.2 p -159.23 -122.8 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.85 -1.156 . . . . 0.0 110.961 175.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -147.56 142.35 26.78 Favored 'General case' 0 N--CA 1.491 1.625 0 CA-C-N 120.934 1.697 . . . . 0.0 111.999 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -91.01 -63.21 1.3 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 124.515 1.126 . . . . 0.0 113.343 176.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 94.4 m-85 -140.77 78.13 1.63 Allowed 'General case' 0 N--CA 1.495 1.808 0 CA-C-N 119.079 0.854 . . . . 0.0 111.237 -173.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 38.79 75.24 0.08 Allowed 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 118.717 2.858 . . . . 0.0 118.717 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.14 -19.83 51.09 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 119.545 2.578 . . . . 0.0 119.545 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 3.9 t -61.49 -41.35 97.14 Favored 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 117.766 2.506 . . . . 0.0 117.766 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.34 -128.04 1.49 Allowed Glycine 0 N--CA 1.489 2.198 0 O-C-N 121.361 -0.837 . . . . 0.0 111.726 177.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -120.04 174.25 6.59 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-O 122.058 0.932 . . . . 0.0 113.242 -173.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.26 147.36 25.59 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.403 -1.435 . . . . 0.0 112.787 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -73.4 -42.14 56.86 Favored 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 165.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.6 t -91.74 110.92 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 170.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 63.6 m -84.62 122.94 29.76 Favored 'General case' 0 CA--C 1.568 1.641 0 O-C-N 121.534 -0.729 . . . . 0.0 112.714 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -73.62 97.83 2.73 Favored 'General case' 0 CA--C 1.573 1.862 0 CA-C-O 122.991 1.377 . . . . 0.0 113.884 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 60.9 p-90 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 124.719 2.199 . . . . 0.0 114.064 -177.577 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.499 1.977 0 N-CA-C 120.745 3.609 . . . . 0.0 120.745 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.254 0.2 OUTLIER -80.56 176.18 10.01 Favored 'General case' 0 CA--C 1.579 2.075 0 CA-C-N 122.044 2.202 . . . . 0.0 114.139 177.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.45 56.27 0.61 Allowed Glycine 0 N--CA 1.501 3.013 0 O-C-N 120.206 -1.558 . . . . 0.0 116.828 176.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.0 mt -129.48 -59.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 C-N-CA 124.273 1.029 . . . . 0.0 109.455 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.31 172.02 42.26 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 119.836 2.694 . . . . 0.0 119.836 -175.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.8 p -110.74 51.23 0.78 Allowed 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -175.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.4 p -169.9 140.01 1.99 Allowed 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.44 1.096 . . . . 0.0 109.627 178.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -66.48 133.67 50.87 Favored 'General case' 0 CA--C 1.576 1.964 0 N-CA-C 115.652 1.723 . . . . 0.0 115.652 -176.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.254 26.3 p30 -71.54 -72.34 0.23 Allowed 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 123.77 0.828 . . . . 0.0 112.884 177.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -144.21 87.75 1.91 Allowed 'General case' 0 CA--C 1.566 1.588 0 CA-C-N 119.42 1.009 . . . . 0.0 110.923 -178.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.79 82.72 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 118.366 2.728 . . . . 0.0 118.366 173.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.94 -23.94 5.58 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 120.097 2.799 . . . . 0.0 120.097 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.9 t -58.82 -40.78 85.17 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 117.907 2.558 . . . . 0.0 117.907 -176.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.15 -126.11 1.47 Allowed Glycine 0 N--CA 1.488 2.137 0 C-N-CA 124.003 0.811 . . . . 0.0 111.368 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -131.18 169.1 16.38 Favored 'General case' 0 CA--C 1.569 1.694 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -172.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.61 142.75 49.96 Favored 'General case' 0 CA--C 1.564 1.507 0 O-C-N 120.569 -1.332 . . . . 0.0 110.796 174.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.2 t -75.03 -38.53 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.294 0 O-C-N 120.954 -1.091 . . . . 0.0 113.57 173.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -87.82 96.5 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.802 -1.186 . . . . 0.0 108.307 176.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 82.1 m -91.25 83.24 5.49 Favored 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 114.079 1.141 . . . . 0.0 114.079 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.58 108.91 4.82 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 122.205 1.002 . . . . 0.0 108.878 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 59.8 m95 . . . . . 0 N--CA 1.495 1.824 0 CA-C-O 124.355 2.026 . . . . 0.0 113.871 -175.329 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.575 1.917 0 N-CA-C 120.421 3.489 . . . . 0.0 120.421 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.04 173.76 6.16 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 121.006 1.73 . . . . 0.0 113.882 177.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -117.81 54.03 0.62 Allowed Glycine 0 N--CA 1.501 2.976 0 O-C-N 120.306 -1.496 . . . . 0.0 116.595 176.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.25 -54.94 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 124.274 1.03 . . . . 0.0 109.631 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.88 173.86 30.27 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 118.09 1.996 . . . . 0.0 118.09 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.8 t -116.04 43.83 2.06 Favored 'General case' 0 N--CA 1.504 2.249 0 N-CA-C 116.083 1.882 . . . . 0.0 116.083 -175.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 18.5 p -166.77 142.55 4.43 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.752 -1.218 . . . . 0.0 110.367 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -57.55 133.78 55.55 Favored 'General case' 0 CA--C 1.581 2.173 0 N-CA-C 117.616 2.45 . . . . 0.0 117.616 -174.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -81.85 -64.14 1.24 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 123.041 0.536 . . . . 0.0 112.406 171.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -148.59 120.98 8.45 Favored 'General case' 0 CA--C 1.566 1.565 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.46 105.64 0.06 Allowed 'General case' 0 CA--C 1.573 1.828 0 N-CA-C 116.834 2.161 . . . . 0.0 116.834 -175.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.68 -45.59 1.13 Allowed Glycine 0 N--CA 1.491 2.354 0 CA-C-O 118.548 -1.14 . . . . 0.0 115.816 -170.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 31.2 t -83.52 -59.01 2.58 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 116.809 2.151 . . . . 0.0 116.809 -178.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.62 -121.64 0.9 Allowed Glycine 0 N--CA 1.487 2.07 0 CA-C-N 119.918 1.236 . . . . 0.0 114.242 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -124.37 172.37 9.19 Favored 'General case' 0 CA--C 1.566 1.573 0 N-CA-C 115.248 1.573 . . . . 0.0 115.248 -167.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.22 144.48 48.46 Favored 'General case' 0 CA--C 1.561 1.381 0 O-C-N 120.542 -1.349 . . . . 0.0 111.073 174.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -72.31 -43.76 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 121.0 -1.063 . . . . 0.0 111.57 168.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -86.12 110.98 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 168.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 97.3 m -73.0 115.59 12.49 Favored 'General case' 0 CA--C 1.567 1.62 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -82.79 97.05 8.4 Favored 'General case' 0 CA--C 1.569 1.687 0 CA-C-O 122.155 0.979 . . . . 0.0 112.988 -173.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 57.1 p-90 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 123.091 1.425 . . . . 0.0 111.969 179.712 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.4 t . . . . . 0 CA--C 1.575 1.937 0 N-CA-C 121.185 3.772 . . . . 0.0 121.185 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 173.36 6.34 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-N 121.364 1.893 . . . . 0.0 113.806 177.034 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.71 51.21 0.73 Allowed Glycine 0 N--CA 1.502 3.034 0 O-C-N 119.971 -1.706 . . . . 0.0 117.326 176.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -132.53 -56.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 C-N-CA 123.938 0.895 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.97 168.13 41.2 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 119.283 2.473 . . . . 0.0 119.283 -174.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.7 p -105.99 55.13 0.68 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -174.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 19.2 p -178.15 140.62 0.23 Allowed 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 125.021 1.329 . . . . 0.0 109.263 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -69.64 136.25 50.93 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 116.274 1.953 . . . . 0.0 116.274 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 49.7 p30 -78.2 -63.66 1.34 Allowed 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 123.194 0.597 . . . . 0.0 112.104 175.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -147.93 124.41 11.01 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.653 -2.351 . . . . 0.0 104.653 175.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.08 105.81 0.06 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.386 1.995 . . . . 0.0 116.386 179.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.89 -47.23 1.03 Allowed Glycine 0 N--CA 1.491 2.329 0 CA-C-O 118.366 -1.241 . . . . 0.0 115.335 -169.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 t -86.08 -61.95 1.63 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.37 -119.98 0.78 Allowed Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.942 1.246 . . . . 0.0 114.351 -175.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -126.89 172.83 10.08 Favored 'General case' 0 CA--C 1.571 1.754 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -167.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -130.5 141.56 50.5 Favored 'General case' 0 CA--C 1.563 1.473 0 O-C-N 120.281 -1.512 . . . . 0.0 110.855 174.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 -41.8 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.02 -1.05 . . . . 0.0 112.628 171.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -90.28 108.01 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 172.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.4 m -83.08 105.36 14.0 Favored 'General case' 0 CA--C 1.567 1.609 0 CA-C-O 121.674 0.75 . . . . 0.0 112.164 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -85.59 97.35 10.03 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 122.053 0.93 . . . . 0.0 112.298 -175.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 53.9 p-90 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 123.108 1.432 . . . . 0.0 112.087 179.537 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 m . . . . . 0 CA--C 1.575 1.919 0 N-CA-C 120.431 3.493 . . . . 0.0 120.431 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.255 0.3 OUTLIER -89.99 169.26 11.36 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-N 122.247 2.294 . . . . 0.0 116.066 -172.449 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.01 51.83 0.68 Allowed Glycine 0 N--CA 1.5 2.932 0 N-CA-C 117.032 1.573 . . . . 0.0 117.032 177.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.07 -56.66 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 C-N-CA 123.883 0.873 . . . . 0.0 110.228 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -69.75 175.91 33.45 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 118.712 2.245 . . . . 0.0 118.712 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 p -114.24 56.23 0.72 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 115.499 1.666 . . . . 0.0 115.499 -174.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.269 11.7 p -164.59 -129.38 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.194 -0.941 . . . . 0.0 110.98 176.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -144.92 142.42 29.85 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 121.143 1.792 . . . . 0.0 111.74 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -91.9 -73.54 0.54 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-N 114.254 -1.339 . . . . 0.0 110.118 172.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -137.72 76.42 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -172.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.22 80.9 0.05 OUTLIER 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 117.99 2.589 . . . . 0.0 117.99 172.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.29 -23.98 6.7 Favored Glycine 0 N--CA 1.5 2.908 0 N-CA-C 119.016 2.367 . . . . 0.0 119.016 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -54.37 -46.41 73.0 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 117.024 2.231 . . . . 0.0 117.024 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 173.47 -132.6 2.36 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 124.053 0.835 . . . . 0.0 111.148 175.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -119.83 -178.63 3.68 Favored 'General case' 0 CA--C 1.567 1.604 0 CA-C-O 122.231 1.015 . . . . 0.0 112.353 -173.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.2 145.11 26.97 Favored 'General case' 0 CA--C 1.562 1.41 0 O-C-N 120.115 -1.616 . . . . 0.0 111.665 172.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.5 t -71.81 -45.77 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 O-C-N 121.185 -0.947 . . . . 0.0 112.044 172.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -91.0 119.31 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 167.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 97.7 m -80.51 95.54 6.51 Favored 'General case' 0 CA--C 1.568 1.65 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -106.23 92.58 4.2 Favored 'General case' 0 CA--C 1.563 1.46 0 C-N-CA 124.365 1.066 . . . . 0.0 109.305 175.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.388 51.8 p-90 . . . . . 0 N--CA 1.507 2.415 0 N-CA-C 118.693 2.849 . . . . 0.0 118.693 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 t . . . . . 0 CA--C 1.574 1.893 0 N-CA-C 119.056 2.984 . . . . 0.0 119.056 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.46 174.07 6.03 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 120.62 1.555 . . . . 0.0 114.489 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.86 56.35 0.64 Allowed Glycine 0 N--CA 1.501 2.969 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 175.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.19 -53.39 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 C-N-CA 124.579 1.152 . . . . 0.0 109.32 177.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.07 173.6 27.74 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 118.783 2.273 . . . . 0.0 118.783 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -115.82 50.09 1.05 Allowed 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 115.914 1.82 . . . . 0.0 115.914 -175.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.271 18.8 p -160.53 -124.26 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.884 -1.135 . . . . 0.0 110.782 175.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -146.05 138.08 25.17 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-N 121.149 1.795 . . . . 0.0 112.126 -179.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.7 p-10 -87.65 -61.85 1.63 Allowed 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.108 171.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -146.83 128.38 15.08 Favored 'General case' 0 CA--C 1.568 1.637 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 174.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -48.85 106.29 0.1 Allowed 'General case' 0 CA--C 1.571 1.771 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.58 -46.55 1.07 Allowed Glycine 0 N--CA 1.491 2.363 0 CA-C-O 118.406 -1.219 . . . . 0.0 115.416 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -84.15 -61.93 1.69 Allowed 'General case' 0 CA--C 1.57 1.726 0 N-CA-C 116.291 1.959 . . . . 0.0 116.291 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.97 -121.47 0.77 Allowed Glycine 0 N--CA 1.489 2.174 0 CA-C-N 120.471 1.487 . . . . 0.0 115.752 -176.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -116.27 176.51 5.07 Favored 'General case' 0 CA--C 1.566 1.578 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -166.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.52 147.85 28.69 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.234 -1.541 . . . . 0.0 112.363 175.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.6 t -75.1 -46.24 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.627 -0.671 . . . . 0.0 111.263 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -87.43 111.31 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 169.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.1 m -76.26 108.7 9.38 Favored 'General case' 0 CA--C 1.566 1.573 0 O-C-N 121.343 -0.848 . . . . 0.0 112.296 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -80.01 106.1 11.78 Favored 'General case' 0 N--CA 1.492 1.64 0 CA-C-O 122.299 1.047 . . . . 0.0 113.485 -170.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.495 1.809 0 N-CA-C 115.915 1.821 . . . . 0.0 115.915 -178.013 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.576 1.957 0 N-CA-C 119.459 3.133 . . . . 0.0 119.459 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.3 0.2 OUTLIER -90.15 179.23 5.97 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 121.613 2.006 . . . . 0.0 115.004 -174.401 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -98.25 -42.78 2.92 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 118.707 2.243 . . . . 0.0 118.707 178.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -82.85 56.41 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.579 2.085 0 N-CA-C 117.486 2.402 . . . . 0.0 117.486 -173.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -153.0 175.25 31.58 Favored Glycine 0 N--CA 1.49 2.255 0 O-C-N 120.902 -1.124 . . . . 0.0 115.302 172.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 55.6 p -122.03 54.7 1.15 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.267 12.4 p -164.49 -130.82 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 C-N-CA 123.875 0.87 . . . . 0.0 110.156 174.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -150.05 133.1 16.2 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 119.988 -1.695 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.13 -58.06 2.92 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 114.567 1.321 . . . . 0.0 114.567 178.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -141.35 77.11 1.58 Allowed 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 118.845 0.748 . . . . 0.0 111.909 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 36.38 75.5 0.06 Allowed 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 119.036 2.976 . . . . 0.0 119.036 175.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.24 -17.95 57.26 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 119.16 2.424 . . . . 0.0 119.16 -173.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.7 t -60.68 -52.75 63.81 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 116.758 2.133 . . . . 0.0 116.758 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.1 -120.86 0.65 Allowed Glycine 0 N--CA 1.489 2.169 0 O-C-N 121.573 -0.705 . . . . 0.0 112.258 175.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -122.62 172.54 8.32 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.941 0.897 . . . . 0.0 112.319 -173.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.0 141.96 34.31 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.393 -1.442 . . . . 0.0 111.606 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.7 m -73.18 -35.21 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 175.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.24 91.75 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-N 120.027 1.285 . . . . 0.0 107.875 175.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.5 m -87.64 108.24 18.99 Favored 'General case' 0 CA--C 1.566 1.586 0 O-C-N 121.578 -0.701 . . . . 0.0 112.28 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -85.83 93.22 8.85 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.547 -0.72 . . . . 0.0 112.382 -178.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.372 29.0 p90 . . . . . 0 N--CA 1.507 2.422 0 N-CA-C 120.2 3.407 . . . . 0.0 120.2 175.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.2 m . . . . . 0 CA--C 1.577 1.982 0 N-CA-C 119.127 3.01 . . . . 0.0 119.127 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.259 0.3 OUTLIER -88.84 170.92 10.32 Favored 'General case' 0 N--CA 1.499 1.996 0 CA-C-N 122.024 2.193 . . . . 0.0 115.691 -172.741 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.9 50.12 0.8 Allowed Glycine 0 N--CA 1.5 2.921 0 N-CA-C 116.734 1.454 . . . . 0.0 116.734 176.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.53 -53.97 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 C-N-CA 124.193 0.997 . . . . 0.0 110.181 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.97 175.91 17.61 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 118.186 2.034 . . . . 0.0 118.186 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 t -116.67 48.03 1.35 Allowed 'General case' 0 N--CA 1.502 2.157 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -176.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 22.9 p -162.68 -120.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.787 -1.196 . . . . 0.0 111.426 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -148.13 138.61 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 CA-C-N 121.477 1.944 . . . . 0.0 112.966 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.41 -68.33 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 114.514 -1.221 . . . . 0.0 111.934 174.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.69 81.43 1.65 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 123.1 0.56 . . . . 0.0 112.057 -172.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 47.9 77.86 0.09 Allowed 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 117.991 2.589 . . . . 0.0 117.991 174.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.47 -16.76 22.88 Favored Glycine 0 N--CA 1.499 2.883 0 N-CA-C 119.876 2.71 . . . . 0.0 119.876 -176.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.2 t -56.83 -47.0 81.31 Favored 'General case' 0 N--CA 1.501 2.09 0 N-CA-C 117.447 2.388 . . . . 0.0 117.447 -178.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.66 -129.71 1.49 Allowed Glycine 0 N--CA 1.486 1.981 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -118.17 179.67 4.03 Favored 'General case' 0 CA--C 1.564 1.491 0 CA-C-O 122.01 0.909 . . . . 0.0 113.1 -174.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -158.79 148.97 19.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.342 -1.474 . . . . 0.0 112.287 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 20.3 m -70.76 -42.88 77.61 Favored 'Isoleucine or valine' 0 CA--C 1.581 2.162 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 165.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -91.08 115.5 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 168.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.0 m -78.55 106.27 10.4 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -98.39 103.97 15.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.374 19.5 p90 . . . . . 0 N--CA 1.507 2.376 0 N-CA-C 118.921 2.934 . . . . 0.0 118.921 179.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.573 1.859 0 N-CA-C 119.43 3.122 . . . . 0.0 119.43 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.324 0.9 OUTLIER -110.42 -161.89 0.77 Allowed 'General case' 0 CA--C 1.58 2.105 0 CA-C-N 120.843 1.656 . . . . 0.0 114.871 -176.107 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.33 63.19 0.42 Allowed Glycine 0 N--CA 1.502 3.041 0 N-CA-C 117.89 1.916 . . . . 0.0 117.89 -175.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.575 1.927 0 C-N-CA 124.343 1.057 . . . . 0.0 108.948 172.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -73.35 177.53 43.02 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 119.766 2.667 . . . . 0.0 119.766 -177.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 p -114.68 54.01 0.79 Allowed 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 115.165 1.543 . . . . 0.0 115.165 -175.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.4 p -169.22 134.27 1.51 Allowed 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 124.332 1.053 . . . . 0.0 109.546 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -70.12 129.25 38.91 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -172.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 37.8 p-10 -75.19 -60.29 2.36 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 177.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -144.01 85.76 1.82 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 123.448 0.699 . . . . 0.0 109.476 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 11.19 74.87 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.207 0 N-CA-C 121.024 3.713 . . . . 0.0 121.024 175.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 121.58 -38.8 2.53 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 117.008 1.563 . . . . 0.0 117.008 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.4 t -63.91 -56.98 11.24 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 116.873 2.175 . . . . 0.0 116.873 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.91 -122.31 0.87 Allowed Glycine 0 N--CA 1.488 2.104 0 O-C-N 121.269 -0.894 . . . . 0.0 113.921 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -136.55 150.37 48.58 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 124.031 0.932 . . . . 0.0 113.487 -170.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.31 141.13 39.14 Favored 'General case' 0 CA--C 1.563 1.447 0 C-N-CA 123.768 0.827 . . . . 0.0 110.984 175.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -73.54 -40.49 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 120.94 -1.1 . . . . 0.0 112.645 171.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -89.52 104.52 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 171.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 89.1 m -77.41 112.93 14.68 Favored 'General case' 0 CA--C 1.568 1.647 0 CA-C-O 122.198 0.999 . . . . 0.0 113.206 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -84.52 91.27 7.82 Favored 'General case' 0 CA--C 1.57 1.743 0 C-N-CA 124.422 1.089 . . . . 0.0 113.424 -177.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.1 t90 . . . . . 0 N--CA 1.503 2.179 0 CA-C-O 125.2 2.429 . . . . 0.0 113.669 -179.143 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.576 1.943 0 N-CA-C 119.995 3.331 . . . . 0.0 119.995 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -78.48 178.45 7.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 121.859 2.118 . . . . 0.0 113.933 177.469 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -123.51 56.13 0.68 Allowed Glycine 0 N--CA 1.501 3.012 0 O-C-N 120.297 -1.502 . . . . 0.0 116.725 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -132.86 -53.45 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.576 1.961 0 C-N-CA 124.411 1.084 . . . . 0.0 109.54 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -63.63 158.89 39.41 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 119.137 2.415 . . . . 0.0 119.137 -177.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -99.47 44.77 1.01 Allowed 'General case' 0 N--CA 1.5 2.075 0 N-CA-C 116.239 1.941 . . . . 0.0 116.239 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.5 p -175.62 152.42 1.3 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 125.156 1.383 . . . . 0.0 109.676 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -67.38 144.81 55.6 Favored 'General case' 0 CA--C 1.58 2.111 0 N-CA-C 116.708 2.114 . . . . 0.0 116.708 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.7 p30 -76.14 -70.03 0.47 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 118.002 -0.999 . . . . 0.0 112.139 172.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 55.6 t80 -153.48 100.96 2.46 Favored 'General case' 0 CA--C 1.563 1.476 0 CA-C-N 120.012 1.278 . . . . 0.0 109.39 -173.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 45.62 67.81 0.68 Allowed 'General case' 0 CA--C 1.574 1.889 0 N-CA-C 119.005 2.965 . . . . 0.0 119.005 173.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.65 -11.97 57.71 Favored Glycine 0 N--CA 1.499 2.874 0 N-CA-C 120.93 3.132 . . . . 0.0 120.93 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.14 -39.26 93.64 Favored 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 117.975 2.583 . . . . 0.0 117.975 -176.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.95 -123.02 1.08 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 124.277 0.942 . . . . 0.0 111.126 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -131.21 171.73 12.95 Favored 'General case' 0 CA--C 1.57 1.745 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -153.89 151.71 29.79 Favored 'General case' 0 CA--C 1.562 1.434 0 O-C-N 120.344 -1.472 . . . . 0.0 111.738 174.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.67 -46.46 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.389 0 O-C-N 121.027 -1.046 . . . . 0.0 111.686 166.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.9 t -88.38 117.95 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 169.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 47.0 m -80.16 106.59 12.29 Favored 'General case' 0 CA--C 1.571 1.784 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -174.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.4 p90 -123.53 72.31 1.13 Allowed 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 122.526 1.155 . . . . 0.0 114.096 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . 0.341 21.9 p90 . . . . . 0 N--CA 1.508 2.454 0 N-CA-C 117.648 2.462 . . . . 0.0 117.648 178.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 t . . . . . 0 N--CA 1.498 1.938 0 N-CA-C 119.609 3.189 . . . . 0.0 119.609 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.36 171.47 13.48 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-N 121.583 1.992 . . . . 0.0 114.57 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -119.75 55.21 0.62 Allowed Glycine 0 N--CA 1.502 3.038 0 N-CA-C 116.149 1.22 . . . . 0.0 116.149 175.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.7 -53.11 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 124.61 1.164 . . . . 0.0 109.099 177.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.28 170.55 34.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 118.631 2.212 . . . . 0.0 118.631 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.2 p -114.63 55.73 0.74 Allowed 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 115.184 1.55 . . . . 0.0 115.184 -175.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 25.2 p -162.92 -129.05 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.14 -0.975 . . . . 0.0 110.967 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -145.24 138.3 26.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 119.983 -1.698 . . . . 0.0 111.301 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -85.79 -58.17 2.76 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 123.926 0.89 . . . . 0.0 111.303 172.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -150.14 134.48 17.25 Favored 'General case' 0 CA--C 1.571 1.762 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 172.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -44.9 113.12 0.51 Allowed 'General case' 0 CA--C 1.573 1.84 0 N-CA-C 116.802 2.149 . . . . 0.0 116.802 -177.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.65 -27.96 16.88 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 118.358 2.103 . . . . 0.0 118.358 -171.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.49 -53.78 5.44 Favored 'General case' 0 CA--C 1.573 1.845 0 CA-C-N 119.806 1.803 . . . . 0.0 115.687 -177.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.5 -133.08 2.71 Favored Glycine 0 N--CA 1.49 2.266 0 O-C-N 121.09 -1.006 . . . . 0.0 113.939 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -113.09 175.73 5.32 Favored 'General case' 0 CA--C 1.566 1.589 0 CA-C-O 122.02 0.914 . . . . 0.0 113.383 -170.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.2 146.54 31.78 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.106 -1.621 . . . . 0.0 112.542 176.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.5 t -77.87 -43.23 28.8 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.578 -0.701 . . . . 0.0 111.874 170.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.29 95.95 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 95.0 m -83.9 110.5 18.44 Favored 'General case' 0 CA--C 1.565 1.54 0 N-CA-C 113.999 1.111 . . . . 0.0 113.999 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -91.44 77.2 5.81 Favored 'General case' 0 CA--C 1.57 1.743 0 CA-C-O 122.7 1.238 . . . . 0.0 114.299 -178.107 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 66.1 p-90 . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 123.051 1.405 . . . . 0.0 112.036 178.752 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.574 1.885 0 N-CA-C 119.561 3.171 . . . . 0.0 119.561 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.365 1.3 pt? -98.35 -161.02 0.84 Allowed 'General case' 0 CA--C 1.577 2.016 0 CA-C-N 121.647 2.021 . . . . 0.0 115.397 -173.096 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.44 64.57 0.41 Allowed Glycine 0 N--CA 1.5 2.938 0 O-C-N 119.758 -1.839 . . . . 0.0 117.647 -175.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.11 -54.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.899 0 C-N-CA 124.227 1.011 . . . . 0.0 108.941 172.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.81 179.12 47.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 119.674 2.63 . . . . 0.0 119.674 -177.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.6 p -115.21 53.06 0.84 Allowed 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 -177.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 16.0 p -167.61 134.49 2.22 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 124.342 1.057 . . . . 0.0 109.695 -179.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -69.37 132.33 46.21 Favored 'General case' 0 CA--C 1.573 1.831 0 N-CA-C 115.462 1.653 . . . . 0.0 115.462 -173.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.2 p-10 -73.68 -67.44 0.59 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 113.455 0.909 . . . . 0.0 113.455 176.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -139.42 76.43 1.56 Allowed 'General case' 0 N--CA 1.494 1.767 0 CA-C-N 118.634 0.652 . . . . 0.0 112.007 -171.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 41.7 79.08 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 118.392 2.738 . . . . 0.0 118.392 175.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.22 -22.93 20.66 Favored Glycine 0 N--CA 1.498 2.81 0 N-CA-C 119.164 2.425 . . . . 0.0 119.164 -174.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -58.22 -49.66 76.31 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 117.552 2.427 . . . . 0.0 117.552 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 174.37 -125.92 1.15 Allowed Glycine 0 N--CA 1.487 2.036 0 O-C-N 121.547 -0.721 . . . . 0.0 112.332 177.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -140.72 146.94 38.42 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -173.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -109.38 142.85 39.74 Favored 'General case' 0 CA--C 1.563 1.443 0 C-N-CA 123.558 0.743 . . . . 0.0 111.366 174.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -71.42 -43.8 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 120.797 -1.189 . . . . 0.0 112.423 170.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t -90.61 113.8 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 169.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.5 m -77.0 98.2 4.88 Favored 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 -175.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -97.2 -14.95 21.11 Favored 'General case' 0 N--CA 1.498 1.952 0 N-CA-C 118.995 2.961 . . . . 0.0 118.995 -178.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.737 0 N-CA-C 117.615 2.45 . . . . 0.0 117.615 -176.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 t . . . . . 0 CA--C 1.574 1.868 0 N-CA-C 119.36 3.096 . . . . 0.0 119.36 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -104.13 173.19 6.41 Favored 'General case' 0 CA--C 1.576 1.959 0 CA-C-N 120.618 1.554 . . . . 0.0 114.452 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.52 56.29 0.63 Allowed Glycine 0 N--CA 1.501 3.026 0 N-CA-C 116.127 1.211 . . . . 0.0 116.127 175.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.5 -52.91 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 C-N-CA 124.488 1.115 . . . . 0.0 109.418 177.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.91 178.44 25.48 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 119.064 2.385 . . . . 0.0 119.064 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -119.82 50.41 1.28 Allowed 'General case' 0 N--CA 1.5 2.05 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 -175.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.253 22.4 p -157.25 -129.31 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.84 -1.162 . . . . 0.0 110.821 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -144.42 135.67 25.4 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.765 1.621 . . . . 0.0 111.071 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.4 p-10 -86.82 -60.41 1.99 Allowed 'General case' 0 N--CA 1.491 1.608 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.336 173.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -147.16 127.42 13.88 Favored 'General case' 0 CA--C 1.566 1.595 0 N-CA-C 105.364 -2.087 . . . . 0.0 105.364 173.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.85 106.8 0.1 Allowed 'General case' 0 CA--C 1.574 1.868 0 N-CA-C 115.83 1.789 . . . . 0.0 115.83 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.1 -46.03 1.1 Allowed Glycine 0 N--CA 1.492 2.406 0 CA-C-O 118.436 -1.202 . . . . 0.0 115.497 -169.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.4 t -83.57 -61.62 1.79 Allowed 'General case' 0 CA--C 1.569 1.677 0 N-CA-C 116.282 1.956 . . . . 0.0 116.282 -178.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 177.53 -121.19 0.76 Allowed Glycine 0 N--CA 1.488 2.133 0 CA-C-N 120.504 1.502 . . . . 0.0 115.803 -177.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.43 174.72 5.91 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -166.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.89 147.03 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 120.348 -1.47 . . . . 0.0 112.113 174.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.7 t -76.93 -44.0 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.575 -0.703 . . . . 0.0 112.61 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.5 t -88.54 95.69 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 CA-C-N 119.668 1.122 . . . . 0.0 108.095 175.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.8 m -85.44 96.26 9.53 Favored 'General case' 0 CA--C 1.565 1.553 0 CA-C-O 121.911 0.862 . . . . 0.0 112.266 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -142.49 151.35 41.6 Favored 'General case' 0 CA--C 1.569 1.677 0 CA-C-O 122.798 1.285 . . . . 0.0 112.321 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 51.4 p-90 . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 124.629 2.157 . . . . 0.0 114.52 173.506 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.574 1.887 0 N-CA-C 120.325 3.454 . . . . 0.0 120.325 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.3 179.55 4.55 Favored 'General case' 0 CA--C 1.579 2.073 0 CA-C-N 121.093 1.77 . . . . 0.0 114.088 178.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -124.21 58.46 0.64 Allowed Glycine 0 N--CA 1.501 3.005 0 O-C-N 120.259 -1.525 . . . . 0.0 116.697 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -131.54 -54.75 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 C-N-CA 124.403 1.081 . . . . 0.0 109.391 176.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -70.58 -179.97 28.76 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 119.232 2.453 . . . . 0.0 119.232 -177.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -121.29 43.79 2.71 Favored 'General case' 0 N--CA 1.504 2.272 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -175.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 21.1 p -163.56 139.81 6.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.79 -1.194 . . . . 0.0 109.821 177.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -63.5 137.81 58.27 Favored 'General case' 0 CA--C 1.577 2.014 0 N-CA-C 116.266 1.95 . . . . 0.0 116.266 -174.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.277 39.1 p-10 -80.68 -80.86 0.13 Allowed 'General case' 0 N--CA 1.489 1.512 0 CA-C-O 118.237 -0.887 . . . . 0.0 113.223 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -121.29 55.42 1.07 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -173.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . 0.264 . . 57.65 7.56 0.56 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 121.762 3.986 . . . . 0.0 121.762 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.61 64.02 0.03 OUTLIER Glycine 0 N--CA 1.491 2.322 0 O-C-N 120.866 -1.146 . . . . 0.0 115.152 -177.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 54.0 t -156.84 -64.68 0.1 Allowed 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 123.589 0.756 . . . . 0.0 111.464 177.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.77 -117.83 0.46 Allowed Glycine 0 N--CA 1.483 1.788 0 O-C-N 121.633 -0.667 . . . . 0.0 112.391 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 88.2 m-85 -129.23 172.23 11.66 Favored 'General case' 0 CA--C 1.566 1.591 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -168.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -134.45 143.87 47.78 Favored 'General case' 0 CA--C 1.563 1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 110.705 173.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.1 t -74.06 -43.92 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 O-C-N 121.106 -0.996 . . . . 0.0 112.326 171.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 94.6 t -93.76 112.24 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 172.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 78.6 m -80.31 96.24 6.59 Favored 'General case' 0 CA--C 1.568 1.645 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -178.05 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 64.1 t80 -128.88 93.92 3.72 Favored 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 123.679 1.704 . . . . 0.0 110.199 179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 48.3 p90 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 124.462 2.077 . . . . 0.0 113.964 -178.511 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 120.275 3.435 . . . . 0.0 120.275 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.43 166.75 18.11 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 121.859 2.118 . . . . 0.0 115.161 -178.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.37 49.96 0.81 Allowed Glycine 0 N--CA 1.5 2.9 0 N-CA-C 116.701 1.441 . . . . 0.0 116.701 176.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -133.58 -55.23 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 124.334 1.054 . . . . 0.0 109.991 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -67.71 169.35 38.09 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 118.311 2.084 . . . . 0.0 118.311 -178.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.8 p -109.77 56.15 0.63 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 115.526 1.676 . . . . 0.0 115.526 -174.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.254 22.5 p -164.26 -131.71 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.124 -0.985 . . . . 0.0 111.111 176.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -146.36 136.26 23.4 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 119.933 -1.73 . . . . 0.0 111.295 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.0 p30 -82.84 -63.32 1.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.012 -0.995 . . . . 0.0 111.136 174.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -145.24 124.0 12.61 Favored 'General case' 0 CA--C 1.566 1.592 0 N-CA-C 104.956 -2.239 . . . . 0.0 104.956 174.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -38.36 111.18 0.16 Allowed 'General case' 0 CA--C 1.573 1.839 0 N-CA-C 117.892 2.553 . . . . 0.0 117.892 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 109.05 -32.25 7.04 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 117.917 1.927 . . . . 0.0 117.917 -171.463 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -80.31 -51.67 8.62 Favored 'General case' 0 CA--C 1.574 1.867 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 -176.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.14 -135.13 3.46 Favored Glycine 0 N--CA 1.49 2.295 0 O-C-N 121.203 -0.936 . . . . 0.0 113.243 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -114.23 178.98 4.09 Favored 'General case' 0 CA--C 1.567 1.607 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -171.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -145.96 145.3 30.6 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.058 -1.651 . . . . 0.0 112.262 175.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.4 t -75.82 -45.34 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 O-C-N 121.393 -0.817 . . . . 0.0 111.691 171.096 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -90.84 107.23 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 171.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.2 m -81.99 96.71 7.8 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -144.45 108.73 4.81 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.907 0.86 . . . . 0.0 109.346 177.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.7 t-105 . . . . . 0 N--CA 1.489 1.483 0 CA-C-O 123.917 1.818 . . . . 0.0 110.59 -179.491 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.497 1.898 0 N-CA-C 119.781 3.252 . . . . 0.0 119.781 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.41 171.6 13.3 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 121.59 1.996 . . . . 0.0 114.571 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -120.48 55.57 0.63 Allowed Glycine 0 N--CA 1.5 2.955 0 N-CA-C 116.015 1.166 . . . . 0.0 116.015 175.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -133.58 -52.55 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.574 1.89 0 C-N-CA 124.737 1.215 . . . . 0.0 109.055 177.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.16 173.92 31.18 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 118.673 2.229 . . . . 0.0 118.673 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -117.8 51.16 1.07 Allowed 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 115.317 1.599 . . . . 0.0 115.317 -175.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.256 25.6 p -157.48 -128.63 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.83 -1.169 . . . . 0.0 110.963 174.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -145.66 135.87 23.87 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-N 120.903 1.683 . . . . 0.0 111.533 -179.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p-10 -83.34 -60.6 2.09 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.988 172.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -147.53 135.3 21.08 Favored 'General case' 0 CA--C 1.572 1.816 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 171.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -45.17 113.69 0.61 Allowed 'General case' 0 CA--C 1.573 1.842 0 N-CA-C 116.795 2.146 . . . . 0.0 116.795 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.26 -26.88 22.28 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 118.431 2.132 . . . . 0.0 118.431 -171.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.57 -54.02 5.24 Favored 'General case' 0 CA--C 1.573 1.849 0 CA-C-N 119.809 1.805 . . . . 0.0 115.606 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.46 -133.0 2.69 Favored Glycine 0 N--CA 1.489 2.189 0 O-C-N 121.079 -1.013 . . . . 0.0 113.942 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -112.86 175.32 5.49 Favored 'General case' 0 CA--C 1.567 1.605 0 CA-C-O 122.121 0.962 . . . . 0.0 113.354 -170.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.09 147.01 33.19 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.159 -1.588 . . . . 0.0 112.092 175.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 66.2 t -77.77 -42.52 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 O-C-N 121.544 -0.722 . . . . 0.0 112.493 172.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -86.66 95.29 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 CA-C-N 119.839 1.2 . . . . 0.0 108.12 175.105 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.9 m -87.02 113.85 23.13 Favored 'General case' 0 CA--C 1.567 1.603 0 O-C-N 121.707 -0.621 . . . . 0.0 112.505 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 62.2 t80 -84.42 141.84 30.54 Favored 'General case' 0 CA--C 1.571 1.774 0 CA-C-O 121.892 0.853 . . . . 0.0 113.122 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.1 t-105 . . . . . 0 N--CA 1.488 1.443 0 CA-C-O 123.884 1.802 . . . . 0.0 109.868 175.804 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 t . . . . . 0 N--CA 1.498 1.97 0 N-CA-C 119.886 3.291 . . . . 0.0 119.886 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.77 166.04 17.29 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 121.615 2.007 . . . . 0.0 114.861 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -110.85 48.77 0.9 Allowed Glycine 0 N--CA 1.501 2.984 0 N-CA-C 116.957 1.543 . . . . 0.0 116.957 177.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.53 -55.67 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 C-N-CA 124.168 0.987 . . . . 0.0 110.267 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.52 34.84 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 118.612 2.205 . . . . 0.0 118.612 -177.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.7 p -112.99 58.15 0.66 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -174.012 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.257 19.4 p -165.71 -132.7 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 110.868 175.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -144.03 139.3 28.91 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 119.877 -1.765 . . . . 0.0 111.313 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.4 p-10 -90.65 -65.61 1.0 Allowed 'General case' 0 N--CA 1.489 1.478 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.95 176.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -139.82 77.44 1.61 Allowed 'General case' 0 N--CA 1.494 1.744 0 CA-C-N 119.06 0.845 . . . . 0.0 111.254 -175.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 32.64 80.68 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 119.403 3.112 . . . . 0.0 119.403 174.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.48 -28.45 14.13 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 118.391 2.116 . . . . 0.0 118.391 -173.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 2.4 t -59.93 -41.37 91.63 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 117.298 2.333 . . . . 0.0 117.298 -179.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.35 -135.94 3.93 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 124.024 0.821 . . . . 0.0 111.814 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -115.36 176.65 4.97 Favored 'General case' 0 CA--C 1.565 1.533 0 CA-C-O 122.084 0.945 . . . . 0.0 113.257 -173.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.0 144.92 37.22 Favored 'General case' 0 CA--C 1.562 1.432 0 O-C-N 120.258 -1.526 . . . . 0.0 111.776 175.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -74.75 -42.26 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 174.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -88.81 94.67 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 CA-C-N 119.883 1.22 . . . . 0.0 108.033 175.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.7 m -85.88 105.8 16.63 Favored 'General case' 0 CA--C 1.565 1.538 0 CA-C-O 121.716 0.769 . . . . 0.0 112.454 -179.329 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -83.74 97.15 8.98 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 122.007 0.908 . . . . 0.0 111.556 -178.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 72.4 t90 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 123.831 1.777 . . . . 0.0 110.569 -178.095 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 119.08 2.993 . . . . 0.0 119.08 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.85 169.15 14.43 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 121.34 1.882 . . . . 0.0 114.585 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -112.48 48.17 0.97 Allowed Glycine 0 N--CA 1.499 2.878 0 N-CA-C 117.097 1.599 . . . . 0.0 117.097 177.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.3 mp -131.5 -54.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 C-N-CA 124.156 0.982 . . . . 0.0 110.179 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -65.8 172.67 23.93 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 118.266 2.066 . . . . 0.0 118.266 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 p -114.34 54.06 0.78 Allowed 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 115.53 1.678 . . . . 0.0 115.53 -175.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . 0.262 22.0 p -165.99 -124.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.18 -0.95 . . . . 0.0 110.841 176.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -147.85 140.44 24.6 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-N 120.94 1.7 . . . . 0.0 111.717 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -82.47 -71.67 0.48 Allowed 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.469 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -145.26 85.91 1.75 Allowed 'General case' 0 CA--C 1.566 1.585 0 CA-C-N 119.548 1.067 . . . . 0.0 111.736 -179.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 50.89 81.66 0.07 Allowed 'General case' 0 CA--C 1.571 1.782 0 N-CA-C 118.017 2.599 . . . . 0.0 118.017 173.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.52 -21.97 8.19 Favored Glycine 0 N--CA 1.5 2.929 0 N-CA-C 120.31 2.884 . . . . 0.0 120.31 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.1 t -59.43 -39.55 83.9 Favored 'General case' 0 N--CA 1.5 2.074 0 N-CA-C 117.689 2.477 . . . . 0.0 117.689 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.5 -132.85 2.61 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 124.108 0.861 . . . . 0.0 111.239 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -117.95 178.47 4.41 Favored 'General case' 0 CA--C 1.565 1.548 0 CA-C-O 122.127 0.965 . . . . 0.0 113.446 -173.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -155.73 146.28 21.96 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.371 -1.456 . . . . 0.0 112.594 175.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . 0.253 9.4 p -69.15 -45.95 78.79 Favored 'Isoleucine or valine' 0 CA--C 1.58 2.096 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 166.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.5 t -91.2 112.75 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.571 1.757 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 169.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 69.5 m -78.47 115.04 17.9 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -71.52 134.32 46.42 Favored 'General case' 0 CA--C 1.575 1.929 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.45 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 58.2 p-90 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 125.281 2.467 . . . . 0.0 112.699 -178.989 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.498 1.927 0 N-CA-C 120.815 3.635 . . . . 0.0 120.815 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . 0.252 0.3 OUTLIER -80.77 174.32 11.73 Favored 'General case' 0 CA--C 1.578 2.025 0 CA-C-N 122.136 2.244 . . . . 0.0 114.381 178.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.49 57.74 0.6 Allowed Glycine 0 N--CA 1.501 2.981 0 O-C-N 120.404 -1.435 . . . . 0.0 116.455 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.2 mp -131.29 -53.91 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 C-N-CA 124.513 1.125 . . . . 0.0 108.981 176.205 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.46 168.67 42.12 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 118.417 2.127 . . . . 0.0 118.417 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -112.66 43.11 1.71 Allowed 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.8 p -164.83 142.77 6.43 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 124.546 1.138 . . . . 0.0 109.729 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.7 140.23 58.85 Favored 'General case' 0 CA--C 1.579 2.085 0 N-CA-C 118.006 2.595 . . . . 0.0 118.006 -171.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 30.9 p30 -79.7 -60.99 2.13 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 123.444 0.698 . . . . 0.0 111.637 172.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -151.7 94.0 1.93 Allowed 'General case' 0 CA--C 1.566 1.595 0 CA-C-N 119.732 1.151 . . . . 0.0 109.202 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . 13.42 83.28 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 121.438 3.866 . . . . 0.0 121.438 175.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.42 -35.74 4.2 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 117.648 1.819 . . . . 0.0 117.648 -174.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 1.7 t -68.88 -45.04 72.0 Favored 'General case' 0 CA--C 1.577 2.005 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 -177.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 160.47 -130.88 2.49 Favored Glycine 0 N--CA 1.489 2.203 0 O-C-N 121.359 -0.838 . . . . 0.0 112.745 -178.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -125.09 171.66 10.1 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -170.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.23 140.96 37.88 Favored 'General case' 0 CA--C 1.564 1.49 0 O-C-N 120.364 -1.46 . . . . 0.0 110.615 175.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 30.1 m -69.03 -39.56 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.058 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.1 t -96.3 118.09 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 168.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.3 m -76.89 100.93 5.72 Favored 'General case' 0 CA--C 1.569 1.681 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -107.64 -30.69 8.44 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 118.002 2.593 . . . . 0.0 118.002 -178.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.497 1.894 0 CA-C-O 124.664 2.174 . . . . 0.0 110.778 -175.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 8.2 t . . . . . 0 CA--C 1.573 1.865 0 N-CA-C 119.177 3.029 . . . . 0.0 119.177 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.43 169.47 8.68 Favored 'General case' 0 CA--C 1.575 1.906 0 CA-C-N 120.664 1.575 . . . . 0.0 114.703 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -114.26 52.26 0.66 Allowed Glycine 0 N--CA 1.5 2.937 0 N-CA-C 116.669 1.428 . . . . 0.0 116.669 177.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 mp -132.23 -54.83 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 C-N-CA 124.112 0.965 . . . . 0.0 110.211 179.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -68.53 177.73 25.27 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 118.825 2.29 . . . . 0.0 118.825 -177.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.7 t -116.43 53.46 0.88 Allowed 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 115.047 1.499 . . . . 0.0 115.047 -175.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -162.16 -129.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.92 -1.113 . . . . 0.0 110.974 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -144.1 139.89 29.13 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.932 -1.73 . . . . 0.0 110.832 178.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 29.5 p-10 -90.97 -60.06 2.01 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 123.637 0.775 . . . . 0.0 111.256 172.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -147.22 127.25 13.67 Favored 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 174.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -47.84 106.56 0.09 Allowed 'General case' 0 CA--C 1.572 1.81 0 N-CA-C 116.001 1.852 . . . . 0.0 116.001 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.39 -46.02 1.1 Allowed Glycine 0 N--CA 1.492 2.381 0 CA-C-O 118.509 -1.162 . . . . 0.0 115.687 -169.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.3 t -83.46 -60.71 2.05 Favored 'General case' 0 CA--C 1.569 1.698 0 N-CA-C 116.611 2.078 . . . . 0.0 116.611 -178.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 178.24 -124.9 0.95 Allowed Glycine 0 N--CA 1.49 2.284 0 CA-C-N 120.314 1.416 . . . . 0.0 115.356 -176.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -115.05 178.19 4.38 Favored 'General case' 0 CA--C 1.566 1.577 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -168.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.6 141.29 33.47 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.346 -1.472 . . . . 0.0 112.087 175.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.86 -39.8 52.39 Favored 'Isoleucine or valine' 0 CA--C 1.576 1.951 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 170.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.1 t -90.77 97.14 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 170.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 68.6 m -82.41 110.83 17.89 Favored 'General case' 0 CA--C 1.564 1.485 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -175.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -82.84 88.47 6.78 Favored 'General case' 0 CA--C 1.571 1.761 0 CA-C-O 122.693 1.235 . . . . 0.0 110.807 173.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 40.8 t-105 . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 124.585 2.136 . . . . 0.0 111.303 -173.987 . . . . . . . . 0 0 . 1 stop_ save_